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Abstract 
Clostridium difficile continues to be a leading cause of healthcare-associated 
infections in the developed world. Increased detection of C. difficile infection (CDI) 
and development of typing schemes to differentiate between strains is primarily due 
to the recognition of global outbreaks of a single strain, BI/NAP1/027 which is 
characterised by three common typing techniques; restriction endonuclease analysis 
(REA), pulsed-field gel electrophoresis (PFGE) and PCR ribotyping. 
 
Phylogenetic analysis using multilocus sequence typing (MLST) divides C. difficile 
into five phylogenetic lineages which align the well-known PCR ribotypes; 027, 023, 
017, 078 and a lineage containing diverse PCR ribotypes. MLST data in this thesis 
confirmed the five phylogenetic lineages were maintained after testing a larger 
collection of isolates from varied sources with further micro-diversity within the 
individual lineages. MLST investigation did not identify a lineage exclusive to non-
human strains or any correlation between sequence type and geographical location. 
Data in this thesis also supports the notion that PCR ribotyping and REA do not 
correspond as well as previously considered. This may result in phylogenetically 
similar strains being designated as a different type or variant. 
 
The toxin A-B+ PCR ribotype 017 strain that forms a predominant lineage is little 
investigated. Through whole genome sequencing (WGS) and single nucleotide 
polymorphism (SNP) analysis, a historical clone of PCR ribotype 017 was identified 
from a London hospital ward. Although no phenotype exclusive to the clonal strain 
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was characterised, this is the first report in the UK investigating the phylohistory of 
isolates from hospitalised patients with CDI due to PCR ribotype 017.  
 
Further investigation of PCR ribotype 017 with a larger and global collection of 
strains revealed two distinct sub-lineages containing multiple independent clonal 
expansions, antimicrobial resistant SNP determinants, deletions and insertions which 
were well distributed geographically and temporally. The data suggests transmission 
between humans and animals and findings support a USA origin with multiple, 
global transmission events. 
 
The key findings of this thesis are that C. difficile as a species is continually evolving 
with the appearance of divergent sub-lineages. WGS is superior to routine typing 
methodologies for tracking this evolution and will have significant impacts for 
outbreak investigation, understanding the phylohistory and phylogeography of C. 
difficile and other pathogens that are a threat to human health. 
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Impact Statement 
The Gram positive bacterium Clostridium difficile causes gastrointestinal disease in 
humans and animals and continues to be a leading cause of healthcare-associated 
infections in the developed world. Prior to 2003, there were few reports of C. difficile 
infection (CDI) yet in 2003 multiple outbreaks of CDI were reported in Europe, 
United States of America (USA) and Canada affecting humans. Typing schemes 
were introduced to differentiate between strains for investigation of outbreaks; 
restriction endonuclease analysis (REA), pulsed-field gel electrophoresis (PFGE) and 
PCR ribotyping and a clonal strain of C. difficile was identified (BI/NAP1/027). 
Multilocus sequence typing (MLST) is a different typing technique useful for 
studying the population and evolutionary genetics of bacteria by exploiting the 
nucleotide sequences of housekeeping gene fragments. By testing a larger collection 
of isolates from varied sources using MLST, this thesis confirms the findings of 
previous studies; C. difficile is made up of five phylogenetic lineages of which four 
align with the well-known PCR ribotypes; 027, 023, 017, 078 and a fifth lineage 
containing diverse PCR ribotypes. Further micro-diversity within the individual 
lineages was also revealed suggesting continued evolution of this species. MLST 
investigation did not identify a lineage exclusive to non-human strains or any 
correlation between sequence type and geographical location suggesting transmission 
of strains between humans and animals and lack of global spread of a clonal strain 
according to sequence type. Furthermore, data in this thesis shows that PCR 
ribotyping and REA do not correspond as well as previously considered. This 
inconsistency may result in phylogenetically similar strains being designated as a 
different type or variant which has significant implications to infection control and 
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management of outbreaks. This thesis further investigated toxin A-B+ PCR ribotype 
017 strains in greater detail. Through whole genome sequencing (WGS) and single 
nucleotide polymorphism (SNP) analysis, a historical clone of PCR ribotype 017 was 
identified from a London hospital ward. Although no phenotype exclusive to the 
clonal strain was characterised, this is the first report in the UK investigating the 
phylohistory of isolates from hospitalised patients with CDI due to the PCR ribotype 
017. This contributes to our understanding of an interesting strain which is toxin A 
negative and reported to be prevalent in Asia. Further investigation of PCR ribotype 
017 by testing a larger and global collection of strains using WGS revealed two 
distinct sub-lineages containing multiple independent clonal expansions, 
antimicrobial resistant SNP determinants, deletions and insertions which were well 
distributed geographically and temporally. The data suggests transmission between 
humans and animals and findings support a USA origin with multiple, global 
transmission events. 
 
The three studies described above are published as papers (available in the public 
domain) and either presented as posters or presented as an oral presentation at an 
international conference. The findings are significant to academia worldwide 
whereby the continual monitoring of the expansion of C. difficile improves our 
understanding of the evolution of this species. This in turn has implications to the 
non-academic world where the data is translational to healthcare and its patients; this 
is imperative. WGS allows us to predict and/or detect a more virulent and/or clonal 
strain early enabling improved diagnostics and prompt outbreak interventions. This 
can only result in improvements to patient morbidity, mortality and associated costs. 
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1 Introduction 
The Gram positive bacterium Clostridium difficile causes gastrointestinal disease in 
humans and animals. Prior to 2003, there were few reports of C. difficile infection 
(CDI) yet in 2003, multiple outbreaks of CDI were reported in Europe, United States 
of America (USA) and Canada (Loo et al., 2005, McDonald et al., 2005, Warny et 
al., 2005, Labbe et al., 2008, Healthcare Commission, 2007). Outbreaks are primarily 
a result of patients with CDI excreting spores; these are highly infectious and allow 
for transmission and spread of infection (Riggs et al., 2007, Buggy et al., 1983, Sorg 
and Sonenshein, 2008, Fimlaid et al., 2013). Since the outbreaks between 2003 and 
2007, the incidence of CDI has increased or decreased dependent upon geographical 
location. Europe has seen a decrease in incidence where counts in the UK have 
dropped from ~17,000 in 2007 to ~3,000 in 2017 (Public Health England, 2017). 
Canada and the USA have seen a steady rise and CDI has now been reported globally 
(Hawkey et al., 2013, Freeman et al., 2010, Public Health England, 2016, Rupnik et 
al., 2009, European Centre for Disease Prevention and Control, 2013).  
 
The main risk factors associated with the development of CDI are consumption of 
broad-spectrum antibiotics, age ≥ 65 years and duration of stay within healthcare 
facilities (Bartlett, 2002, Kelly and LaMont, 2008). CDI is routinely treated with 
either metronidazole or vancomycin which are generally effective but other therapies 
such as faecal transplantation have also shown to be successful (Shahinas et al., 
2012, Kassam et al., 2012, Kassam et al., 2013, van Nood et al., 2013, Kelly et al., 
2014, Aroniadis et al., 2016). The development of infection and onward transmission 
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is prevented by antimicrobial stewardship and infection control practices (Gerding et 
al., 2008a, McNulty et al., 1997, Dingle et al., 2017). 
1.1 The organism Clostridium difficile 
The genus Clostridium is a member of the bacterial family Peptostreptococcaceae 
(formally Clostridiaceae). The type strain for the genus Clostridium is Clostridium 
butyricum (Yutin and Galperin, 2013, Lawson and Rainey, 2015) and due to 
differences recently observed on 16S rRNA sequence analysis between C. difficile 
and C. butyricum, Clostridium perfringens and Clostridium tetani, it has been 
proposed that C. difficile be re-named Clostridioides difficile (Lawson et al., 2016). 
Currently, Clostridium difficile remains the widely used terminology and is therefore 
used in this thesis. 
 
The prokaryotic genus Clostridium are anaerobic, Gram-positive, rod-shaped 
bacteria and has achieved its status as a consequence of five species that are 
pathogenic to humans and animals; C. botulinum (botulism), C. perfringens (gas 
gangrene), C. tetani (tetanus), Clostridium sordellii (multi-organ disease) and 
C. difficile (gastrointestinal infection). The capability of C. difficile to form spores 
enables its survival in multiple environmental niches such as soil and water (al Saif 
and Brazier, 1996, Janezic et al., 2016). C. difficile has been found in different water 
sources such as the sea, rivers, lakes, inland drainage and swimming pools (al Saif 
and Brazier, 1996, Zidaric et al., 2010, Pasquale et al., 2011, Romano et al., 2012). 
C. difficile was initially named Bacillus difficilis and first described in 1935 as part of 
the neonatal microflora (Hall and O’Toole, 1935) and further characterised by 
Snyder in 1937 (Snyder, 1937). There were no other documented reports of B. 
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difficilis until 1960, when the renamed organism, C. difficile was cultured from the 
intestinal contents of a seal  (McBee, 1960).  
1.2 C. difficile infection 
C. difficile was first suggested as a human pathogen when it was isolated from bodily 
samples of patients (Smith and King, 1962). In 1978 the first confirmed case of CDI 
was reported (Larson et al., 1978)  and in 1999, the use of clindamycin, which was a 
commonly used antibiotic at the time, was associated with the occurrence of CDI 
(Johnson et al., 1999). Typical clinical features of CDI include; watery diarrhoea, 
abdominal pain and cramps, lower quadrant tenderness, fever, leucocytosis and 
hypoalbuminaemia (Mylonakis et al., 2001). CDI is highly variable, ranging from 
uncomplicated mild diarrhoea to life threatening toxic megacolon and 
pseudomembranous colitis (PMC) requiring surgical intervention or leading to death. 
CDI is the most frequent cause of healthcare-acquired infectious diarrhoea in 
developed countries and one of the major problems with CDI is reoccurrence of 
disease which is common with a rate of 15% to 35% (Garey et al., 2008, Johnson, 
2009). These contribute to the significant morbidity and financial burden associated 
with CDI.  
1.3 Risk factors for C. difficile infection 
The surface area of a healthy human gastrointestinal tract is colonised with bacterial 
species: the gut microbiota. The dense gut microbiota has a symbiotic relationship 
with the host providing protection against exposure to dietary antigens, viable 
pathogens and bacterial products (Kato et al., 2001, Ozaki et al., 2004, Miyajima et 
al., 2011). Changes to the microbiota that have a negative effect on the host is termed 
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‘dysbiosis’ (Hawrelak and Myers, 2004). C. difficile is considered a member of the 
normal gut microbiota in less than 5% of healthy adults (Viscidi et al., 1981) and is 
recognised as a gut coloniser in domestic animals and livestock (Songer, 2004, 
Arroyo et al., 2005, Rodriguez-Palacios et al., 2009). In states of dysbiosis, 
C. difficile is able to flourish and invade the mucosal cells allowing toxins produced 
by C. difficile to cause similar infection in both humans and animals (Limaye et al., 
2000). The two major risk factors for gut dysbiosis permitting CDI are the 
consumption of broad-spectrum antibiotics and age ≥ 65 years (Bignardi, 1998). The 
most frequently implicated antibiotics; clindamycin, penicillins, cephalosporin and 
the fluoroquinolones disrupt the microbiota of the gut and advancing age is thought 
to result in immune system failure known as ‘senescence’ of the immune response, 
resulting from a combination of comorbidities, immune related changes in the faecal 
flora and normal age related changes (Ginaldi et al., 2001).  
1.4 Virulence factors 
Strains of C. difficile implicated in CDI have been demonstrated to possess a 
multitude of virulence factors, these include toxins, surface associated proteins, 
sporulation and germination. 
1.4.1 Toxins A and B 
The pathogenesis of C. difficile in cases of CDI is hypothesised to primarily result 
from the production of two glucosylating enterotoxins, TcdA and TcdB which both 
cause damage to epithelial cells (Voth and Ballard, 2005, Chumbler et al., 2016) and 
are considered a major virulence factor in CDI. Their genes tcdA and tcdB are 
chromosomally located along with three accessory genes forming the 19.6 kb 
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Pathogenicity locus (PaLoc [Figure 1.1 A]). This is made up of: tdcR which encodes 
an alternative ribonucleic acid (RNA) polymerase sigma factor, a positive regulator 
of toxin production (Mani and Dupuy, 2001), tcdC, a negative regulator of toxin 
production which interferes with the RNA polymerase formed with tcdR 
(Matamouros et al., 2007), and tcdE, a gene thought to encode an holin like protein 
(Dupuy et al., 2008).  
 
Strains of C. difficile do not always possess tcdA and tcdB genes and therefore may 
demonstrate variation in toxin production. This variation was exploited and a 
toxinotyping scheme was developed in 1998 (Rupnik et al., 1998) which was 
performed against ‘VPI 10463’, the first strain of C. difficile to have its toxin genes 
sequenced (von Eichel-Streiber et al., 1992). Toxinotyping is a PCR restriction 
fragment length poloymorphism based typing method assigning strains as 
toxinotypes. The reference strain VPI 10463 is designated as toxinotype 0 and strains 
similar are defined as ‘nonvariant’ strains of toxinotype 0. All other strains with 
changes in genes tcdA and/or tcdB are defined as ‘variant strains’.  Changes in the 
PaLoc range from minimal deletions limited to only tcdA and a few point mutations 
in tcdB to significant changes in tcdB and large deletions leaving only a residue of 
the PaLoc. Currently, there are 34 known toxinotypes which individually are 
designated with roman numerals (I to XXXIV). The genomic organisation of the 
PaLoc region of C. difficile and different toxinotypes are depicted in Figure 1.1. 
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Figure 1.1: Genomic organisation of the PaLoc region of C. difficile 
A figure adapted from a publication by Rupnik and Janezic which depicts the genetic variation in toxin types of C. difficile (Rupnik and Janezic, 
2016). The genomic organisation of A) the PaLoc of toxinotype 0 B) Minor toxinotypes and C) Major toxinotypes. Changes in variant 
toxinotypes can be single SNPs (seen as RFLPs), deletions, or insertions. RFLPs (vertical stripes) are more common in the tcdB gene, while 
deletions and insertions (shown with diagonal stripes or graphical symbols) are more common in the tcdA gene. 
A 
B 
Toxinotype 0 
Toxinotype XII 
Toxinotypes; I, II, XIII, XVII, XIX, XX, XXVI, XXVII, XXIX 
 
Toxinotypes; IIIa-e, IV, V, IXa-d, XIVa, b, XXI, XXII, XXXIII 
 
 
Toxinotypes; VI, VII, VIII, XVI, XXV, XXVIII 
 
 
 
Toxinotype Xa,b 
Toxinotypes; XXX, XXXI, XXXII, XXXIV 
Toxinotype XIa-d 
C 
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The PaLoc is absent from non-toxigenic strains and in strains lacking this locus, the 
region is replaced by non-coding deoxyribonucleic acid (DNA) (Braun et al., 1996). 
Experiments by Brouwer et al., have demonstrated that the PaLoc is mobile and is 
able to transfer from a toxigenic strain to a non-toxigenic strain (Brouwer et al., 
2013). Strains that do not produce either toxin are non-pathogenic (Kuehne et al., 
2010) and although the majority of pathogenic strains produce both toxins (A+B+), 
clinically relevant toxin A negative toxin B positive (A-B+) strains have been 
frequently described (Alfa et al., 2000) and are discussed further in Section 1.13. 
1.4.2 Other toxins 
Approximately 20% of strains of C. difficile have been observed to produce an actin 
modifying ADP-ribosylating binary toxin (Gerding et al., 2014), C. difficile 
transferase (CDT) (Schwan et al., 2009).  It has been suggested that CDT has a role 
in adherence and colonisation of C. difficile to gut epithelial cells by stimulating 
microtubule-based protrusions from host cells (Schwan et al., 2009).  
1.4.3 Sporulation and germination 
C. difficile has the capacity to form spores; a dormant state that allows the bacterium 
to survive in conditions otherwise detrimental to their vegetative cell existence 
(Lawley et al., 2009, Paredes et al., 2005). Spores of C. difficile are highly resistant 
to adverse chemical and physical stress and can persist and contaminate an 
environment for up to several months (Setlow, 2007). The spore structure is made up 
of multiple layers including an exosporium, coat, cortex, membrane and a DNA core 
(Lawley et al., 2009). C. difficile spores are excreted with faeces from colonised and 
infected patients and can be ingested by a susceptible host (Deakin et al., 2012). The 
38 
 
spore is initially protected from the acids and enzymes in the stomach by their 
multiple layer structure until it reaches the intestinal tract where it is exposed to 
germinants such as bile salts (Giel et al., 2010). Here, the spore commences 
germination losing its spore-specific properties resulting in the upregulation of 
several genes and the reversal to a vegetative state.  
 
In Bacillus subtilis, the gene Spo0A is a key transcriptional regulator that is required 
in the early stages of sporulation (Molle et al., 2003). C. difficile possesses a 
homolog of this gene and its role in CDI has been studied in a murine model of 
disease. These studies demonstrated that C. difficile Spo0A mutant derivatives can 
cause intestinal disease but are unable to persist within and effectively transmit 
between mice indicating that the C. difficile Spo0A gene plays a key role in persistent 
infection and host-to-host transmission (Deakin et al., 2012). 
1.4.4 Surface associated proteins 
Cell surface proteins are essential to the bacterial cells interaction within its 
environment. They may be responsible for motility, adhesion and invasion of host 
cells as well as defending against host responses (Lin et al., 2002, Niemann et al., 
2004). C. difficile expresses numerous cell surface associated molecules including 
surface layer proteins (SLPs) (Spigaglia et al., 2013), pili (Maldarelli et al., 2014) 
and flagella (Dingle et al., 2011b, Aubry et al., 2012, Baban et al., 2013, Barketi-Klai 
et al., 2014).  
 
The bacterial surface layer (S-layer) of C. difficile is proteinaceous, two-dimensional 
and coats the entire outer surface of the vegetative cell (Fagan and Fairweather, 
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2014). The S-layer is composed of the high molecular weight SLP and low molecular 
weight SLP. SLPs have been demonstrated to facilitate the initial colonisation of the 
gut by C. difficile (Sambol et al., 2000, Johnson et al., 2001) and low molecular 
weight SLPs play an antigenic role in immune evasion (Bianco et al., 2011, Ryan et 
al., 2011). The two SLPs are generated by post-translational cleavage of a pre-protein 
(SlpA) by the cell wall cysteine protease, Cwp84. SlpA is the most abundant protein 
of the S-layer and may act as an important colonisation factor (Ni Eidhin et al., 2008, 
Ryan et al., 2011, Sambol et al., 2000). 
 
Pili (Latin for hair) are filamentous surface appendage structures initially identified 
in Gram-negative organisms (Anderson, 1949). Pili are associated with bacterial 
adhesion to host cells (Kline et al., 2009) and have been implicated in urinary, genital 
and gastrointestinal infections (Mulvey et al., 1998, Swanson, 1973, Boudeau et al., 
2001). In Gram-positive bacteria, pili were first observed in Corynebacterium renale 
in 1968 (Yanagawa et al., 1968) and more recently have been observed in members 
of the Clostridia Class (Piepenbrink et al., 2015, Purcell et al., 2015). Pili in 
C. difficile have been associated with phenotypic variation and biofilm formation 
(Maldarelli et al., 2016) potentially contributing to the species virulence. 
 
Flagella are whip-like protein appendages on a bacterial cell surface that drive 
motility of many bacterial species (Berg, 2003). Flagella have been shown to enable 
bacteria to colonise host cells in Campylobacter jejuni and Vibrio chloerae 
(Nachamkin et al., 1993, Richardson, 1991) and play a role in adherence in V. 
chloerae (Postnova et al., 1996). 
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Strains of C. difficile that exhibit peritrichous flagella are implicated in host cell 
colonisation (Tasteyre et al., 2001) and more recently, a direct link between flagella 
regulation and toxin production has been made (Dingle et al., 2011b, Aubry et al., 
2012, Barketi-Klai et al., 2014). C. difficile flagella are genetically encoded by three 
distinct operons; F1, F2 and F3 (Stabler et al., 2009). Through the mutagenesis and 
complementation assays, Valiente et al., investigated the function of the flagella 
associated genes and demonstrated their importance in motility, cell aggregation, 
biofilm formation, epithelial cell adhesion and recognition by the human immune 
system protein, toll-like receptor 5 (Valiente et al., 2016). 
1.5 Diagnosis of C. difficile infection 
The gold standard for the laboratory diagnosis of CDI is the direct detection of C. 
difficile toxin in faeces and the most recent guidance from the Department of Health 
states that a combination of two tests should be used  (HPA, December 2008). These 
should be a Polymerase Chain Reaction (PCR) assay for the detection of tcdB or a 
glutamate dehydrogenase enzyme immunoassay followed by a sensitive enzyme 
immunoassay test for the detection of toxin in a stool sample. The laboratory 
diagnosis of CDI is often inconclusive due to the fact that the symptoms of CDI are 
similar to other intestinal disease and use of laxatives and side effects of some 
antimicrobials often result in diarrhoea. Generally, CDI is diagnosed clinically and 
the laboratory test results help confirm or rule out CDI. 
1.6 Clinical management and therapeutic options 
Once a patient has been diagnosed as suffering CDI, current antimicrobial therapy 
should be discontinued or altered. First line treatment is limited to only a few agents; 
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oral metronidazole and vancomycin with the latter being used for severe or recurrent 
cases of CDI and doses of vancomycin can be tapered or pulsed as a way of 
improving response and recovery (Gerding et al., 2008b). A more recently licensed 
antimicrobial, fidaxomicin is the first of a new class of narrow spectrum macrocyclic 
antibiotic drugs (Louie et al., 2011, Golan and Epstein, 2012). Fidaxomicin is 
bactericidal, has a prolonged post-antibiotic effect allowing for reduced dosing and 
has fewer side effects and a lower rate of reoccurrence when compared with 
metronidazole and vancomycin (Babakhani et al., 2011). 
 
Therapies other than the use of antimicrobial drugs are available as last resort or are 
in development. The concept of ‘faecal microbiota transplantation’, also known as 
‘faecal biotherapy’ and ‘bacteriotherapy’, was first described as a treatment of food 
poisoning and severe diarrhoea in Chinese literature from the 4
th
 to the 16
th
 century 
(Zhang et al., 2012) and referred to as ‘yellow soup’. Faecal transplantation is 
practiced with the aim of restoring normal faecal microbiota where it has re-emerged 
as a treatment option for severe and recurrent CDI and many trials have investigated 
its efficacy with promising results (Kassam et al., 2013, Shahinas et al., 2012, van 
Nood et al., 2013, Kelly et al., 2014, Aroniadis et al., 2016). Studies investigating the 
optimal combination of gut bacteria as a treatment of severe or recurrent CDI are 
aiming to produce a customised microbiota pill to replace the faecal bacteria which 
potentially contain pathogens with normal healthy bacterial flora (Reeves et al., 
2011, Reeves et al., 2012, Lawley et al., 2012, Petrof et al., 2013).  
 
Bile salt analogues such as cholate metabenzene sulfonic acid that targets the 
interaction between C. difficile spores and taurocholate inhibiting germination have 
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been investigated as a potential therapeutic option (Howerton et al., 2013). Toxin 
binding agents such as Cholestyramine, a bile salt ion-exchange resin which has been 
shown to form a complex with C. difficile toxins and Tolevamer, a non-antibiotic 
polymer binds to C. difficile toxins have been examined in clinical studies, however, 
neither has been as efficacious as antimicrobial therapy (Weisman et al., 2015). 
 
Immunotherapy such as vaccination brings sight of improving the current treatment 
options especially for recurrent CDI. A toxoid vaccine candidate produced by Sanofi 
Pasteur is currently being tested in phase III clinical trials and a recombinant vaccine 
consisting of two truncated toxins A and B by Valneva is in pre-clinical stages of 
development (Anosova et al., 2015, Greenberg et al., 2012, Foglia et al., 2012, 
Karczewski et al., 2014). Toxin-specific monoclonal antibody therapy as a treatment 
option is under investigation by Merck, and Sanofi Pasteur are developing a pair of 
monoclonal antibodies against toxins A and B (Lowy et al., 2010, Babcock et al., 
2006, Anosova et al., 2015). 
1.7 Management of outbreaks and infection control 
Spores excreted with faeces from colonised and infected patients are easily 
transmitted via persons, fomites and air and are thought to be the main factors of 
environmental persistence and host transmission (Deakin et al., 2012). Spores of C. 
difficile demonstrate capacity to survive, persist and spread in hostile environments 
and cause outbreaks of CDI amongst susceptible hosts in wards, hospitals and other 
healthcare facilities (Kim et al., 1981). Infection control measures are required to 
limit the spread of C. difficile between patients and patients suspected of having CDI 
should be isolated to limit the spread of spores to other patients. Daily cleaning of the 
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environment and equipment that has been in contact with a patient with CDI with a 
chlorine agent is required, as is good hand hygiene by patients and staff, most 
notable with soap and water since alcohol gels are ineffective against C. difficile 
spores and can induce sporulation (Jabbar et al., 2010).  
 
The consumption of antibiotics is a risk factor for the development of CDI, it has 
been demonstrated that by prescribing narrow-spectrum antibiotics as opposed to 
broad-spectrum antibiotics (where appropriate) can reduce the incidence of CDI. 
Antimicrobial stewardship, the monitoring and controlled use of antimicrobials has 
shown to reduce the burden of CDI (Fowler et al., 2007, Muto et al., 2007, Dingle et 
al., 2017, Pear et al., 1994).  
 
All National Health Service trusts are required to participate in the Department of 
Health’s mandatory CDI monitoring system whereby all cases of CDI in patients 
over the age of two years must be reported. Each acute care provider in the United 
Kingdom (UK) has a target number of CDI cases that they must not breach per 
financial year. Each CDI case should be assessed by performing a root cause analysis 
to determine if it was related to a lapse in the quality of care provided to patients. As 
part of a root cause analysis, samples and isolates maybe referred to their local Public 
Health England (PHE) C. difficile Ribotyping Network (CDRN) laboratory. The 
seven CDRN laboratories in the UK offer C. difficile PCR ribotyping (Section 1.8.1); 
these results are valuable for inferring and excluding transmission of C. difficile. 
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1.8 Genotyping schemes and routine surveillance  
Typing methodologies enable bacterial isolates of the same species to be categorised 
as either related or distinct (Sabat et al., 2013) which has utility for the management 
of outbreaks by infection control teams. Identifying similarities or differences 
between strains of the same species and combining this with time and place of 
infection enables clinicians and epidemiologists to identify cross-transmission and/or 
outbreaks of infection. This is valuable for local, national and global surveillance 
whereby the number of infections and pathogen evolution can be monitored for 
changing prevalence’s and/or pathogen virulence respectively. 
 
Historically, typing methodologies have been based on exploiting phenotypic 
variations but molecular methods are now routinely used (Sabat et al., 2013). 
 
Molecular typing approaches have been developed to study C. difficile and 
transmission including; multilocus sequence typing (MLST), multilocus variable-
number tandem-repeat analysis (MLVA), Amplified fragment length polymorphism 
(AFLP), Pulsed-field gel electrophoresis (PFGE), Restriction endonuclease analysis 
(REA) and PCR ribotyping (Table 1.1). They vary in their discriminatory power 
(ability to differentiate between two unrelated strains) and therefore their application. 
Whole genome sequencing (WGS) is increasingly used to investigate outbreaks and 
epidemiology with finer resolution though this technique is not yet part of routine 
investigation of outbreaks of CDI in the UK (WGS is further discussed in Section 
1.16, Page 58).  
 
45 
 
All typing methods apart from MLST are applied to the investigation of cross-
transmission and/or outbreaks of infection (MLST is discussed further in Section 
1.12, Page 53). PCR ribotyping is the most widely adopted scheme in Europe for 
genotyping strains of C. difficile with the Lead CDRN laboratory in Leeds, UK 
holding the collection of strains and assigning new PCR ribotypes (Public Health 
England., 2016); 877 PCR ribotypes have been identified (Dr Warren Fawley, 
personal communication 12/04/2018). In contrast, PFGE is the method of genotyping 
C. difficile in the USA. PCR ribotyping and PFGE are used for identifying cross-
transmission, outbreaks of CDI in healthcare facilities and surveillance of the 
species. 
 
 
 
Table 1.1: Molecular typing methods used for C. difficile 
 
 
 
 
 
 
 
 
AFLP - Amplified fragment length polymorphism 
REA - Restriction endonuclease analysis 
PFGE - Pulsed-field gel electrophoresis 
PCR Ribotyping - Polymerase chain reaction Ribotyping 
MLVA - Multilocus variable-number tandem-repeat analysis 
MLST - Multilocus sequence typing 
 
Application Methodology Reference 
 
Outbreaks 
AFLP (Bowman et al., 1991) 
REA (Clabots et al., 1993) 
PFGE (Kato et al., 1999) 
PCR Ribotyping (Stubbs et al., 1999) 
MLVA (Marsh et al., 2010) 
 
Evolutionary 
Studies & Surveillance 
 
MLST (Lemee et al., 2004) 
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1.8.1 PCR ribotyping 
PCR ribotyping was initially described in 1986 (Kuijper et al., 2006) and has since 
been applied to multiple bacterial genera (Eldar et al., 1997, Chesneau et al., 2000, 
Joung and Cote, 2002, Miteva et al., 2001, Yurlova et al., 1996, Salmenlinna and 
Vuopio-Varkila, 2001). The original method utilised for C. difficile was published in 
1999 (Stubbs et al., 1999) and involves PCR amplification of the 16S to 23S 
intergenic spacer region of DNA using conserved primers (Figure 1.2). This region 
of DNA is both variable in length in base pairs (bp) and copy number between PCR 
ribotypes of the same species. It is this variation that following PCR amplification 
generates multiple PCR products which vary in size. While the ribosomal genes are 
quite conserved, the intergenic spacer regions vary considerably between C. difficile 
strains. Electrophoretic resolution of these DNA fragments generates profiles which 
are interpreted as a fingerprint, unique to that PCR ribotype, and can be used to 
distinguish C. difficile strains belonging to different PCR ribotypes (Figure 1.3). 
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1000 bp 
Lane 
PCR ribotype 027 
 
 
 
 
 
 
 
Figure 1.2: PCR ribotyping amplification of C. difficile 
 
This figure illustrates the region of the C. difficile genome that is amplified during 
PCR ribotyping. 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 1.3: PCR ribotyping agarose gel electrophoresis of C. difficile 
 
A figure of a typical PCR ribotyping agarose gel electrophoresis image of C. difficile. 
Lanes 1, 7, 13 and 20 are a 100 bp reference ladder, lanes 2 to 6, 8 to 12 and 14 to 17 
are ribotyping profiles for different isolates and lanes 18 and 19 are negative extract 
and negative PCR controls respectively. Lanes 2, 14, 15 and 17 are also labelled to 
indicate a particular PCR ribotype; 027. The number of bands per lane indicates the 
copy number of the intergenic spacer region for that isolate and the size of the band 
indicates the length of the intergenic spacer region. 
100 bp 
1   2     3     4    5     6    7    8     9  10   11  12  13  14  15  16  17   18   19  20 
Region amplified 
during PCR 
Intergenic spacer region 
C. difficile has multiple copies varying 
in size of between ~250 – 600 bp  
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1.9 Global emergence of PCR ribotype 027  
Increased recognition of CDI and the development of a PCR ribotyping scheme to 
differentiate between C. difficile strains was primarily due to the recognition of 
global outbreaks of a particular PCR ribotype; 027.  
 
The earliest record of PCR ribotype 027 was in 1985 when the strain CD196 was 
isolated from a patient with CDI in a Parisian hospital (Popoff et al., 1988). PCR 
ribotype 027 was again isolated from a patient with CDI in a Minneapolis hospital in 
1988 and designated BI-1 according to REA typing (Razaq et al., 2007). In 2003-
2004, outbreaks in hospitals with patients experiencing notably severe CDIs were 
reported in Canada (Loo et al., 2005, McDonald et al., 2005) and between August 
2004 and July 2007, more than 20,000 nosocomial cases of BI-1 were reported in the 
Quebec region (Labbe et al., 2008). Concurrently, BI-1 had also been isolated in 
several states in the USA (Warny et al., 2005) and in March 2004 a report was made 
by the Stoke Mandeville Hospital, UK describing a major outbreak including 334 
CDI cases and 38 deaths (Healthcare Commission, 2007). Outbreak strains from the 
UK, USA and Canada were found to be due to the dissemination of a strain identified 
as BI by REA, NAP1 by PFGE and PCR ribotype 027 by PCR ribotyping and 
referred to as BI/NAP1/027 (Killgore et al., 2008). This was so named an ‘epidemic’ 
strain due to its propensity to cause outbreaks and the subsequent global spread is 
depicted in Figure 1.4. Reasons for the global emergence and spread of the epidemic 
PCR ribotype 027 strain of C. difficile are discussed in Section 1.10, Page 50. 
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Figure 1.4: Map of isolation dates and global geographical spread of C. difficile 
PCR ribotype 027 
 
 
Figure produced by M. Cairns and adapted from a publication by Valiente et al., 
which depicts the dates and global spread of the epidemic C. difficile PCR ribotype 
027 strain (Valiente et al., 2014). 
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1.10 Virulence and transmissibility of PCR ribotype 027  
The establishment of PCR ribotype 027 and its apparent propensity to cause more 
severe diarrhoea, higher mortality and more re-occurrences of symptoms (Loo et al., 
2005, Warny et al., 2005, Vohra and Poxton, 2011, Redelings et al., 2007) gave rise 
to this strain being described as ‘hypervirulent’ as well as epidemic when compared 
to other PCR ribotypes. A variety of phenotypic characteristics have been postulated 
to contribute to this ability to cause outbreaks and more severe CDI such as; 
increased toxin production (Warny et al., 2005, Curry et al., 2007, Freeman et al., 
2007), presence of an 18 bp deletion and a frameshift mutation due to a single bp 
deletion in the tcdC gene affecting toxin expression (Dupuy et al., 2008, MacCannell 
et al., 2006). Some PCR ribotypes including PCR ribotype 027 produce a binary 
toxin (Stubbs et al., 2000, Sundriyal et al., 2010) encoded by two genes, cdtA and 
cdtB (Carter et al., 2007) which has been linked with increased severity of disease 
(Barbut et al., 2005, McEllistrem et al., 2005). Isolates of PCR ribotype 027 are also 
reported to sporulate earlier in the bacterial growth cycle and produce more spores in 
total compared to non-PCR ribotype 027 isolates and this was postulated to increase 
the rate of transmission (Merrigan et al., 2010, Fawley et al., 2007). Germination 
rates for isolates of PCR ribotype 027 have been shown to be higher (Burns et al., 
2010a) and exhibit higher germination efficiencies compared to other PCR ribotypes 
in the presence of 0.1 % (w/v) sodium taurocholate (Moore et al., 2013).  
 
However, these observations remain contentious due to other evidence not 
supporting these suggestions (Dupuy et al., 2008, Burns et al., 2011)  nor that these 
characteristic are PCR ribotype specific (Burns et al., 2010b). C. difficile spore 
germination in response to sodium taurocholate varied significantly even amongst 
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isolates of PCR ribotype 027 (Heeg et al., 2012). Therefore, no definitive virulence 
factors have convincingly been attributed to isolates of PCR ribotype 027. 
1.11 Distribution of C. difficile PCR ribotypes 
Since the emergence and explosion of outbreaks of CDI associated with PCR 
ribotype 027, there have been significant changes to the diversity of C. difficile. In 
the UK, rates of CDI, most notably PCR ribotype 027 have declined as depicted in 
Figure 1.5. This has occurred simultaneously with an increase in a variety of other 
PCR ribotypes, and in general, the pattern of PCR ribotypes in the UK has become 
more heterogeneous (Public Health England., 2016). This is likely due to multiple 
factors including; increased testing and PCR ribotyping, changing antibiotic usage 
patterns and emergence of new strains. Europe has also seen an increase in PCR 
ribotype diversity. Previously, 65 different PCR ribotypes were identified across 26 
countries with PCR ribotype 027 the most commonly isolated (18.4%) (Bauer et al., 
2011). More recently, a European-wide study found 125 PCR ribotypes with no 
dominant PCR ribotype (Davies et al., 2016). Recent data from the USA suggests a 
different PCR ribotype diversity compared to Europe; although diversity has 
increased, PCR ribotype 027 remains the leading cause of CDI in the USA (Rusk, 
2011). Although CDI is a major problem in Europe, Canada and USA, less is known 
about its epidemiology for other continents. The few studies that have been 
performed in other geographical locations, for example Asia, demonstrate that CDI is 
a significant cause of nosocomial disease (Hawkey et al., 2013). There is a pressing 
need to understand the sources and routes of transmission of C. difficile beyond PCR 
ribotyping. 
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Figure 1.5: Prevalence and diversity of C. difficile PCR ribotypes in England by quarter (April 2008 to March 2015) 
 
Courtesy of the 2016 CDRN report (Public Health England., 2016). 
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1.12 Phylogenetic studies  
Multilocus sequence typing (MLST) is a useful approach for studying population and 
evolutionary genetics and the epidemiology of bacteria. It is a molecular 
epidemiological typing technique that permits microbial isolate characterisation by 
exploiting the nucleotide sequences of housekeeping gene fragments. The method 
utilises the DNA sequences of multiple (usually seven) housekeeping genes 
(approximately 450-500 bp). Each housekeeping gene is defined as distinct 
sequences (alleles), and for each isolate, the combination of sequences define the 
allelic profile or sequence type (Griffiths et al., 2010). The rationale is that a single 
genetic event resulting in a new allele can occur by point mutation (altering only a 
single nucleotide site), or by a recombinational replacement (will often change 
multiple sites).  
 
MLST was first developed by Brian Spratt’s research group for Neisseria 
meningitides (Spratt, 1999) and has since successfully been used to study the 
population genetics of other organisms including; Streptococcus pneumoniae 
(Rayner et al., 2015), Staphylococci species, Streptococcus pyogenes (Enright et al., 
2001), Haemophilus influenzae (Meats et al., 2003), Campylobacter jejuni (Dingle et 
al., 2011a), Enterococcus faecium (Homan et al., 2002, Burgos et al., 2014, de Been 
et al., 2015) among others.  
 
There are many terms used to describe and classify the phylogenetic relatedness 
between bacterial strains; Table 1.2 describes some of the common terms used in the 
literature and in this thesis. 
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Table 1.2: Phylogenetic relatedness terminology 
 
Terminology Definition 
Lineage 
A single, temporal phylogenetic division of a continual line 
of ancestral decent 
Sub-lineage A sub-ordinate descent of a lineage 
Clade 
A phylogenetic division where strains share a common 
ancestor (not necessarily linear in terms of ancestral decent) 
Clone Strains that are indistinguishable in genotype 
 
In this thesis and associated publications where I am first author, I refer to lineage 
and sub-lineage and not clade. 
 
MLST studies on diverse collections of C. difficile strains suggest that the species 
can be divided into five ancestral lineages. These five MLST lineages of C. difficile 
can be divided by PCR ribotype; 027, 017, 023, 078 and a large group including the 
rest of the PCR ribotypes with PCR ribotype 078 representing an interestingly highly 
divergent lineage (Lemee et al., 2004, Lemee et al., 2005, Griffiths et al., 2010, 
Dingle et al., 2011a). These lineages are depicted in Figure 1.6. 
 
The rapid spread of PCR ribotype 027 has detracted attention from other virulent 
PCR ribotypes of C. difficile (PCR ribotype 017 [Section 1.13, Page 56], PCR 
ribotype 078 [Section 1.14, Page 57] and PCR ribotype 023 [Section 1.15, Page 58]) 
and coupled with the identification of PCR ribotype specific lineages other than PCR 
ribotype 027, the study of other PCR ribotypes and lineages has come to prominence. 
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Figure 1.6: The five phylogenetic lineages of C. difficile by MLST analysis 
 
A figure adapted from a publication by Dingle et al., illustrates the phylogenetic relationships among 78 sequence types comprising the five 
lineages (Dingle et al., 2011a). Branch colouring; black = lineage 1 (mixed PCR ribotypes), red = lineage 2 (PCR ribotype 027), blue = lineage 3 
(PCR ribotype 023), orange = lineage 4 (PCR ribotype 017), and green = lineage 5 (PCR ribotype 078). The numerical figures depicted within 
the encircled lineages are designated sequence types.  
 1.13 The emergence of toxin A-B+ strains and PCR ribotype 017 
The first documentation of a toxin A-B+ strain of C. difficile was by Haslam et al., in 
1986 who identified a clinical isolate (8864) of C. difficile that did not produce toxin 
A using an enzyme-linked immunoabsorbent assay (Haslam et al., 1986). This was 
confirmed using either an enzyme-linked immunoabsorbent assay or probes specific 
to toxin A in 1991 (Torres, 1991), 1992 (Borriello et al., 1992, Lyerly et al., 1992) 
and 1993 (Depitre et al., 1993). It was later shown that the toxin A negative samples 
did possess the toxin A gene using PCR (Pituch et al., 1998) and that the loss of 
toxin A expression was due to a nonsense point mutation (von Eichel-Streiber et al., 
1999). 
 
The earliest reports of outbreaks of CDI due to toxin A-B+ C. difficile strains 
originated in Canada in 1998 (Alfa et al., 2000) and the Netherlands between 1997 
and 1998 (Kuijper et al., 2001). This was followed with further isolation in both 
Japan (Komatsu et al., 2003, Kato et al., 1999), the UK, Belgium and USA (Johnson 
et al., 2003) and Ireland (Drudy et al., 2007b). Outbreak strains of toxin A-B+ were 
compared using three typing methodologies and 20/23 isolates were found to be PCR 
ribotype 017 (others being PCR ribotypes; 110, 036 and 047) (Johnson et al., 2003).  
 
PCR ribotype 017 is toxinotype VIII and it has since been reported in Poland (Pituch 
et al., 2001, Pituch et al., 2006), Israel (Samra et al., 2002), China (Huang et al., 
2010), Korea (Kim et al., 2010a, Kim et al., 2010b, Shin et al., 2008) (where PCR 
ribotype 017 was the predominant PCR ribotype), Argentina (Goorhuis et al., 2009), 
Israel (Samra et al., 2002), Australia (Elliott et al., 2011) and Thailand 
(Ngamskulrungroj et al., 2015). Given that some diagnostic laboratories rely on 
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detecting toxin A only, the incidence of toxin A-B+ PCR ribotype 017 is likely to be 
significantly under reported.  
1.14 The emergence of PCR ribotype 078 
PCR ribotype 078 is the predominant PCR ribotype isolated from animal species 
with CDI, most notably pigs, calves and horses (Keel et al., 2007, Jhung et al., 2008, 
Goorhuis et al., 2008, Rupnik et al., 2008). C. difficile has also been found in 
contaminated food for human consumption with PCR ribotype 078 being the most 
frequently implicated (Rodriguez-Palacios et al., 2009, Broda et al., 1996, Songer et 
al., 2009, Simango and Mwakurudza, 2008). It was found in 4.8% (5/119) of seafood 
and fish samples from a grocery store; all toxin positive isolates were found to be 
PCR ribotype 078 (Metcalf et al., 2011). 
 
Although CDI is primarily associated with exposure to a healthcare associated 
environment, patients from the community can develop CDI; these numbers also 
appear to be on the rise. With the increased recognition of C. difficile from food 
products for human consumption, there are concerns regarding transmission between 
animals and humans (or possibly humans to animals). Although C. difficile is not a 
proven food-borne pathogen, there is evidence that the same strain can cause 
symptomatic disease in both pigs and humans (Debast et al., 2009) and studies from 
several countries have found certain strains to be indistinguishable between human, 
animal and food origin (Jhung et al., 2008, Goorhuis et al., 2008, Debast et al., 2009, 
Gould and Limbago, 2010).  
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1.15 The potential emergence of other PCR ribotypes 
MLST analyses revealed a distinct lineage of C. difficile that predominantly contains 
strains of PCR ribotype 023 (Figure 1.6). Although this PCR ribotype is not well 
described like PCR ribotypes 027, 078 and 017, two studies have reported its 
prevalence in Europe (Bauer et al., 2011, Barbut et al., 2007) and retrospective 
analysis in the UK associated PCR ribotype 023 with severe CDI (Wren et al., 2009).  
 
MLST analyses more recently identified a novel 6
th
 lineage that formed a well-
separated branch in the phylogenetic tree and contained sequence type 122 and PCR 
ribotype 131 (Knetsch et al., 2012). Other common PCR ribotypes including 001, 
002, 014, 015 and 106, do not form distinct lineages by MLST analysis like seen 
with PCR ribotypes 027, 078, 017 and 023, but instead, occur within the same 
heterogeneous group (Figure 1.6).  
1.16 Genome-based analysis 
Application of both PCR ribotyping and MLST techniques has demonstrated the 
utility of these methods in describing the epidemiology and population structure of 
C. difficile. Typing methods lack the sensitivity to precisely discriminate between 
isolates so as to infer or exclude transmission events. Genotyping methodologies also 
only detect variation in specific regions of a genome. In order to address this it is 
necessary to describe the whole genome of a strain under investigation.  
 
WGS methodologies enable the genomic DNA sequence of an organism or 
population to be determined (Heather and Chain, 2016).  In comparison to other 
typing methods which target specific and limited regions of the genome, WGS 
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techniques provide greater resolution than conventional typing methodologies with 
the ability to distinguish strains that differ at only a single nucleotide per genome 
(Roetzer et al., 2013). The capacity of WGS to describe genome content means that it 
can readily identify DNA acquisition and loss events (Xu et al., 2016); current typing 
methodologies may or may not reveal the horizontal transfer of genes amongst 
strains.  
 
WGS has been demonstrated to be superior to conventional genotyping for 
phylogenetic, evolutionary and outbreak analyses, the methodology has become the 
‘gold-standard’ for the description of bacterial phylogenetic relatedness of multiple 
species of bacterial pathogens (examples are provided in Table 1.3). Since the advent 
of ‘first generation’ DNA sequencing technologies in 1977 with Sanger’s ‘chain-
termination’ technique (Sanger et al., 1977), sequencing technology has significantly 
evolved. The expansion of ‘next-generation’ high throughput sequencing 
technologies have the advantages of; a requirement for less input DNA, increased 
turn-around-time of data, reduced cost and improved accuracy. The common next-
generation technologies are; Illumina (Solexa) sequencing, Roche 454 sequencing, 
Ion Torrent sequencing and SOLiD sequencing. This has been followed by ‘third-
generation’ sequencing technologies which emerged in 2010 (McCarthy, 2010). 
These include Pacific BioSciences (PacBio) and Oxford Nanopore Technologies and 
generate significantly increased read lengths. Table 1.4 summarises a comparison of 
sequencing technologies. 
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Table 1.3: Selected studies using WGS for pathogens 
 
Pathogen 
Number of 
isolates 
Focus of study Reference 
Mycobacterium 
tuberculosis 
86 Outbreak related transmission (Roetzer et al., 2013) 
2,099 Drug resistance (Walker et al., 2015) 
24 WGS direct from clinical samples (Brown et al., 2015) 
13 
Comparison of genetic variation to 
phenotypic characteristics 
(Satta et al., 2016) 
Vibrio cholerae 5 
Identification of geographic source 
of outbreak 
(Chin et al., 2011) 
Staphylococcus aureus 
63 
Micro-evolution, geographical 
clustering, intercontinental spread 
and transmission events 
(Harris et al., 2010) 
181 
Transmission between residents of 
healthcare facilities and 
environmental contamination 
(Harrison et al., 2016) 
1,013 
Macro-epidemiology of Meticillin 
resistant S. aureus (MRSA) 
(Reuter et al., 2016) 
308 Identification of high-risk clones (Aanensen et al., 2016) 
Vancomycin Resistant 
Enterococci 
45 
Evidence for genetic relatedness 
between long term carriage and 
bloodstream infections 
(Brodrick et al., 2016) 
Measles virus 27 Outbreak related transmission (Gardy et al., 2015) 
Salmonella spp. 
6,887 
Comparison with conventional 
typing methodology 
(Ashton et al., 2016) 
29 
Comparison with conventional 
typing methodology 
(Bale et al., 2016) 
Campylobacter spp. 1,713 
Evaluation of  molecular diagnostic 
assays 
(Jansen van Rensburg et al., 2016) 
Candida auris 41 
Identification of  clonal populations 
on three continents 
(Lockhart et al., 2017) 
 
 Table 1.4: WGS technologies 
Generation Technology (Company) Reference Chemistry Read length Strengths Weaknesses 
First 
Sanger Sequencing  
(Applied Biosystems Inc, 
California, USA) 
(Fleischmann et al., 1995) 
Chain 
termination 
Up to 900 bp 
Improved on the mainstay 
approach of multiple PCRs 
Low throughput 
Second 
(next) 
Illumina  
(Illumina Ltd,  
Cambridge, UK) 
(Bentley et al., 2008) Synthesis Up to 600 bp 
Versatile for a variety of 
applications 
High cost compared 
with other 
technologies 
Roche 454  
(Roche Diagnostics Ltd, Basel, 
Switzerland) 
(Margulies et al., 2005) Synthesis Up to 1 kb Long reads 
High cost compared 
with other 
technologies 
Ion Torrent  
(Ion Torrent Systems Inc, 
Gilford, USA) 
(Rusk, 2010) Synthesis Up to 400 bp 
Short run time and low cost 
compared with other 
technologies 
Low throughput and 
short read length 
SOLiD sequencing 
(ThermoFisher Scientific Inc, 
Massachusetts, USA) 
(Shendure et al., 2005) Ligation Up to 100 bp 
High throughput and high 
accuracy 
Short read length 
Third 
PacBio 
(Pacific Biosciences Inc, 
California, USA) 
(Chin et al., 2011) 
Single-
molecule,  
real-time 
long reads 
Up to 20,000 bp 
Long reads, short run time and 
ability to sequence regions of 
high G/C content 
Poor accuracy 
MinION  
(Oxford Nanopore 
Technologies, Ltd, Oxford, UK) 
(Madoui et al., 2015) Nanopore 
Theoretically, no 
instrument restriction 
on read length  
Long reads, sequencing in 
real-time and portable 
platform 
Poor accuracy 
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1.17 Genome sequencing of C. difficile 
Following on from the identification of PCR ribotype specific lineages through 
MLST analysis and the heightened interest associated with PCR ribotype 027, using 
DNA sequencing and phenotypic assays Stabler et al., performed a three-way, 
whole-genome comparison between the original PCR ribotype 027 Paris strain 
(CD196), the index PCR ribotype 027 strain from the Stoke Mandeville outbreak in 
the UK (R20291) and the first published sequence strain of C. difficile, strain 630, 
PCR ribotype 012 which was isolated from a patient with severe PMC and caused an 
outbreak of diarrheal disease in a Swiss hospital (Sebaihia et al., 2006, Wust et al., 
1982, Stabler et al., 2009). Phenotypic differences were observed with motility, 
antibiotic resistance and toxicity, lineage specific genes were present in the two PCR 
ribotype 027 genomes and the modern epidemic PCR ribotype 027 strains had five 
unique genetic regions absent from both the non-epidemic PCR ribotype 027 and the 
PCR ribotype 012 strains. Subsequently, a SNP based study of 21 PCR ribotype 027 
strains of C. difficile revealed chronological microevolution and confirmed PCR 
ribotypes; 017, 027 and 078 strains to form individual lineages with the latter 
appearing to be highly divergent (He et al., 2010).  
 
Using illumina WGS technology  to sequence the genomes of a global collection 
(n=151) of C. difficile BI/NAP1/027 isolates primarily from hospital patients 
between 1985 and 2010, He et al., identified 3,686 SNPs which inferred the presence 
of two phylogenetic sub-lineages; fluoroquinolone resistance (FQR) 1 and FQR2 (He 
et al., 2013). The authors suggest both FQR1 and FQR2 evolved independently and 
acquired an identical mutation in the DNA gyrase gene leading to high level 
fluoroquinolone resistance. FQR1 and FQR2 are depicted in Figure 1.7. 
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The authors imply that the FQR1 sub-lineage originated in Pennsylvania, USA in 
2001 whereas the FQR2 sub-lineage emerged in USA with the first documented 
isolate from Montreal in 2003. The FQR2 sub-lineage was shown to disseminate 
across the Atlantic with multiple introductions into the UK causing hospital 
outbreaks between 2004 and 2006. Isolates from the base of the phylogeny and 
outside of both epidemic sub-lineages are from various geographical locations and 
are not thought to be associated with major hospital outbreaks suggesting that these 
represent pre-epidemic isolates from which the two epidemic sub-lineages emerged. 
Additionally, fluoroquinolone antibiotics were one of the most commonly prescribed 
antibiotic classes in the late 1990s and early 2000 in the USA  (Linder et al., 2005) so 
it is plausible to suggest that during this time, this created a selective pressure for the 
acquisition and maintenance of fluoroquinolone resistance and provided the 
environment for the emergence of both sub-lineages.  
 
Only two and seven SNPs defined the branches leading to the two epidemic sub-
lineages respectively. However, besides the DNA gyrase gene mutation there were 
no SNPs that were shared by both sub-lineages and little evidence that a substantial 
change in phenotype could result from any of the SNPs that define the two epidemic 
sub-lineages.  
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Figure 1.7: Global phylogeny of C. difficile PCR ribotype 027 
 
A figure adapted from a publication by He et al., that depicts the global phylogeny of 
151 C. difficile 027/BI/NAP1 isolates based on core genome SNPs (He et al., 2013). 
Coloured nodes indicate the geographic source of the isolates. The position of the 
inferred root is indicated by a dashed line, and dashed outlines enclose the isolates 
with the mutation associated with fluoroquinolone resistance. 
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1.18 Aims of thesis 
Given the poor understanding of the phylohistory and phylogeography of C. difficile, 
the focus of this thesis is to enhance the understanding of the phylogeny of this 
species with an overarching aim to investigate and understand the changing evolution 
of C. difficile by: 
 
 Investigating the population structure of a collection of C. difficile strains 
isolated from diverse human, animal and food sources, continents using 
different typing methodologies and comparing the correlation of typing 
methodologies used for inter-laboratory comparison (chapter 3, Page 93). 
 
 Investigating the genetic relatedness of a collection of C. difficile PCR 
ribotype 017 strains isolated from London hospitals using WGS and 
phenotypic assays (chapter 4, Page 135). 
 
 Investigating the global population structure of C. difficile PCR ribotype 017 
using WGS and antimicrobial susceptibility assays (chapter 5, Page 177). 
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Chapter 2 
Materials and Methods
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2 Materials and Methods 
2.1 Materials 
Unless otherwise indicated, chemicals and biochemicals were supplied by Sigma-
Aldrich, Gillingham, UK and bacterial growth media and commercially prepared 
agar plates were supplied by Oxoid, Basingstoke, UK. 
2.1.1 Bacterial study isolates 
All bacterial isolates used in this thesis are shown in Appendix 1, Page 229, Table 
4.1, Page 143 and Appendix 2, Page 249 for Chapters 3, 4 and 5 respectively and 
their sources are described on Page 27. Isolates were received from collaborators on 
agar plates, swabs or in broth suspensions and were recovered by inoculating to 
blood agar (Section 2.2.2, Page 70).The maximum passage number for the isolates 
provided by the London CDRN Laboratory was three.  
2.1.2 Bacterial control isolates 
The C. difficile PCR ribotype 017 reference strain M68 and its reference genome; 
GenBank accession number FN668375 (He et al., 2010) were used as controls for 
assays, sequencing and analysis. This strain was selected as the control since it is the 
fully sequenced annotated PCR ribotype 017 strain and is widely used and well 
described. The C. difficile PCR ribotype 027 reference strain R20291 was also used 
as a control for PCR ribotyping assays since this was part of the standard operating 
procedure for PCR ribotyping at the CDRN regional London laboratory. 
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2.1.3 Data collection 
Meta data for isolates (source, origin, sample date and geographical location) were 
collated by contacting the source (Page 27) and by examination of patient request 
forms for isolates provided by the CDRN regional London laboratory. 
2.2 Microbiological methods 
2.2.1 Sterilisation 
All reagents (where indicated), media and solutions were sterilised by autoclaving at 
121 degree Celcius (°C) for 20 minutes in a wet autoclave (LTE Scientific, Oldham, 
UK) or dry steam sterilisation was performed at 134 °C for 15 minutes in an AAJ 
autoclave (Astell Scientific, Sidcup, UK). Filter sterilisation was performed using a 
10 ml syringe (BD Plastipak, Oxford, UK) and a 0.2 μm (32 mm) Acrodisc® syringe 
filter with Stupor
®
 membrane (Pall Life Sciences, UK). 
2.2.2 Bacterial growth media 
Isolates were routinely grown on blood agar which was either prepared in-house or 
commercially purchased. In-house blood agar plates were prepared by dissolving 16 
g of Columbia blood agar base in 500 ml Milli-Q grade water (Millipore, Billerica, 
USA) in a 500 ml bottle. The suspension was inverted to mix and then autoclaved at 
121 °C for 20 minutes and allowed to cool. Once cooled to handheld temperature, 7 
% (vol/vol) defribrinated horse blood (Scientific Laboratory Supplies, UK) was 
added, the bottle gently inverted to mix and the suspension then poured to petri 
dishes (Thermo Scientific, USA) to make 20 ml plates. All other growth media made 
in-house are described in Table 2.1. 
 
71 
 
2.2.3 Bacterial growth conditions 
Agar plates were routinely incubated at 37 °C under anaerobic conditions using a 
Don Whitley A85 anaerobic workstation filled with a mixture of 80 % nitrogen, 10 
% hydrogen and 10 % carbon dioxide (Don Whitley Scientific, West Yorkshire, 
United Kingdom).  
 
Table 2.1: Details of growth media made in-house 
 
Media Acronym Composition Supplemented 
Brain heart 
infusion (BHI) 
broth 
BHIS 
18.5 g Brain heart infusion 
2.5 g Yeast extract 
500 ml Milli-Q grade water 
*C. difficile supplement 
25 % L-cysteine 
Yeast peptone 
sporulation 
medium 
SM 
8 g Peptone 
4 g Yeast extract 
2.5 g NaCL 
500 ml Milli-Q grade water 
*C. difficile supplement 
1 ml Tween 80  
(0.2 % vol/vol) 
Blood agar with 
sodium 
taurocholate  
BA_ST 
100 µl 0.1 % filter sterilised 
sodium taurocholate spread over 
plate and allowed to air dry 
around a flame 
Nil 
 
*contains the antibiotics D-cycloserine and Cefoxitin to inhibit the growth of other 
bacterial organisms (OXOID). 
 
2.2.4 Storage of isolates 
All C. difficile isolates were stored at -80 °C in duplicate. Using a loop, biomass 
from 72 hour growth on blood agar was swept and inoculated into 1.5 cryovials 
containing 20 % glycerol, 20 % SM medium and 60 % molecular grade water. These 
were stored at -80 °C (New Brunswick Scientific, St Albans, UK). 
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2.2.5 Hospital ward environmental screen 
The infection control nurses at University Hospital Lewisham (UHL) performed an 
environmental screen by dampening Amies swabs (Medical Wire, UK) with sterile 
water prior to swabbing the following environmental surfaces; nurses station 
keyboard and telephone, mobile computer, patient bay door handle, sink tap, table 
ledge, window ledge, toilet arm rest, housekeeping room door handle, dirty utility 
rooms slipper-pan, wash bowl, apron holder, door handle, store room hoist, drugs 
trolley, medical notes trolley, pantry door handle, side-room door handle, side-room 
bed frame, side-room window ledge, side-room patient locker, side-room floor and 
side-room toilet. 
 
All swabs were referred to the CDRN regional London laboratory. To recover 
C. difficile, swabs were inoculated directly onto Brazier agar medium and incubated 
anaerobically for 48 hours. Brazier agar medium contains cholic acid to promote 
spore germination, and cycloserine and cefoxitin to inhibit the growth of other 
bacterial organisms. Growth from Brazier agar medium was subbed to blood agar 
and incubated anaerobically for 48 hours. Pure growth was subjected to PCR 
ribotyping (Section 2.3.1, Page 77). 
 
To enhance the recovery of C. difficile that maybe in small numbers, swabs were also 
inoculated into Robertson’s cooked meat medium (RCM) and incubated for five days 
at room temperature (RCM aids the recovery of bacterial organisms as it contains 
glucose for rapid, heavy growth of anaerobic bacteria). Following incubation, RCM 
broths were sub-cultured to Brazier agar medium and incubated anaerobically for 48 
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hours. This was followed by subbing to blood agar and PCR ribotyping (Section 
2.3.1, Page 77). 
 
To again enhance recovery of C. difficile by killing all vegetative cells from other 
genera and species that are likely to also be present on the swab samples, alcohol 
shock was performed on the RCM broths. Briefly, 1.5 ml RCM broth was added to a 
bijoux containing 0.5 ml saline. Equal volume, 2 ml of Industrialised Methylated 
Spirit (IMS) [VWR, USA]) was added to the bijoux which was vortexed and left to 
stand at room temperature for 45 – 60 minutes. After incubation, three drops from 
the lower layer of the bijoux was subbed to Brazier agar medium. This was followed 
by sub-culture to blood agar and subjected to PCR ribotyping (Section 2.3.1, Page 
77). 
2.2.6 Growth kinetic assays 
To measure the growth rates of C. difficile, 10 ml pre-equilibrated BHIS broth were 
inoculated with three colonies of blood agar culture and incubated at 37 °C 
anaerobically on a shaking platform (Orbital Shaker SSL1, Stuart
TM
 Staffordshire, 
UK) at 60 rpm for 24 hours. New cultures were made by inoculating fresh, pre-
equilibrated BHIS broths with 1/100 of the initial 24 hour culture. Every hour for the 
first 9 hours and then again at 24 hours, 1 ml aliquots of each new culture were 
removed and their optical density (OD) at λ590 (OD600) was measured in a 
spectrophotometer (WPA CO8000, Biochrom, UK).  
2.2.7 MIC assays 
Minimum Inhibitory Concentrations (MICs) of a panel of antibiotics were 
determined using the broth dilution method as previously described (Andrews, 
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2001). Briefly, isolates were grown on blood agar anaerobically for 48 hours. Ten ml 
aliquots of BHI broth with C. difficile supplement and cysteine were made in 20 ml 
universal containers (VWR, USA) and placed in the anaerobic cabinet and allowed to 
equilibrate anaerobically overnight. 
 
Antibiotics were reconstituted according to manufacturer’s guidelines. Stock 
antibiotic solutions were made by making 20 ml of 10 mg/ml stock in sterile water 
(0.2 g in 20 ml). A 1/10 dilution of the 10 mg/ml stock (1 ml / 9 ml sterile water) was 
then made. Ten antibiotic concentrations were made in a universal of 25 ml BHI 
broth; 256 µg/ml, 128 µg/ml, 64 µg/ml, 32 µg/ml, 16 µg/ml, 8 µg/ml, 4 µg/ml, 2 
µg/ml, 1 µg/ml and negative antibiotic control (broth only). Using a 24-well plate, 
990 µl of the antibiotic dilutions were aliquoted to appropriate wells and incubated 
anaerobically at 37 °C for 3 to 4 hours (including a well for the broth without 
antibiotic as a negative organism control). The 10 ml broths in the cabinet were 
inoculated with three colonies and incubated anaerobically (including an un-
inoculated broth as a negative control) on a shaking platform (Orbital Shaker SSL1, 
Stuart
TM
 Staffordshire, UK) at 60 rpm for 3 to 4 hours. Once an OD600 = 0.3 was 
reached, 10 µl of the 10 ml broth was aliquoted to the appropriate wells (including 
the un-inoculated broth). The plate was incubated anaerobically at 37 °C on a 
shaking platform at 60 rpm for 16 hours. Following this, the OD600 of each well were 
measured in a micro titre reader (Gen 5, BioTek, Vermont, USA) to ascertain the 
MIC. 
 
The following antimicrobials were tested for the range 1 to 256 µg/ml 1) chapter 4: 
metronidazole, vancomycin, erythromycin, lincomycin, fuscidic acid, naladixic acid, 
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rifampicin and rifaximin and 2) chapter 5: chloramphenicol, rifampicin, tetracycline, 
erythromycin, naladixic acid, gentamicin, teicoplanin and ampicillin. Breakpoints 
described by the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) were used to 
determine MICs (The European Committee on Antimicrobial Susceptibility Testing., 
2017, Clinical and Laboratory Standards Institute., 2013, Clinical and Laboratory 
Standards Institute., 2012). A well of broth with no organism or antibiotic was used 
as a negative control and the C. difficile PCR ribotype 017 reference strain M68 was 
used as a positive control (Section 2.1.2, Page 69).  
2.2.8 Vegetative cell and spore count assays 
Cultures were made by inoculating 10 ml pre-equilibrated BHIS broths with three 
colonies of 48 hours blood agar culture. These were incubated anaerobically at 37 °C 
on a shaking platform (Orbital Shaker SSL1, Stuart
TM
 Staffordshire, UK) at 60 rpm 
for 24 hours. New cultures were made by inoculating fresh, pre-equilibrated SM 
broths with a 1/20 dilution of the initial 24 hour culture. The ODs were measured 
until each new culture reached OD600 = 0.5. Fresh SM broths were inoculated with 
1/20 of the new culture and incubated at 37 °C anaerobically on a shaking platform 
at 60 rpm. After 24, 72 and 144 hours, for vegetative cell counts; 500 µl of culture 
were aliquoted to 1.5 ml microcentrifuge tubes, serially diluted in sterile 1 x 
phosphate buffered saline (PBS) and plated onto BA_ST. For spore counts, 500 µl of 
culture were aliquoted to 1.5 ml microcentrifuge tubes, incubated at 65 °C for 30 
minutes to heat inactivate the vegetative cells. The aliquots were serially diluted in 
sterile 1 x sterile PBS and plated onto BA_ST. All plates were incubated at 37 °C 
anaerobically. After 24 hours, colony counts were enumerated on plates and 
calculations performed to give colony forming units (cfu)/ml. 
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2.2.9 Disinfectant assays 
Cultures of pre-equilibrated, 10 ml, SM broths plus 0.2 % (vol/vol) Tween 80 were 
inoculated with three colonies of 48 hours blood agar culture.  These were incubated 
at 37 °C anaerobically on a shaking platform at 60 rpm for 16 hours. New cultures 
were made by inoculating fresh, pre-equilibrated SM broths plus 0.2 % (vol/vol) 
Tween 80 with 1/20 of the initial 16 hour culture and incubated at 37 °C 
anaerobically on a shaking platform at 60 rpm. After 24 hours, for each new culture, 
two 1 ml aliquots were removed to 1.5 ml microcentrifuge tubes; one was treated 
with 1 ml Achtichlor Plus disinfectant (EcoLab, UK) for 30 minutes and the other 
with 1 ml 1 x sterile PBS for 30 minutes. Each aliquot was centrifuged at 8,000 x g 
for 5 minutes, washed with 1 ml 1 x sterile PBS and centrifuged at 8,000 x g for 5 
minutes. The supernatant was removed and the pellet re-suspended in 1 ml sterile 1 x 
PBS. Each aliquot was serially diluted 1/10 in sterile 1 x PBS and 10 µl were 
inoculated onto BA_SD and incubated at 37 °C anaerobically. After 24 hours, colony 
counts were enumerated on plates and calculations performed to give cfu/ml. 
2.2.10  Phenotypic data analysis 
All statistical analyses of phenotypic data were carried out in GraphPad Prism 
software (California, USA), using One-Way and Two-Way analysis of variance 
(ANOVA) for individual comparisons and Tukey’s for multiple comparisons. A p 
value of less than 0.05 was reported as statistically significant (* p < 0.05; ** p < 
0.01; *** p < 0.001). 
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2.3 Molecular methods 
2.3.1 PCR ribotyping  
For DNA extraction, biomass from 48 hour blood agar growth were swept and re-
suspended into a 1.5 ml microcentrifuge tube containing 5 % (wt/vol) solution of 
Chelex-100 resin (BIO-RAD, USA) and heated to 100 ºC for 20 minutes. An un-
inoculated aliquot of Chelex-100 resin solution was also used as a negative 
extraction control. The suspension was separated by centrifugation at 13,000 x g for 
12 minutes and the supernatant aliquoted to a fresh 1.5 ml microcentrifuge tube. 
 
For PCR, 5 µl of the DNA extract was added to a 45 µl PCR mixture containing 25 
mM of each primer (Table 2.2), 2.5 U HotStar Taq DNA polymerase (Qiagen, UK), 
0.4 mM dNTPs (Fisher Scientific, UK) and 3.75 mM MgCl2 (Qiagen, UK) per 
reaction.  
 
Table 2.2: Primers used for PCR ribotyping 
 
Locus 
Primer 
Name 
Primer Sequence (5’-3’) 
Amplicon 
Size 
16S gene P3 CTGGGGTGAAGTCGTAACAAGG 
564 bps 
23S gene P5 GCGCCCTTTGTAGCTTGACC 
Purchased from Sigma Aldrich, UK. 
 
 
The reaction mixture was subjected to a PCR using a GeneAmp 9600 thermal cycler 
(Perkin-Elmer, Beaconsfield, UK). The PCR thermocycling conditions were 30 
cycles at 95 ºC for 1 minute, 92 ºC for 1 minute, 55 ºC for 1 minute and 72 ºC for 1.5 
minutes. This was followed by hold steps of 95 ºC for 1 minute, 55 ºC for 45 seconds 
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and 72 ºC for 5 minutes. The PCR ribotyping products were concentrated to 20 µl by 
heating at 75 ºC for 40 minutes. The PCR ribotyping products were separated by 
agarose gel electrophoresis using Ready Agarose precast 0.5 % Tris-acetate-
Ethylenediaminetetraacetic acid (TAE) agarose gels containing ethidium bromide 
(BIO-RAD, USA). This was performed in 3 % TAE buffer (BIO-RAD, USA) at 100 
mA for 3.5 hours alongside a 100 bp ladder (Invitrogen, UK). Banding patterns were 
analysed using GelCompar software (Applied Maths, Belgium). 
2.3.2 Multilocus sequence typing 
Genomic DNA (gDNA) was extracted either by cell lysis, phenol chloroform and 
ethanol precipitation or Tris-EDTA (TE) boilate methodology. 
 
Phenol chloroform methodology 
For cell lysis, overnight growth in BHIS was centrifuged at 4,000 x g for 5-10 
minutes at 4 ºC. The supernatant was discarded and the pellet lysed by resuspending 
in 3 ml ETDA. To make a lysate, 750 µl lysozyme (20 mg/ml 100 µl mutanolysin 
(10 KU/ml), 100 µl lysostaphin (5 mg/ml) and 20 µl RNase (100 mg/ml [Invitrogen, 
UK]) were added to the cell suspension and the lysate was incubated at 37 ºC for 1 
hour. This was followed by adding 90 µl Proteinase K (25 mg/ml) and 90 µl of 20 % 
Sodium Dodecyl Sulphate (SDS) to the lysate and this was incubated at 50 ºC for 1 
hour. 
 
Genomic DNA (gDNA) was extracted from the lysate by performing 
phenol:chloroform:isoamyl alcohol (25:24:1) and chloroform (24:1) washes in 15 ml 
phase lock gel light (PLG) tubes (5 PRIME, Scientific Laboratory Supplies, UK). All 
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PLG tubes were centrifuged prior to use at 4,000 x g for 2 minutes to prepare the gel 
in the tube as advised in the manufacturer’s instructions. 
 
The lysate was mixed with 3 ml of phenol:chloroform:Isoamyl Alcohol (25:24:1) in 
a PLG tube and vortexed for 10 seconds. The PLG was centrifuged at 4,000 x g for 5 
minutes at 4 ºC to separate the phases and the upper-phase supernatant from above 
the gel was transferred to a fresh PLG tube with 3 ml of phenol:chloroform:Isoamyl 
Alcohol (25:24:1) and the above step was repeated. The upper-phase lysate was 
transferred to a fresh PLG tube with 3 ml of chloroform, vortexed for 10 seconds and 
centrifuged at 4,000 x g for 5 minutes at 4 ºC and the above step repeated. The 
upper-phase supernatant was transferred to a 15 ml solvent safe tube containing 8 ml 
of chilled 100 % ethanol and incubated overnight at -20 °C. 
 
The gDNA from the phenol:chloroform:Isoamyl Alcohol (25:24:1) extraction was 
precipitated by centrifuged at 4,000 x g for 15 minutes at 4 ºC. The supernatant was 
discarded and the gDNA purified by adding 1 ml of 70 % ethanol and centrifuged at 
4,000 x g for 15 minutes at 4 ºC. The supernatant was again discarded and the pellet 
was washed by adding another 1 ml of 70 % ethanol and centrifuged at 4,000 x g for 
15 minutes at 4 ºC. The supernatant was discarded and the solvent safe tube was 
pulse-centrifuged and left to air-dry for 5 minutes. The DNA pellet was resuspended 
in 50-100 µl 1x TE buffer and left overnight at 4 °C. 
 
Tris-EDTA (TE) boilate 
Biomass from 48 hour blood agar culture were swept and re-suspended into a 1.5 ml 
microcentrifuge tube containing 1.5 ml TE and heated at 100 °C for 10 minutes. The 
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suspension was separated by centrifugation at 13,000 x g for 2 minutes and the 
supernatant aliquoted to a fresh 1.5 ml microcentrifuge tube. 
 
The quality of the gDNA was confirmed using agarose gel electrophoresis; products 
were visualised on a 1 % (wt/vol) TAE agarose gel resolved at 100 mV for 1 hour 
and stained with 1.5 µl of 0.5 µg/µl ethidium bromide solution (Promega, UK) in 
TAE buffer alongside a 100 bp ladder (Invitrogen, UK). 
 
MLST was performed using the scheme described by Griffiths et al., (Griffiths et al., 
2010). The primers used to detect seven housekeeping genes (adk, atpA, dxr, glyA, 
recA, sodA and tpi) are shown in Table 2.3. 
 
For each of the seven MLST loci, 50 µl PCR reactions were performed in 96-well 
plates. The PCR mixture contained 39.75 µl of molecular grade water, 5 µl of 10 x 
PCR buffer (Qiagen, UK), 1 µl of a 10 µM concentration of each forward and 
reverse primer, 1 µl of 10 mM deoxynucleoside triphosphate (dNTP) mix 
(Invitrogen, UK), 0.25 µl of HotStart Taq DNA polymerase (Qiagen, UK) and 2 µl 
of C. difficile gDNA. The MLST PCR was performed using a GeneAmp 9600 
thermocycler (Perkin-Elmer, UK) and thermocycling conditions were; 35 cycles at 
94 ºC for 15 seconds, 50 ºC for 1 minute, 72 ºC for 1 minute. This was followed by a 
hold step of 72 ºC for 7 minutes. 
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Table 2.3: Primers used for MLST 
 
Locus 
Primer 
Name 
Primer Sequence (5’-3’) 
Amplicon 
Size 
adk 
adk1F TTACTTGGACCTCCAGGTGC 
635 bps 
adk1R TTTCCACTTCCTAAGGCTGC 
atpA 
atpA1F TGATGATTTAAGTAAACAAGCTG 
674 bps 
atpA1R AATCATGAGTGAAGTCTTCTCC 
dxr 
dxr3F GCTACTTTCCATTCTATCTG 
525 bps 
dxr3R CCAACTCTTTGTGCTATAAA 
glyA 
glyA1F ATAGCTGATGAGGTTGGAGC 
625 bps 
glyA1R TTCTAGCCTTAGATTCTTCATC 
recA 
recA2F CAGTAATGAAATTGGGAGAAGC 
705 bps 
recA2R ATTCAGCTTGCTTAAATGGTG 
sodA 
sodA5F CCAGTTGTCAATGTATTCATTTC 
585 bps 
sodA5R ATAACTTCATTTGCTTTTACACC 
tpi 
tpi2F ATGAGAAAACCTATAATTGCAG 
640 bps 
tpi2R TTGAAGGTTTAACACTTCCACC 
Purchased from Invitrogen, UK. 
 
 
MLST PCR products were confirmed using agarose gel electrophoresis; these were 
visualised on a 1 % (wt/vol) agarose gel resolved at 100 mV for 1 hour and stained 
with 1.5 µl of 0.5 µg/µl ethidium bromide solution (Promega, UK). 
 
Once confirmed, the PCR products were purified by precipitation with 20 % 
polyethylene glycol (molecular weight, 8,000) and 2.5 M NaCl. The nucleotide 
sequences were determined for each DNA strand using the amplification primers in 
Table 2.3 and BigDye Ready Reaction Mix (Applied Biosystems, UK) as follows: 
each 10 µl sequencing reaction mixture comprised 2 µl of PCR amplicon, 4 µl of a 
1:15 dilution of either forward or reverse PCR primer (0.66 µM), 0.25 µl of BigDye 
Ready Reaction Mix, 1.875 µl of 5 x sequencing buffer (20 ml of stock solution 
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comprised 200 µl of 1 M MgCl2, 8 ml of 1 M Tris-HCl, pH 9 and 11.8 ml of 
molecular grade water and 1.875 µl of 5 x sequencing buffer (20 ml of stock solution 
comprised 200 µl of 1 M MgCl2, 8 ml of 1 M Tris-HCl, pH 9, and 11.8 ml of 
molecular biology-grade water) and 1.875 µl of molecular grade water.  
 
The reaction conditions were 30 cycles of 96 ºC for 10 seconds, 50 ºC for 5 seconds 
and 60 ºC for 2 minutes. Unincorporated dye terminators were removed by 
precipitation of the termination products with two volumes of ethanol and 0.1 
volume of sodium acetate (pH 5.2 [3M]) followed by vortexing and incubation at 
room temperature for 1 hour. The plate was centrifuged at 2,750 x g for 10 minutes, 
the resulting pellet was washed with 150 µl of 70 % ethanol and the plate was 
centrifuged at 2,750 x g for 10 minutes. The supernatant was carefully pipetted away 
and the pellet was allowed to air dry for 5 minutes. The pellets were resuspended 
with 10 µl Hi-Di Formamide (Thermo Scientific, USA). 
 
The precipitated PCR products were analysed on a ABI 3730 DNA analyser 
(Applied Biosystems, USA) and nucleotide sequences were extracted using Chromas 
v1.61 (Queensland, Australia). Allele designations were obtained by parsing forward 
and reverse sequencing reads through the C. difficile pubMLST batch profile query 
page which contains a database of all C. difficile MLST profiles 
(http://pubmlst.org/cdifficile/). Novel sequence types (n=18) and existing C. difficile 
pubMLST database sequence types (n=123) [82 previously published and 41 
unpublished and used with submitters permission]) were analysed using Multiple 
Alignment using Fast Fourier Transform (MAFFT) 
(http://mafft.cbrc.jp/alignment/software/) and Archeopteryx 
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(www.phylosoft.org/archeopteryx). Phylogenies were calculated by MAFFT and 
MrBayes (Ronquist and Huelsenbeck, 2003, Huelsenbeck and Ronquist, 2001). 
MAFFT used the neighbour-joining method (Saitou and Nei, 1987) using all 
ungapped sites with 1000 boot strap resamplings.  
 
2.3.3 Whole genome sequencing 
2.3.3.1 Genomic DNA extraction  
The gDNA extraction performed for WGS was a modification of the 
phenol:chloroform:Isoamyl Alcohol (25:24:1) methodology described in section 
2.3.2 for MLST. Ten millilitre BHIS broths were inoculated with three colonies from 
48 hour blood agar culture. An un-inoculated broth was also used as a negative 
extraction control. Broths were incubated anaerobically for 18 hours. The biomass 
was harvested by centrifugation of the broths at 4,000 x g for 10 minutes and the 
pellet was re-suspended in 10 ml sterile 1 x PBS. Centrifugation was repeated and 
the pellet was stored overnight at -20 ºC. The pellet was re-suspended in 800 µl fresh 
25 % sucrose in TE buffer and 100 µl of 20 mg/ml Lysozyme; this suspension was 
incubated at 37 ºC for 45 minutes. Forty microliters of 20 mg/ml Proteinase K, 1.2 µl 
of 100 mg/ml RNase A, 160 µl of 0.5 M EDTA pH8.0 (Na salt) and 100 µl of fresh 
10 % Sarkosyl (10 mg/ml) were added to the suspension which was left on ice for 1 
to 2 hours and then incubated in a 50 ºC water bath overnight. The lysate was made 
to 2 ml with TE buffer. In a fume hood, the 2 ml lysate was mixed with 2.5 ml 
phenol:chloroform:Isoamyl Alcohol (25:24:1) in a PLG tube and vortexed for 10 
seconds. The PLG tube was centrifuged at 4,000 x g for 15 minutes at 4 °C to 
separate the phases and the upper-phase supernatant from above the gel was 
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transferred a fresh PLG tube with 2.5 ml phenol:chloroform:Isoamyl Alcohol 
(25:24:1) and the above step repeated but with centrifugation for 10 minutes.  
 
The upper-phase supernatant was transferred to a fresh PLG tube containing equal 
volume of chloroform, vortexed for 10 seconds and centrifuged at 4,000 rpm for 5 
minutes. This step was repeated and the upper-phase supernatant was transferred to a 
15 ml solvent safe tube containing 2.5 volume of chilled ethanol and incubated at 
-20 ºC for 15 minutes to precipitate the DNA. The precipitate was centrifuged at 
4,000 x g for 10 minutes, supernatant gently pipetted away and the pellet washed 
with 1 ml chilled 70 % ethanol and centrifuged at 4,000 x g for 15 minutes again. 
The supernatant was gently pipetted away and the solvent safe tube allowed to air 
dry for 5 minutes. The pellets were re-suspended in 120-300 µl of 1 x TE buffer and 
allowed to re-suspend at 4 ºC overnight. gDNA was confirmed using agarose gel 
electrophoresis; the presence of a thick, smeary high molecular weight band was 
visualised on 0.5 % (w/v) agarose gel resolved at 110 V for 50 minutes and stained 
with 1.5 µl of 0.5 µg/µl ethidium bromide solution.  
2.3.3.2 DNA quantification using the Qubit Fluorometer System 
To obtain an accurate quantification of the gDNA, the Qubit Fluorometer System 
(Invitrogen, UK) was used according to manufacturer’s instructions. gDNA samples 
were quantified using the Qubit dsDNA broad range and high sensitivity assay kits 
(Invitrogen, UK) as required. Two standards were used for each batch of samples 
tested and for each DNA sample or standard, a total volume of 200 l was prepared 
by diluting the sample or provided standard in Qubit working solution. Qubit 
working solution was made for each standard and gDNA sample by diluting the 
Qubit reagent 1:200 in Qubit buffer. The assay tubes were then prepared by adding 
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10 l of standard or 2 l gDNA sample 190 μl or 198 l of working solution 
respectively. These were vortexed for 2-3 seconds and incubated at room 
temperature for 2 minutes. Assay tubes were loaded onto the Qubit Fluorometer, 
their absorbance was read and gDNA concentration in the original suspension was 
calculated. 
2.3.3.3 Library construction and sequencing 
Library construction and sequencing was performed using an Illumina HiSeq 2000 
Sequencing System (Illumina, California, USA) by the Pathogen Genomics 
Sequencing Team at the Wellcome Trust Sanger Institute (Cambridge, UK) and by 
M. Cairns using a Illumina MiSeq Sequencing System (Illumina, California, USA) at 
the London School of Hygiene and Tropical Medicine (LSHTM). To ensure the data 
from both platforms and different runs was consistent, the control strain M68 was 
processed with each and every sequencing run. Libraries were created as previously 
described (Harris et al., 2010) or using the Nextera XT kit (Illumina, California, 
USA) according to the manufacturer’s instructions. The Nextera XT DNA library 
preparation consisted of five main stages. The main stages are described and 
illustrated in Figures 2.1 and 2.2. In order to check the final size and concentration of 
DNA libraries made after clean-up, the libraries were analysed using the Agilent 
2100 Bioanalyzer (Agilent Technologies, UK [Section 2.3.3.4, Page 88]). 
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Figure 2.1: Flowchart of the Nextera XT assay for WGS  
 
Courtesy of illumina (IIIumina ®. 2016). 
Tagmentation of gDNA (Figure 2.2) 
Uses an engineered transposome to simultaneously 
fragment and tag (“tagment”) the gDNA with 
adapter sequences 
PCR Amplification (Figure 2.2) 
The tagmented DNA is amplified using a limited-
cycle PCR program. The PCR step adds Index 
adapters and sequences required for cluster 
formation 
PCR Clean-Up 
The amplified library is cleaned-up using AMPure 
XB beads (Beckman Coulter, UK) to purify the 
library DNA and provide a size selection step that 
removes short library fragments 
Library Normalisation 
Normalises the quantity of each library to ensure 
more equal library representation in your pooled 
sample 
Library Pooling 
The libraries were pooled to combine equal 
volumes of normalized libraries in a single tube 
Load onto MiSeq 
The library pool was diluted and heat-denatured 
before loading libraries onto the sequencing run 
Agilent 2100 
Bioanalyzer 
Check the final size 
and concentration of 
DNA libraries 
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A = Nextera XT transposome with adapters combined with template DNA 
B = Tagmentation to fragment and add adapters  
C = Limited cycle PCR to add sequencing primer sequences and indices 
 
 
 
 
Figure 2.2: Illustration of the Nextera XT assay tagmentation and PCR 
amplification steps 
 
A figure that provides an illustration of the Nextera XT assay tagmentation and PCR 
amplification steps for WGS. Courtesy of illumina (IIIumina ®. 2016). 
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2.3.3.4 Validation of libraries using the Agilent Bioanalyzer 2100 
The Agilent 2100 Bioanalyzer (Agilent Technologies, UK) and Agilent High 
Sensitivity Kit (Agilent Technologies, UK) were used according to the 
manufacturer’s instructions. Briefly, gel-dye mix was prepared by equilibrating DNA 
dye and DNA gel matrix to room temperature for 30 minutes, vortexing for 10 
seconds and pulse centrifugation. Twenty-five microliters of DNA dye concentrate 
was added to the DNA gel matrix vial and vortexed for 10 seconds. The solution was 
applied to a fresh spin filter and centrifuged at 2,240 x g for 15 minutes. Following 
centrifugation, the spin filter was discarded and 9 l of gel-dye mix was added to the 
appropriate well of a DNA chip which was placed on the chip priming station. The 
syringe was set to 1 ml and then pressure was slowly applied to the syringe to 
distribute the gel around the chip. Following priming, DNA marker, DNA ladder and 
sample/s were added to the appropriate wells. The chip was vortexed for 60 seconds 
at 2,400 rpm, loaded onto and analysed using the Bioanalyzer. This illustrated traces 
of successfully sequenced libraries whereby a typical library would show a broad 
size distribution of between ~250 and 1000 bps. Libraries were then normalised, 
pooled and loaded onto the MiSeq according to the manufacturer’s instructions 
(Figure 2.1). 
2.3.3.5 Whole genome sequence data mapping and assembly 
A variety of freely available software packages were used to process the sequence 
data, these are either referenced or a Uniform Resource Locator (URL) is provided 
for reference (Table 2.4). 
 
89 
 
Table 2.4: Software packages used in this thesis for processing WGS data 
 
Software Function URL or Reference 
Trimmomatic Trims and crops sequences http://www.usadellab.org/cms/index.php?page=trimmomatic 
BWA MEM Maps reads (Li et al., 2009) 
SAMtools Reading/writing/editing/indexing/viewing SAM/BAM/CRAM format http://www.htslib.org/ 
VCFtools Identifies SNPs http://vcftools.sourceforge.net/downloads.html 
Velvet Assembles short reads (Zerbino, 2010) 
Velvet Optimiser Multi-threaded Perl script http://bioinformatics.net.au/software.velvetoptimiser.shtml 
BLAST Search for sequence and amino acid similarity http://www.ncbi.nlm.nih.gov 
MAFFT Multiple sequence alignment http://mafft.cbrc.jp/alignment/software/ 
Perl Programming language https://www.perl.org/get.html 
R Statistical computing and graphics R development core team, https://www.r-project.org/ 
ABACAS Contiguation of assembled sequences (Assefa et al., 2009) 
Prokka Annotation of prokaryotic genomes (Seemann, 2014) 
RaXML Maximum-likelihood based phylogenetic inference (Stamatakis, 2014) 
BEAST Bayesian analysis of molecular sequences (Drummond et al., 2012) 
mclust Cluster analysis (Fraley et al., 2012) 
Artemis Displays sequence features and results of analysis http://www.sanger.ac.uk/science/tools/ 
ACT Displays pairwise comparisons between two or more sequences http://www.sanger.ac.uk/science/tools/ 
 
ABACAS - Algorithm Based Automatic Contiguation of Assembled Sequences 
ACT - Artemis Comparison Tool 
BEAST - Bayesian Evolutionary Analysis Sampling Tree 
BLAST - Basic Local Alignment Search Tool 
BWA MEM - Burrow-Wheeler Aligner 
MAFFT - Multiple Alignment using Fast Fourier Transform 
mclust - Normal Mixture Modeling for Model-Based Clustering, Classification, and Density Estimation  
RaXML - Randomised Accelerated Maximum Likelihood 
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The sequence data were processed and quality controlled according to a standard 
pipeline as previously described (Preston et al., 2014). Briefly, FASTQ-formatted 
sequencing reads were quality controlled with a minimum-quality Phred score of 30 
(as a rolling average over 4 bases) using Trimmomatic; a fast, multithreaded 
command line tool that can trim and crop FASTQ data. The resulting reads were 
mapped, using BWA-MEM, a software package for mapping sequences against a 
reference genome, in this case, against the control strain M68 reference genome. 
SNP mutations in the samples that had read depths of 60 and had 70 % of reads 
identified with the same allele (99.8 % of SNPs were supported by ~90 % of 
contributing reads) and a minimum quality score of 30 were identified using 
Sequence Alignment Map (SAM) tools and VCFtools software. 
 
The methodology used in this thesis for SNP detection applies a core-genome 
methodology; the core-genome refers to genes common to all strains in a species. 
SNPs in ‘core genes’ were determined by aligning sequences against the reference 
control genome; GenBank accession number FN668375 (He et al., 2010). If there 
were regions of sequence/s present in the genome of the ‘test’ strain/s but absent in 
the reference control genome, then these regions were not analysed for SNPs. The 
methodology used in this thesis for SNP detection also does not read regions of 
repetitive DNA (sequence patterns that occur in multiple copies throughout the 
genome). Therefore, any SNPs in repetitive regions are not detected.  
 
Velvet and Velvet Optimiser were used to de novo assemble the trimmed reads into 
contiguous pieces of DNA sequence. A multi-threaded Perl script was used for the 
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optimisation of Velvet. Perl is a programming language that facilitates analysis, 
manipulation and graphical presentation of experimental data. 
2.3.3.6 BLAST 
Searches for sequence and amino acid similarity were routinely performed using 
BLAST, specifically the blastn and blastp algorithms. 
2.3.3.7 Sequence alignment 
Sequence alignments were performed using the multiple sequence alignment 
program ‘Multiple alignment program for amino acid of nucleotide sequences’ 
(MAFFT). 
2.3.3.8 Nucleotide sequence accession numbers 
All Illumina sequence data from this thesis were submitted to the European 
Nucleotide Archive under accession numbers ERP009770 and PRJEB11868. 
2.3.3.9 Phylogenetic analysis 
Pipeline, post-analyses, genetic, phylogenetic and phylogeographic analysis were 
carried out using Perl and R. Algorithm Based Automatic Contiguation of 
Assembled Sequences (ABACAS) software was used to contiguate assembled 
contigs, and based on the control strain M68 reference sequence, Prokka, a software 
tool was used for rapid genome annotation. 
 
Maximum-likelihood phylogenetic trees were generated using Randomised 
Accelerated Maximum Likelihood (RaXML) and BEAST software to produce a SNP 
phylogeny from the SNPs as well as geographical and temporal data combined in 
phylogeographic analysis and mclust software for maximum likelihood cluster 
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analysis. A minor allele frequency (MAF) of less than 1 % were used to remove any 
SNPs that may be associated with recombination and which would mask the true 
phylogeny, and SNPs within 1 bp distance of an insertion or deletion (absent from 
the reference strain M68) site were excluded from further analysis.  
2.3.3.10 Identification of genomic deletions and insertions 
To investigate genomes for indication of horizontal gene transfer, a key mechanism 
driving C. difficile evolution, programmatic and visual inspection of the comparisons 
was performed using the Artemis Comparison Tool (ACT), a JAVA application that 
displays pairwise comparisons between two or more DNA sequences which can be 
used to analyse regions of similarity and differences between genomes. Artemis 
software was also used to browse genomes and visualise sequence features. 
Insertions were regions of DNA that were present in a test strain but absent from the 
reference control M68 whereas deletions were regions of DNA that were present in 
the control strain M68 but absent from a test strain. 
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Chapter 3 
Characterisation of C. difficile strains isolated 
from diverse sources and geographical 
locations using MLST and PCR ribotyping 
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3 Characterisation of C. difficile strains isolated from 
diverse sources and geographical locations using MLST and 
PCR ribotyping 
3.1 Statement of contribution 
Genomic DNA extraction and PCR ribotyping was performed by M. Cairns, MLST 
PCR assays and MLST designations were performed by Professor Wren’s 
Laboratory Research Group at the LSHTM collectively (five individuals) including 
M. Cairns (20%) and collation of data was performed by M. Cairns.  
 
3.2 Introduction 
PCR ribotyping, PFGE, REA and MLVA are valuable molecular tools for outbreak 
investigation where rapid genotyping of C. difficile strains is necessary for infection 
control purposes. However, the genome targets used in these methods are too 
discriminatory to resolve the phylogenetics that would facilitate tracing the origins of 
C. difficile. For example, with PCR ribotyping, recombination of repeats present in 
the intergenic spacer region between the 16S and 23S rRNA might lead to the 
formation of a novel PCR ribotype without a clear phylogenetic link to the PCR 
ribotype prior to recombination. However, recombination in a MLST housekeeping 
gene target would change the allelic profile on a single locus only; a novel sequence 
type would still be closely related to the original sequence type maintaining the 
phylogenetic link making MLST useful for phylogenetic studies. 
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Few studies have investigated C. difficile using MLST. Lemee, et al., developed the 
first MLST scheme for C. difficile and investigated a collection of 72 isolates from 
various hosts, geographic sources and toxigenic types (Lemee et al., 2004). They 
demonstrated that C. difficile had a predominantly clonal population structure 
consisting of stable subpopulations that are globally disseminated. They found no 
correlation between sequence type and geographic origin nor were they able to 
characterise any host specificity but they did find toxin A-B+ isolates shared the 
same sequence type. The Lemee group further utilised MLST and examined a 
collection of 29 isolates selected as representative of the main clusters defined by 
MLST in their previous study (Lemee et al., 2005) and confirmed the finding from 
their previous study that toxin A-B+ strains form an individual lineage. Another 
MLST investigation by Griffiths, et al., confirmed toxin A-B+ strains to form an 
individual lineage and additionally identified a further four different phylogenetic 
lineages of C. difficile that contained common PCR ribotypes; 027, 078, 023 and a 
lineage containing multiple mixed PCR ribotypes (Griffiths et al., 2010). A larger 
study tested a collection of 1290 isolates from humans with CDI between September 
2006 and December 2009 (both hospital and community) and confirmed the clonal 
population structure and presence of five phylogenetic lineages (Dingle et al., 2011a) 
depicted in Figure 1.6, Page 55. 
 
During this time, comparative phylogeny using whole genome microarray analysis 
also identified four clonal lineages made up of PCR ribotypes; 017, 027 and 078 and 
a heterogeneous grouping of mixed PCR ribotypes (Stabler et al., 2006). A WGS 
study based on SNPs in conserved core genes also confirmed the existence of these 
four phylogenetic lineages (He et al., 2010) and all three studies found PCR ribotype 
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078 to be highly divergent from all other PCR ribotypes (Griffiths et al., 2010, 
Stabler et al., 2006, He et al., 2010). MLST, whole genome microarray analysis and 
WGS SNP analysis, although different molecular approaches, concur that there are at 
least four phylogenetic lineages of C. difficile. 
 
PCR ribotype 078 which forms a highly divergent lineage through MLST analysis 
has been associated with strains isolated from non-human sources including animals 
and food for human consumption (Jhung et al., 2008, Gould and Limbago, 2010, 
Songer et al., 2009). However, only few studies have shown that strains of PCR 
ribotype 078 isolated from human and animal sources are similar in genotype using 
typing methodologies other than PCR ribotyping; strains from humans and animals 
have been found related by MLVA (Goorhuis et al., 2008) and MLST (Debast et al., 
2009).  There are no reports detailing the relatedness of strains of PCR ribotype 078 
from food sources using typing methodologies other than PCR ribotyping.  
 
Outbreak strains from the UK, USA and Canada were found to be due to the 
dissemination of a strain of PCR ribotype 027, sequence type 1 (Killgore et al., 2008) 
and a global collection of PCR ribotype 027 strains were found to be clonal (He et 
al., 2013). However, little is known about the phylogeny of other PCR ribotypes and 
sequence types when comparing strains from different geographical locations. 
 
Inter-laboratory comparisons between sequence types, PCR ribotypes, NAP types 
and REA types would be useful however the adequacy of their correlation is 
unknown. Recent to our study Tenover et al., showed that that there is poor 
correlation, with only 84/92 PCR ribotype 027 isolates were NAP1 by PFGE and BI 
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by REA (Tenover et al., 2011). MLST studies have found correlation between 
individual lineages, PCR ribotypes and sequence types (i.e. lineage 2, PCR ribotype 
027 and sequence type 1). However, similarities in PCR ribotyping banding patterns 
have been reported between PCR ribotypes 126 and 078 (Spigaglia et al., 2010) and 
078 with 033, 066 and 045 (Rupnik et al., 2001). It is unknown if these PCR 
ribotypes are similar in their ancestry and share the same MLST sequence type which 
would suggest the occurrence of micro-diversity in the individual lineages. 
 
 
3.3 Hypotheses of the research described in this chapter 
Prior to this investigation, MLST studies on C. difficile had focused on isolates from 
either; various hosts and geographic sources, or hospital and community and various 
PCR ribotypes. No MLST study had yet tested a collection of isolates encompassing 
all of these variables nor had a study compared the C. difficile sequence types of 
strains isolated between human, animal and food or varying geographical origins. By 
testing a larger and more varied collection of strains would provide robust evidence 
to support the number of phylogenetic lineages of C. difficile previously identified. 
By performing MLST on strains of C. difficile isolated from animals and relating to 
strains isolated from humans and food sources will enable more in-depth associations 
to be made and may concur with PCR ribotyping data that has shown strains isolated 
from humans, animals and food sources to be related. This has significant 
implications with regards to transmission and zoonosis. Performing MLST and PCR 
ribotyping on strains isolated from various geographical locations will help identify 
clonal clusters associated with global spread which may infer how the species is 
evolving and if selective pressure has played a role. Finally, by examining the 
relatedness of PCR ribotypes, MLST sequence types and REA types will 
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demonstrate how well these typing techniques correlate which will have implications 
for inter-laboratory comparisons globally. This study was designed to test the 
following hypotheses: 
 
Chapter 3: hypothesis 1 
Application of MLST to a large collection of C. difficile isolates from diverse 
sources, geographical origin and PCR ribotype will retain the five distinct 
phylogenetic lineages observed in previous studies (Lemee et al., 2004, Lemee et al., 
2005, Dingle et al., 2011a). 
 
Chapter 3: hypothesis 2 
C. difficile strains isolated from human, animal and food origin are not 
phylogenetically distinct by MLST.  
 
Chapter 3: hypothesis 3 
C. difficile strains isolated from different geographical origin are phylogenetically 
distinct by MLST.  
 
Chapter 3: hypothesis 4 
Molecular characterisation of C. difficile using MLST, PCR ribotyping and REA 
provides adequate correlation for inter-laboratory comparison. 
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3.4 Results 
A total of 385 C. difficile isolates were collated from collaborators (Page 27) and 
breakdowns of the isolates are illustrated in the following sections with details of 
alleles, provider, source, geographical location and isolation date shown in Appendix 
1, Page 229.  All isolates were propagated on appropriate culture media (Sections 
2.2.2, Page 70 and 2.2.3, Page 71) from which genomic DNA was extracted using 
methods described for PCR ribotyping and MLST (Sections 2.3.1, Page 77 and 2.3.2, 
Page 78 respectively). PCR ribotyping was performed by PCR amplification and 
agarose gel electrophoresis (Section 2.3.1, Page 77) and MLST was performed by 
PCR amplification, agarose gel electrophoresis and sequencing (Section 2.3.2, Page 
78). Sequence types were constructed from this data and used to elucidate the 
phylogenetic relatedness of the strain panel and answer the hypotheses under 
analysis. 
3.4.1 Analysis of C. difficile isolated from various sources, geographical 
origin using PCR ribotyping 
PCR ribotyping and agarose gel electrophoresis was performed on all 385 isolates 
with reference strains R20291 (PCR ribotype 027) and M68 (PCR ribotype 017) used 
as controls. PCR analysis identified 68 different PCR ribotypes (319/385) and found 
66 isolates (66/385) to be non-typeable (Table 3.1).  
 
 
 
 . 
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Table 3.1: Number and proportion of isolates by PCR ribotype 
 
PCR ribotype Number of isolates Percentage of isolates 
078 107 27.8% 
027 53 13.8% 
001 16 4.2% 
002 16 4.2% 
106 10 2.6% 
126 10 2.6% 
017 9 2.3% 
015 7 1.8% 
014 5 1.3% 
023 5 1.3% 
050 4 1.0% 
237 4 1.0% 
005 3 0.8% 
010 3 0.8% 
012 3 0.8% 
087 3 0.8% 
127 3 0.8% 
262 3 0.8% 
020 2 0.5% 
054 2 0.5% 
081 2 0.5% 
094 2 0.5% 
176 2 0.5% 
*Other 45 11.7% 
Nontypeable 66 17.1% 
TOTAL 385 100% 
 
*Forty-five isolates were of other PCR ribotypes with only one isolate; 003, 009, 
011, 013, 018, 021, 022, 026, 029, 030, 031, 033, 036, 042, 046, 052, 053, 059, 062, 
064, 070, 085, 097, 107, 111, 116, 118, 135, 139, 140, 186, 196, 212, 216, 239, 243, 
259, 264, 268, 271, 274, 280, 281, 282 and 291. 
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3.4.2 Analysis of C. difficile isolated from various sources, geographical 
origin using MLST 
MLST was performed on all 385 isolates with reference strains R20291 (PCR 
ribotype 027) and M68 (PCR ribotype 017) used as controls. MLST analysis 
identified 48 known sequence types (365/385) and found 18 sequence types (20/385) 
to be novel (Table 3.2).  
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Table 3.2: Number and proportion of isolates by sequence type 
 
Sequence type Number of isolates Percentage of isolates 
11 155 40.3% 
1  61 15.8% 
3 25 6.5% 
8 12 3.1% 
42 10 2.6% 
37 9 2.3% 
35 6 1.6% 
2 6 1.6% 
5 6 1.6% 
6 5 1.3% 
44 5 1.3% 
10 4 1.0% 
15 4 1.0% 
55 4 1.0% 
63 4 1.0% 
48 3 0.8% 
54 3 0.8% 
61 3 0.8% 
12 2 0.5% 
13 2 0.5% 
17 2 0.5% 
18 2 0.5% 
26 2 0.5% 
33 2 0.5% 
41 2 0.5% 
43 2 0.5% 
46 2 0.5% 
67 2 0.5% 
*Other 20 5.2% 
**Novel 20 5.2% 
TOTAL 385 100% 
 
*Twenty isolates were of other sequence types with only one isolate; 7, 79, 716, 721, 
722, 729, 732, 734, 739, 745, 749, 751, 752, 753, 756, 757, 762, 64, 66 and 86. 
 
**Eighteen isolates were novel sequence types with one isolate; 131, 132, 133, 134, 
135, 136, 137, 138, 140, 141, 142, 143, 144, 145, 146, 147, 148 and 139 with three 
isolates. 
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3.4.3 Analysis of PCR ribotype and MLST sequence type associations 
To confirm known associations between sequence type and PCR ribotype profiles 
already reported and to identify novel associations, PCR ribotyping and MLST 
analysis data were collated and compared. Of those isolates with a PCR ribotype 
designated (319/385), 39 PCR ribotype/sequence type associations previously 
reported were found (Table 3.3) and 46 novel PCR ribotype/sequence type 
associations were revealed (Table 3.4). 
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Table 3.3: PCR riboype and sequence type associations previously identified 
 
PCR ribotype Sequence type Number of isolates 
078 11 106 
027 1 53 
001 3 15 
002 8 10 
106 42 9 
017 37 8 
015 44 4 
023 5 4 
010 15 3 
012 54 3 
015 10 3 
005 6 2 
014 2 2 
020 2 2 
050 18 2 
054 43 2 
262 3 2 
003 57 1 
009 3 1 
013 45 1 
014 49 1 
018 17 1 
021 56 1 
022 66 1 
023 22 1 
026 7 1 
046 35 1 
050 16 1 
053 63 1 
064 33 1 
070 55 1 
081 9 1 
085 39 1 
097 21 1 
118 42 1 
139 52 1 
140 26 1 
186 51 1 
216 33 1 
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Table 3.4: Novel PCR riboype and sequence type associations 
 
PCR ribotype Sequence type Number of isolates 
126 11 10 
237 11 5 
002 35 4 
127 11 3 
087 46 2 
094 12 2 
176 1 2 
002 2 1 
002 48 1 
002 146 (novel) 1 
005 131 (novel) 1 
011 138 (novel) 1 
014 13 1 
014 132 (novel) 1 
017 86 1 
029 137 (novel) 1 
030 48 1 
031 29 1 
033 11 1 
036 62 1 
042 6 1 
050 6 1 
052 136 (novel) 1 
059 53 1 
062 44 1 
081 139 (novel) 1 
087 145 (novel) 1 
106 135 (novel) 1 
107 139 (novel) 1 
111 140 (novel) 1 
116 10 1 
135 41 1 
196 144 (novel) 1 
212 5 1 
239 147 (novel) 1 
243 139 (novel) 1 
259 141 (novel) 1 
262 143 (novel) 1 
264 142 (novel) 1 
268 3 1 
271 6 1 
274 133 (novel) 1 
280 11 1 
281 11 1 
283 134 (novel) 1 
291 148 (novel) 1 
 
 
 
 
107 
 
Some PCR ribotypes were associated with multiple sequence types and some 
sequence types were associated with multiple PCR ribotypes. These are listed in 
Tables 3.5 and 3.6 respectively. 
 
 
 
Table 3.5: PCR riboype and associated sequence type/s 
 
PCR ribotype Associated sequence types 
001 3 
002 2, 8, 35, 48, 146  
003 12, 57 
005 6, 72, 89, 90, 131 
009 3 
010 15 
011 36, 77, 138  
012 54 
013 45, 71, 78 
014 2, 13, 14, 49, 50, 132 
015 10, 44 
017 37, 86 
018 17 
019 67 
020 2, 28, 68 
021 56, 70 
022 66 
023 5, 22, 25 
026 7 
027 1 
029 137 
030 48 
031 29 
033 11 
035 40 
036 1, 62 
038 48 
039 26 
042 6 
046 35 
050 6, 16, 18 
052 136 
053 63 
054 43 
056 34, 58 
059 53 
060 38 
062 44, 75 
063 5 
064 33 
066 11 
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PCR ribotype Associated sequence types 
067 27 
070 15, 55 
072 3, 69 
076 2 
078 11 
081 9, 139 
085 39 
087 46, 145 
094 12 
097 21 
103 53, 73, 76 
104 48 
106 41, 42, 135  
107 139 
110 10 
111 140 
115 3 
116 10 
118 42 
126 11 
127 11 
129 13 
135 41 
137 4 
138 23 
139 52 
140 26 
153 32 
159 8 
174 42 
176 1 
186 51 
191 46 
194 41 
196 144 
202 20, 24 
212 5 
216 33 
220 2 
224 65 
225 12 
228 92 
237 11 
239 147 
243 139 
259 51, 141 
262 3, 143 
264 142 
268 3 
271 6 
274 133 
280 11 
281 11 
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PCR ribotype Associated sequence types 
283 134 
291 148 
305 3 
316 59 
319 74 
320 46 
321 41 
323 31 
326 91 
336 60 
 
 
Those underlined are novel PCR ribotype/sequence type associations and those in 
bold are novel sequence types found in our study. 
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Table 3.6: Sequence types and associated PCR ribotype/s 
 
Sequence type Associated PCR ribotypes 
1 027, 176 
2 002, 014, 020 
3 001, 009, 262, 268 
5 023, 212 
6 005, 042, 050, 271 
7 026 
8 002 
9 081 
10 015, 116 
11 066, 078, 126, 127, 237, 280, 281 
12 094 
13 014 
15 010 
16 050 
17 018 
18 050 
21 097 
22 023 
26 140 
29 031 
33 064, 216 
35 002, 046 
37 017 
39 085 
41 135 
42 106, 118 
43 054 
44 015, 062 
45 013 
46 087 
48 002, 030 
49 014 
51 186 
52 139 
53 059 
54 012 
55 070 
56 021 
57 003 
62 036 
63 053 
66 022 
86 017 
131 005 
132 014 
133 274 
134 283 
135 106 
136 052 
137 029 
138 011 
111 
 
Sequence type Associated PCR ribotypes 
139 081, 107, 243 
140 111 
141 259 
142 264 
143 262 
144 196 
145 087 
146 002 
147 239 
148 291 
 
Those underlined are novel PCR ribotype/sequence type associations and those in 
bold are novel sequence types found in our study. 
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3.4.4 Phylogeny of C. difficile isolated from various sources, 
geographical origin, PCR ribotype and MLST sequence type 
Previous MLST studies identified five distinct phylogenetic lineages of C. difficile 
that contained common PCR ribotypes; 027, 078, 017, 023 and a lineage containing 
multiple mixed PCR ribotypes (Lemee et al., 2004, Lemee et al., 2005, Griffiths et 
al., 2010, Dingle et al., 2011a). To determine if the five distinct phylogenetic 
lineages observed in previous studies would be maintained when applying MLST to 
a large, diverse collection of C. difficile isolates, phylogenetic analysis was 
performed using the pubMLST database (http://pubmlst.org/cdifficile/) and 
calculating phylogenies using MAFFT and MrBayes. Analysis comprised of; 82 
previously published sequence types, 41 unpublished sequence types (used with the 
submitter’s permission), and the 18 novel sequence types found in our study (Table 
3.7). Phylogenetic analysis using the sequence types listed in Table 3.7 was used to 
investigate the relative evolutionary relatedness of sequence types and the resultant 
phylogeny is depicted in Figures 3.1 and 3.2. 
 
 
 
Table 3.7: Sequence types used for MLST analysis 
 
Sequence types learnt from: Sequence Type 
Sequence types already in the 
MLST database 
 
1,  2,  3,  4,  5,  6,  7,  8,  9,  10,  11,  12,  13,  14,  15,  16,  17,  18,  
19,  20,  21,  22,  23,  24,  25,  26,  27,  28,  30,  31,  32,  33,  34,  35,  
36,  37,  38,  39,  40,  41,  42,  43,  44,  45,  46,  48,  49,  50,  51,  52,  
53,  54,  55,  56,  57,  58,  59,  60,  63,  65,  66,  67,  68,  69,  70,  71,  
72,  73,  74,  75,  76,  77,  78,   89,  90,  91,  92,  102,  103,  104,  105 
and  106 
 
Sequence types used with 
submitters permission 
 
29,  47,  61,  62,  64,  79,  80,  81,  82,  83,  84,  85,  86,  87,  88,  93,  
94,  95,  96,  97,  98,  99,  100,  101,  107,  108,  109,  110,  111,  
112,  113,  114,  115,  116,  117,  118,  119,  120,  121,  122 and  123 
 
Sequence types novel to this 
study 
 
131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 
145, 146, 147 and 148 
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(A) 
(B) 
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Figure 3.1: Relative evolutionary relatedness of the five main lineages of C. 
difficile based on MLST analyses 
 
Data for figure collated by M. Cairns, figure produced by Dr R. Stabler (LSHTM) 
and adapted from a publication by Stabler et al., (Stabler et al., 2012).  
 
(A) Overview of phylogeny and (B) details of lineage 5. 
 
Branch colouring; black = lineage 1 (mixed PCR ribotypes & sequence types), red = 
lineage 2 (sequence type 1/PCR ribotype 027), blue = lineage 3 (sequence type 
22/PCR ribotype 023), orange = lineage 4 (sequence type 37/PCR ribotype 017) and 
green = lineage 5 (sequence type 11/PCR ribotype 078). The key sequence types for 
each lineage are in bold. 
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Figure 3.2: Overview of phylogeny of C. difficile based on MLST analyses  
 
An overview of the relative evolutionary relatedness of the five main lineages of C. 
difficile based on MLST analysis. Data for figure collated by M. Cairns, figure 
produced by Dr R. Stabler (LSHTM) and adapted from a publication by Stabler et 
al., (Stabler et al., 2012). The figure includes significant genotypic and/or phenotypic 
characteristics for the key PCR ribotypes for the given lineage where known. 
 
Sequence type 1/PCR ribotype 027 
Toxin A+B+ 
Associated with global, clonal outbreaks 
and severe CDI 
Sequence type 11/PCR ribotype 078 
Toxin A+B+ 
Associated with infection in animals and 
contamination of food for human consumption 
Sequence type 22/PCR ribotype 023 
Toxin A+B+ 
Associated with severe CDI  
Sequence type 37/PCR ribotype 017 
Toxin A-B+ 
A predominant cause of CDI in Asia 
Mixed sequence types & PCR ribotypes 
Toxin A+B+ 
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Our data indicate that the five distinct phylogenetic lineages of C. difficile observed 
in previous studies are maintained when applying MLST to a larger collection of 
isolates from diverse sources, geographical origin and PCR ribotype (Figures 3.1 and 
3.2). 
 
Lineage 1 (139/365) consisted of 51 sequence types which were heterogeneous in 
terms of PCR ribotypes. Lineage 2 consisted of 14 sequence types which can be sub-
divided into two sublineages; a sequence type 1 sublineage (2i) and a sequence type 
32 sublineage (2ii). Sublineage 2i contained sequence type 1/PCR ribotype 027, 
sequence type 67/PCR ribotype 019 and sequence type 41 (PCR ribotypes 
106/164/321). Sublineage 2i also contained sequence type 62/PCR ribotype 036 and 
sequence type 140/PCR ribotype 111 which is a novel combination to our study. 
Sublineage 2ii contained six sequence types (32, 47, 61, 95, 97 and 123). Lineage 3 
included sequence type 22/PCR ribotype 023, with three additional sequence types; 
5, 25 and 96. Lineage 4 included sequence type 37/PCR ribotype 017 and an 
additional 12 sequence types. Lineage 4 can be subdivided into two sublineages; a 
sequence type 37 sublineage (4i) and a sequence type 23 sublineage (4ii). Sublineage 
4i contains four sequence types, including both PCR ribotype 017 sequence types (37 
and 86) as well as sequence type 39/PCR ribotype 085. Sublineage 4ii contains eight 
sequence types including sequence type 142/PCR ribotype 264 and sequence type 
23/PCR ribotype 138. Sublineage 4ii has significant divergence from sublineage 4i 
and may represent a sixth lineage. Lineage 5 included sequence type 11/PCR 
ribotype 078 and an additional two sequence types which were both novel; 132 and 
147.  
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3.4.5 MLST of C. difficile isolates by source  
To determine if C. difficile strains isolated from human, animal and food origins are 
phylogenetically distinct by MLST, the sequence type profiles of the collection of 
isolates from a variety of sources were compared. Table 3.8 lists the number and 
percentage of isolates in this study by source. Table 3.9 lists the human isolates by 
lineage and sequence type. Table 3.10 lists in individual sub-tables, the animal, food 
and household isolates by lineage and sequence type. Human isolates were of 
multiple sequence types and fell into either lineage 1, 2, 3, 4 or 5 (Table 3.9). 
Although the number of animal and food source isolates in this study is small, our 
data does show a range of sequence types and lineages associated with strains 
isolated from animals and food (Table 3.10). Our study identified the following 
sequence types to be associated with strains isolated from animals and food; 1, 2, 3, 
8, 11, 35, 48, 61 and 132. Most of the animal isolates (85.2% [92/108]) were 
sequence type 11. All sequence types for the animal isolates were of sequence types 
associated with human isolates (excluding ST132 which was novel to our study). 
These data indicate that strains isolated from humans, animals and food origins are 
not phylogenetically distinct by MLST. 
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Table 3.8: Number and percentage of isolates by source 
 
Source Number of isolates Percentage of isolates 
Human 211 54.8% 
Bovine 80 20.8% 
Porcine  17 4.4% 
Food 16 4.1% 
Murine  5 1.3% 
Equine 4 1% 
Canine 1 0.3% 
Kangaroo 1 0.3% 
Household  1 0.3% 
Unknown 49 12.7% 
TOTAL 385 100% 
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Table 3.9: Phylogeny of isolates of human origin 
 
Lineage 
Number 
of isolates 
Sequence 
type 
Number 
of isolates  
 Lineage 
Number 
of isolates 
Sequence 
type 
Number 
of isolates  
1 103 
*novel 13  
2 50 
140 (novel) 1 
139 (novel) 2  1 42 
2 4  67 2 
3 11  62 1 
6 4  32 1 
8 9  41 1 
9 1  41 1 
010 4  61 1 
12 2  
3 5 
5 4 
13 1  22 1 
15 4  
4 11 
142 (novel) 8 
16 1  37 1 
17 2  039 1 
18 1  86 1 
21 1  
5 42 
11 40 
26 2  147 (novel) 1 
29 1  148 (novel) 1 
33 2  Total number of isolates 211 
34 1      
35 1      
42 9      
43 2      
44 4      
45 1      
46 2      
48 1      
49 1      
51 1      
52 1      
53 1      
54 3      
55 4      
56 1      
57 1      
63 3      
66 1      
 
*Thirteen isolates were novel sequence types with only one isolate in lineage 1; 
sequence types; 131, 133, 134, 135, 136, 137, 138, 141, 143, 144, 145 and 146. 
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Table 3.10: Phylogeny of isolates of animal, food and household origin 
 
 
Bovine  
Lineage Number of isolates  Sequence type Number of isolates 
1 1 3 1 
2 6 1 6 
5 73 11 73 
Total number of isolates 80 
 
 
Canine 
Lineage Number of isolates  Sequence type Number of isolates 
1 1 2 1 
Total number of isolates 1 
 
 
Equine  
Lineage Number of isolates  Sequence type Number of isolates 
1 2 
3 1 
8 1 
2 1 1 1 
5 1 11 1 
Total number of isolates 4 
 
 
Murine 
Lineage Number of isolates  Sequence type Number of isolates 
1 5 35 5 
Total number of isolates 5 
 
 
Porcine  
Lineage Number of isolates  Sequence type Number of isolates 
1 4 
ST8 1 
ST48 2 
ST132 (novel) 1 
5 14 *ST11 14 
Total number of isolates 18 
*One isolate was from a Kangaroo. 
 
 
Food and household 
Lineage Number of isolates  Sequence type Number of isolates 
2 9 
*ST1 7 
ST61 2 
5 8 ST11 8 
Total number of isolates 17 
*One isolate was from a household. 
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3.4.6 MLST of C. difficile isolates by geographical origin 
The study by Lemee et al., investigated 72 strains of C. difficile isolated from various 
global locations and found no correlation between sequence type and geographical 
location (Lemee et al., 2004). This study aimed to determine if C. difficile strains 
isolated from different geographical origins are phylogenetically distinct by MLST 
using a larger collection of strains from various geographical locations. Table 3.11 
lists the number and percentage of isolates in this study by geographical origin 
(where provided). The majority of isolates were from the USA and UK and so these 
have been broken down further; Tables 3.12 and 3.13 list the number and percentage 
of isolates by sequence type for the USA and UK respectively. Our data shows that 
multiple lineages are associated with different geographical locations and multiple 
sequence types are associated with isolates from the UK and USA. 
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Table 3.11: Number and percentage of isolates by geographical origin and 
lineage 
 
Geographical 
Location 
Number of 
isolates 
Percentage of 
isolates 
Lineage/s 
USA 168 43.6% 1, 2 and 5 
UK 120 31.2% 1, 2, 3, 4 and 5 
Australia 36 9.4% 1,4 and 5 
Belgium 2 0.5% 4 
Canada 2 0.5% 2 
Ireland 2 0.5% 4 and 5 
Italy 2 0.5% 5 
Spain 2 0.5% 5 
Switzerland 2 0.5% 1 and 5 
France 1 0.3% 2 
Germany 1 0.3% 1 
Unknown 47 12.2% 1, 2, 3, 4 and 5 
TOTAL 385 100% 1, 2, 3, 4 and 5 
 
 
 
 
 
Table 3.12: Number and percentage of isolates from the USA by sequence type 
 
Sequence type Number of isolates Percentage of isolates 
11 108 64.3% 
1 36 21.4% 
3 6 3.6% 
35 5 3.0% 
61 3 1.8% 
8 2 1.2% 
48 2 1.2% 
67 2 1.2% 
*Other 4 2.4% 
TOTAL 168 100% 
 
* Four isolates were of other sequence types with only one isolate; sequence types 2, 
32, 41 and 46. 
 
 
 
 
 
 
 
 
123 
 
Table 3.13: Number and percentage of isolates from the UK by sequence type 
 
Sequence type Number of isolates Percentage of isolates 
1 19 15.8% 
3 10 8.3% 
42 8 6.7% 
11 7 5.8% 
8 6 5.0% 
37 5 4.2% 
10 4 3.3% 
44 4 3.3% 
6 3 2.5% 
2 3 2.5% 
33 2 1.7% 
5 2 1.7% 
12 2 1.7% 
17 2 1.7% 
55 2 1.7% 
63 2 1.7% 
*Other 23 19.2% 
**Novel 16 13.3% 
TOTAL 120 100% 
 
*Twenty-three isolates were of other sequence types with only one isolate, sequence 
types; 13, 15, 16, 18, 21, 22, 26, 35, 39, 41, 43, 45, 46, 48, 49, 51, 52, 53, 54, 56, 57, 
62 and 66. 
 
**Sixteen isolates were novel sequence types; 131, 133, 134, 135, 136, 137, 138, 
140, 141, 143, 144, 146 and 139 for three isolates. 
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3.4.7 Molecular characterisation of C. difficile using the different 
typing techniques; MLST, PCR ribotyping and REA 
Outbreak strains are often referred to as PCR ribotype 027/NAP1/BI, suggesting that 
the three typing methods correlate however the adequacy of inter-laboratory 
correlation between PCR ribotypes, PFGE types and REA types is unknown. To 
investigate the notion that not all REA type BI strains are PCR ribotype 027 by PCR 
ribotyping, 16 assumed PCR ribotype 027 strains identified as type BI by REA in the 
USA were PCR ribotyped (Table 3.14). 
 
Table 3.14: PCR ribotyping profiles of REA type BI strains 
 
 
 
 
 
 
 
 
 
 
 
We found 3 (3/16) strains were not PCR ribotype 027 but instead were 176, 198 and 
244 (Table 3.14). Although different PCR ribotypes, it was observed that the PCR 
ribotyping banding patterns for 176 and 198 are extremely similar to that of 027 
(plus or minus one band [Figure 3.3]). PCR ribotype 244 was observed to be two 
bands different so not as similar.  
Strain PCR ribotype 
BI-1 027 
BI-2 027 
BI-3 027 
BI-4 027 
BI-5 027 
BI-6 176 
BI-6p 027 
BI-6p2 027 
BI-7 027 
BI-8 027 
BI-10 027 
BI-11 198 
BI-12 027 
BI-13 027 
BI-14 244 
BI-15 027 
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Lane 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: PCR ribotyping agarose gel electrophoresis of strains BI-6 (PCR 
ribotype 176), R20291 (PCR ribotype 027) and BI-11 (PCR ribotype 198) 
 
 
DNA extraction, PCR ribotyping and agarose gel electrophoresis performed by M. 
Cairns, figure produced by M. Cairns and adapted from a publication by Valiente et 
al., (Valiente et al., 2012). PCR ribotyping amplicon banding patterns as observed by 
agarose gel electrophoresis.  
 
Lane 1= BI-11 (PCR ribotype 198/sequence type 1) 
Lane 2 = R20291 (PCR ribotype 027/sequence type 1 [positive control]) 
Lane 3 = BI-6 (PCR ribotype 176/sequence type 1) 
Lane 4 = Negative extract control 
Lane 5 = Negative PCR control 
Lane 6 = 100 bp ladder 
 
This figure depicts the plus/minus band similarity between PCR ribotyping patterns 
(locations of missing bands are encircled in blue).   
 
 
 
 
 
     1       2        3         4        5          6        
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The MLST lineage 2 most often contains PCR ribotype 027/sequence type 1. To 
investigate the diversity of strains found in MLST lineage 2, the sequence types and 
PCR ribotypes of 71 isolates found in MLST lineage 2 were compared. Results are 
listed in Table 3.15. 
 
Table 3.15: MLST lineage 2 isolates 
 
Lineage Sequence type PCR ribotype Number of isolates 
 
1 
027 53 
 Nontypeable 6 
 176 2 
 61 Nontypeable 3 
2 67 262 2 
 32 Nontypeable 1 
 62 036 1 
 
41 
Nontypeable 1 
 135 1 
 
 
MLST lineage 2 contained sequence types other than 1 and PCR ribotypes other than 
027 (Table 3.15). With our larger collection of strains, our data has found further 
sequence types, 61 and 62 associated with lineage 2.  
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3.5 Discussion 
To date, MLST studies on C. difficile have focused on human isolates from limited 
geographical regions. In our study MLST profiles of 385 C. difficile isolates were 
investigated, including previously undocumented PCR ribotypes taken from human, 
animal and food sources and from multiple geographical locations. Despite the 
diverse origins of the isolates in our study, the five phylogenetic lineages of 
C. difficile previously reported (Griffiths et al., 2010, Dingle et al., 2011a, Stabler et 
al., 2006, He et al., 2010) were confirmed (Figure 3.1). 
 
PCR analysis identified 68 different PCR ribotypes (319/385) and found 66 isolates 
(66/385) to be non-typeable (Table 3.1). This is an increase in diversity of PCR 
ribotypes compared to previous studies; n=62 (Lemee et al., 2004), n=49 (Griffiths et 
al., 2010) and n=61 (Dingle et al., 2011a) strengthening our ability to investigate the 
pylohistory of C. difficile. Unsurprisingly the majority of isolates in our study were 
PCR ribotype 078 (27.8%) and PCR ribotype 027 (13.8%) as listed in Table 3.1; 
these were the commonest cause of CDI in animals (Keel et al., 2007, Jhung et al., 
2008, Goorhuis et al., 2008, Rupnik et al., 2008) and humans respectively (Loo et al., 
2005, Warny et al., 2005, Redelings et al., 2007). 
 
MLST analysis identified 48 known sequence types (365/385) and found 18 
sequence types (20/385) to be novel (Table 3.2). This is an increase in diversity of 
sequence types compared to the Lemee et al., (Lemee et al., 2004) and Griffiths et 
al., (Griffiths et al., 2010) studies with n=34 and n=40 sequence types respectively 
but less than the Dingle et al., study with n=69 sequence types (Dingle et al., 2011a). 
The study by Dingle et al., was based on 1290 isolates, our study was significantly 
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less with 385 isolates, however, our study included isolates of more diverse PCR 
ribotypes; 14 of the 20 novel sequence types in our study were of PCR ribotypes not 
included in the study by Dingle et al.,. This likely explains why our study identified a 
further 18 novel sequence types compared with the previous study by Dingle et al., 
(Appendix 1, Page 229). 
 
Previous studies have investigated 45 (Griffiths et al., 2010) and 29 (Dingle et al., 
2011a) PCR ribotypes and reported 74 PCR ribotype/sequence type associations i.e. 
PCR ribotype 027 isolates are sequence type 1 and vice versa. Using a larger 
collection of PCR ribotypes (n=67), we identified 39 previously described and 46 
novel PCR ribotype/sequence type associations (including 20 novel sequence types 
[Table 3.4]). The finding of 20 novel sequence types indicates further micro-diversity 
with sub-lineages within lineages which suggests the continued evolution of C. 
difficile strains and the potential emergence of hypervirulent strains.  
 
In the current study, it was found that lineage 1 (139/365) consisted of 51 sequence 
types which were heterogeneous in terms of PCR ribotypes. This is consistent with 
that found by previous MLST studies on C. difficile (Griffiths et al., 2010, Dingle et 
al., 2011a). 
 
Lineage 2 consisted of 14 sequence types which can be sub-divided into two 
sublineages; a sequence type 1 sublineage (2i) and a sequence type 32 sublineage 
(2ii). Sublineage 2i contained sequence type 1/PCR ribotype 027, sequence type 
67/PCR ribotype 019 which concurs with the study by Griffiths et al., (Griffiths et 
al., 2010) and sequence type 41 (PCR ribotypes 106/164/321) which is consistent 
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with the study by Dingle et al., (Dingle et al., 2011a). Sublineage 2i also contained 
sequence type 62/PCR ribotype 036 and sequence type 140/PCR ribotype 111 which 
is a novel combination to our study. Sublineage 2ii contained six sequence types (32, 
47, 61, 95, 97 and 123) with only sequence type 32/PCR ribotype 153 known 
previously (Griffiths et al., 2010). We found lineage 3 included sequence type 
22/PCR ribotype 023, with three additional sequence types; 5 and 25 as previously 
reported (Griffiths et al., 2010, Dingle et al., 2011a) plus sequence type 96 which has 
not been reported before in this lineage. We found lineage 4 included sequence type 
37/PCR ribotype 017 which was previously reported (Lemee et al., 2004, Griffiths et 
al., 2010, Dingle et al., 2011a) and an additional 12 sequence types. Lineage 4 can be 
subdivided into two sublineages; a sequence type 37 sublineage (4i) and a sequence 
type 23 sublineage (4ii). Sublineage 4i contains four sequence types, including both 
PCR ribotype 017 sequence types (37 and 86) as well as sequence type 39/PCR 
ribotype 085. Sublineage 4ii contains eight sequence types including sequence type 
142/PCR ribotype 264 and sequence type 23/PCR ribotype 138. Sublineage 4ii has 
significant divergence from sublineage 4i and may represent a sixth lineage. Lineage 
5 included sequence type 11/PCR ribotype 078 as previously reported (Griffiths et 
al., 2010, Dingle et al., 2011a) and an additional two sequence types which were both 
novel; 132 and 147. This all suggests continued evolution of C. difficile species. 
 
Strains isolated from humans, animals and food origins were not phylogenetically 
distinct by MLST (Tables 3.8, 3.9 and 3.10). As previously shown (Griffiths et al., 
2010, Dingle et al., 2011a), human isolates are of multiple sequence types and can 
fall into either lineage 1, 2, 3, 4 or 5 (Table 3.9).  
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Although the number of animal and food source isolates in this study is small, our 
data does show a range of sequence types and lineages associated with strains 
isolated from animals and food (Table 3.10). Our study identified the following 
sequence types to be associated with strains isolated from animals and food; 1, 2, 3, 
8, 11, 35, 48, 61 and 132. Some of these were previously identified by Lemee et al., 
(sequence types; 1, 3, 8) (Lemee et al., 2004). Strains of C. difficile isolated from 
animals have been shown to be sequence type 11 (Griffiths et al., 2010) as is found 
in this study with 85.2% (92/108) of strains isolated from animals being sequence 
type 11. Non-human isolates were found in lineages 1, 2 and 5 amongst strains 
isolated from humans. All sequence types for the animal isolates were also associated 
with human isolates (excluding sequence type 132). Sequence type 132 was novel; 
whether it is a sequence type exclusively associated with animals cannot be 
determined in this study due to only one isolate of this sequence type. Our data did 
not find a lineage exclusive to non-human strains indicating that the strains in our 
study were able to colonise or infect non-human sources equal to humans. 
 
No correlation between sequence type and geographical location using MLST was 
found (Table 3.11). This lack of geographical association indicates that there has not 
been a rapid spread of a particular strain. A limitation to this study is that the 
majority of isolates were from the UK and USA; however, representative strains 
from other geographical locations were included (Australia, Belgium, Canada, 
France, Germany, Ireland, Italy, Spain and Switzerland).  
 
Our data indicate that the molecular characterisation of C. difficile using MLST, PCR 
ribotyping and REA does not provide adequate correlation for inter-laboratory 
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comparison. Sixteen assumed sequence type 1/PCR ribotype 027 strains identified as 
BI by REA in USA were PCR ribotyped in this study and three were found not to be 
PCR ribotype 027 but instead, 176, 198 and 244. This is similar to data shown 
elsewhere which have found that not all PCR ribotype 027 strains are type BI by 
REA (Tenover et al., 2011). The close phylogeny of PCR ribotype 027/sequence type 
1, PCR ribotype 176/sequence type 1 and PCR ribotype 198/sequence type 1 is 
supported by data from a previous study where comparative genomic hybridisation 
and Bayesian phylogeny was performed and suggested these strains may share a 
common ancestor (Stabler et al., 2006). Our data also found the PCR ribotyping 
banding patterns to be highly similar for PCR ribotypes 027, 176 and 198 (Figure 
3.3).  
 
Reported elsewhere, a strain of PCR ribotype 176 was responsible for two outbreaks 
in 2008 and 2009 in Poland (Nyc et al., 2011) and a study in the Czech Republic 
analysed 624 C. difficile strains from eleven hospitals in 2013 and found 40% of 
isolates were PCR ribotype 176. Interestingly, other studies have found PCR ribotype 
176 to be incorrectly identified as PCR ribotype 027 using the Xpert
®
 C. difficile 
assay (Krutova et al., 2014). The Xpert
®
 C. difficile assay detects the presence of C. 
difficile (and also specifically PCR ribotype 027) in stool samples using PCR (Sloan 
et al., 2008). It is a multiplex PCR for three targets present in the toxigenic C. 
difficile genome: the tcdB gene for toxin B production, the cdtB gene for binary toxin 
production and the single nucleotide deletion at position 117 in the regulatory tcdC 
gene. Similar to the study by Krutova et al., twelve strains of PCR ribotype 244 were 
misidentified as PCR ribotype 027 using the Xpert
®
 C. difficile assay in Australia 
(Lim et al., 2014). Like PCR ribotype 027, they found PCR ribotype 244 was 
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associated with more severe disease and a higher mortality rate. Their WGS SNP 
analysis also found PCR ribotype 244 and 027 to be distinct but closely related. 
Previous to this, it was recognised in New Zealand that ten patients with CDI due to 
PCR ribotype 244 had severe infection, 50% of which were community acquired (De 
Almeida et al., 2013). A further study in Australia identified a clonal outbreak due to 
PCR ribotype 244; again these patients had severe infection, the majority were 
community acquired and patients were younger in age (Eyre et al., 2015). C. difficile 
PCR ribotype 176 and 244 strains produce binary toxin and possess the single 
nucleotide deletion in the tcdC gene at position 117 like that of PCR ribotype 027 
(Krutova et al., 2017, Lim et al., 2014) which explains why they were detected by the 
the Xpert
®
 C. difficile assay in the reports just mentioned. This means that these 
targets are not specific to PCR ribotype 027 as previously thought. The comparative 
genomic hybridisation and Bayesian phylogeny study performed by Stabler et al., 
also found PCR ribotype 244 (strain BI-14) in lineage 2 but, as an outlier within the 
lineage (Stabler et al., 2006). The PCR ribotyping banding pattern for PCR ribotype 
244 also differed by two bands to PCR ribotype 027 instead of only one band like 
with PCR ribotypes 176 and 198. 
 
Additional sequence types and PCR ribotypes were also found associated with 
lineage 2 in this study (Table 3.15). This is similar to that found by other studies. 
Griffiths et al., found sequence types 32 and 67 (Griffiths et al., 2010) and Dingle et 
al., found sequence type 67 (Dingle et al., 2011a) within lineage 2. Griffiths et al., 
also found an additional PCR ribotype, 036 associated with sequence type 1 which 
was similar in PCR ribotyping banding pattern like what our study has found with 
PCR ribotypes 176 and 198. With our larger collection of strains, our data has found 
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further sequence types, 61 and 62 associated with lineage 2. This suggests that 
lineage 2 has evolved further with new sequence types and supports the notion that 
PCR ribotyping and REA analysis do not correspond as well as previously thought. 
Both typing methods rely on the examination of DNA migration through a matrix, 
usually an agarose gel and comparison to a standard. Simple changes in DNA can 
have distinct changes in resulting profiles. For example, a change in the repeat copy 
number, inter-chromosomal homologous recombination for PCR ribotyping, primer 
binding sites or SNPs within restriction sites for REA can produce differences in 
banding patterns, which may result in the strain being designated as a different type 
or variant even though they are phylogenetically similar. In light of the phylogenetic 
similarities between multiple PCR ribotypes i.e. 027, 198 and 076, it would be 
plausible to investigate as future work the phenotypic similarities between PCR 
ribotypes that are different PCR ribotypes but highly similar in PCR ribotyping 
profile and phylogeny by MLST. 
 
3.6 Conclusion 
With a large and diverse collection of strains (n=385), our study confirmed the five 
lineages of C. difficile found by other studies with evidence of further micro-
diversity of the C. difficile species. By including isolates from a variety of sources 
and geographical origin, our data found no lineage exclusive to C. difficile strains 
isolated from non-human sources or a geographical origin. Our study has revealed 
new links between closely related PCR ribotypes and sequence types, providing 
insights into the microevolution of C. difficile. 
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Our study confirmed that not all C. difficile REA type BI strains are PCR ribotype 
027 but other PCR ribotypes such as 176, 198 and 244. Considering the similarity in 
phylogeny of these PCR ribotypes in this study and other studies (Stabler et al., 
2006, Krutova et al., 2017, Lim et al., 2014), suggests C. difficile REA type BI, PCR 
ribotype 027 and non-PCR ribotype 027 strains have co-evolved or possibly evolved 
from each other. Given that PCR ribotyping is the most widely used typing method 
worldwide, and that MLST studies confirm the close grouping of different PCR 
ribotypes such as PCR ribotypes 176, 198, 244 with 027, suggests that although PCR 
ribotyping is useful, it must be considered that there should be heightened awareness 
of the clinical significance of these closely related PCR ribotypes.  
 
MLST is an appropriate method for studying the phylogeny of C. difficile and the 
continued collection and genotyping of diverse C. difficile strains from all sources is 
vital for monitoring the emergence and disappearance of evolving virulent clones. 
Although five lineages of C. difficile have been confirmed using MLST, these should 
be investigated in more detail using WGS which offers superior resolution compared 
to MLST. Therefore, I have further investigated an individual lineage in more detail 
in chapters 4 and 5; C. difficile PCR ribotype 017. 
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Chapter 4 
Genetic and phenotypic characterisation  
of a hospital outbreak of  
C. difficile PCR ribotype 017
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4 Characterisation of a hospital outbreak of C. difficile 
PCR ribotype 017 using WGS and phenotypic assays 
4.1 Statement of contribution 
Isolate selection, PCR ribotyping and genomic DNA extractions were performed by 
M. Cairns. WGS were performed both at the WTSI by D. Harris and at the LSHTM 
by M. Cairns. The collection of epidemiology data were performed by M. Cairns 
with help from the infection control team at UHL. SNP calling were performed by 
Dr Mark Preston. De novo assembly were performed by M. Cairns with help from 
Dr Richard Stabler. Phenotypic assays, statistical analysis and data interpretation 
were performed by M. Cairns.  
4.2 Introduction 
MLST and WGS studies have confirmed the existence of at least five clonal lineages 
of C. difficile (Dingle et al., 2011a, Stabler et al., 2006) and this was confirmed in 
chapter 3 using MLST (Stabler et al., 2012). 
 
C. difficile PCR ribotype 027 has been well studied, but less is known about other 
PCR ribotypes that make up the five lineages identified by MLST and WGS such as 
PCR ribotype 017. It is known that pathogenic strains of PCR ribotype 027 produce 
both toxins A and B (A+B+) and an unrelated CDT that has been implicated in 
virulence. By contrast, PCR ribotype 017 strains lack most of the tcdA gene (A-B+) 
and completely lack the CDT gene yet have emerged worldwide causing significant 
disease (Johnson et al., 2003, Pituch et al., 2006, Goorhuis et al., 2009, Hawkey et 
al., 2013). The reasons for the emergence of a less toxigenic lineage remain unclear. 
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The epidemiology of C. difficile in the Asia/Pacific regions and eastern parts of 
Europe also appears to differ from elsewhere where the prevalence of toxin A-B+ 
strains is higher in these locations compared to other PCR ribotypes including 027 
which is toxin A+B+ (Hawkey et al., 2013). Like PCR ribotype 027, C. difficile 
toxin A-B+ strains have been associated with increased disease severity where they 
have been related to PMC in patients (Shin et al., 2008, Elliott et al., 2009, Limaye 
et al., 2000, Sambol et al., 2000, Johnson et al., 2001).  
 
The Department of Health guidelines recommend use of a chlorine-containing 
cleaning agent for routine environmental disinfection in hospitals; however, studies 
have suggested that PCR ribotypes have differing susceptibilities to disinfectants. A 
study by Dawson et al., compared the efficacy of nine commonly used hospital 
disinfectants (including chlorine-containing cleaning agents) against a selection of 
difference PCR ribotypes and found their efficacy was either dependent on the 
concentration, PCR ribotype or both (Dawson et al., 2011). The study found the 
percentage spore count for PCR ribotype 017 was significantly higher than that for 
PCR ribotypes 027 (Dawson et al., 2011).  
 
UHL in South London experienced multiple clusters of non-severe CDI caused by 
PCR ribotype 017 that occurred at different times between 2009 and 2013; 21 
isolates were recovered from 20 patients, 17 of which were taken from patients 
whilst on one elderly care ward during this time period (Table 4.1, Page 143). Due to 
these clusters, an environmental screen was performed on the ward (30/08/2010) 
followed by hydrogen peroxide vapour (HPV) decontamination (30/09/2010). 
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However, subsequent to this, isolates of PCR ribotype 017 were again recovered 
from patients with CDI from the same ward.  
 
WGS offers considerable advantages over traditional phenotypic and genotypic 
typing methods where it has superior resolution and can perform a fine-grain 
analysis that facilitates the accurate tracing of the sources and routes of transmission 
(Parkhill and Wren, 2011). As well as SNP analysis, WGS can identify regions of a 
genome suggestive of horizontal gene transfer and horizontal transfer of genes on 
mobile genetic elements; conventional typing methodologies are unable to do this.  
Mobile genetic elements refer to DNA that can move around within and between 
genomes and include; conjugative transposons, plasmids, bacteriophages and introns 
(Frost et al., 2005). Mobile genetic elements are important since they play a major 
role in bacterial evolution and virulence whereby they often carry genes associated 
with virulence (Wiedenbeck and Cohan, 2011). Approximately, 11% of the C. 
difficile genome is made up of mobile genetic elements and a significant proportion 
of these elements are conjugative transposons (Sebaihia et al., 2006). Studied 
conjugative transposons in C. difficile include; Tn916 (Roberts and Mullany, 2009), 
Tn5397 (Mullany et al., 1996), Tn4453a and Tn4453b  (Wren et al., 1988) and 
Tn1549 (Sebaihia et al., 2006, Garnier et al., 2000) each with varying accessory 
regions and putative virulence factors. 
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4.3 Hypotheses of the research described in this chapter 
PCR ribotype 017 is interesting; it forms its own phylogenetic lineage by MLST and 
WGS analysis, it is toxin A negative but is still pathogenic, it has shown to produce 
more spores than the hypervirulent PCR ribotype 027 and a London hospital has 
experienced multiple clusters of CDI caused by this PCR ribotype. These data 
warrant further investigation of this PCR ribotype using WGS in order to investigate 
its transmission and virulence. Detection of transmission has an implication for 
infection control and surveillance and identification of a virulent phenotype would 
justify heightened awareness, surveillance and investigation of improvements to 
laboratory diagnostics like that with PCR ribotype 027 and the Xpert
®
 C. difficile 
assay described in chapter 3. This study was designed to test the following 
hypotheses: 
 
Chapter 4: hypothesis 1 
The C. difficile isolates from UHL are clonal and represent a phylogenetically 
distinct cluster when compared to C. difficile isolates from other London hospitals. 
 
Chapter 4: hypothesis 2 
The C. difficile isolates from UHL are phenotypically different to C. difficile isolates 
from other London hospitals.  
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4.4 Results  
With my role as lead CDRN scientist at the London laboratory, I noticed that there 
were multiple isolates of PCR ribotype 017 being reported to UHL. I discussed this 
finding with the infection control nurses at UHL and this study commenced. 
 
A total of 37 C. difficile isolates were used in this study and their details are listed in 
Table 4.1. These were; 22 strains isolated from humans who at different times were 
on the same hospital ward at UHL and two strains isolated from the same hospital 
ward. An additional 13 contemporaneous strains isolated from humans from other 
London hospitals were also included for comparison. 
 
Twenty-three of the UHL isolates were part of an ongoing cluster, one of which (H-
UHL-1) was a historical isolate from 2005 which predates the other 22 isolates in the 
cluster which were isolated between 2009 and 2013, and even the existing building 
where the elderly care ward was located. Two of these cluster isolates were 
environmental (E-UHL-19 and E-UHL-20) and recovered from the toilet and floor 
of the elderly care ward side-room at UHL when an environmental screen was 
performed. 
 
All isolates in this study were propagated on appropriate culture media (Sections 
2.2.2, Page 70 and 2.2.3, Page 71) from which genomic DNA was extracted using 
methods described for PCR ribotyping and WGS (Sections 2.3.1, Page 77 and 
2.3.3.1, Page 83 respectively). PCR ribotyping was performed by PCR amplification 
and agarose gel electrophoresis (Section 2.3.1, Page 77). In preparation for WGS, 
DNA was quantified (Section 2.3.3.2, Page 84) and WGS was performed using 
142 
 
Illumina Sequencing Technology (Sections 2.3.3.3, Page 85 and 2.3.3.4, Page 88). 
SNPs and haplotypes were identified by sequence mapping and assembly (Sections 
2.3.3.5, Page 85 to 2.3.3.9, Page 92 inclusive), and de novo genome assembly 
analysis and visual inspection using ACT was performed to identify regions of DNA 
that were; present in a test strain but absent from the reference control M68 
(insertions) and present in the control strain M68 but absent from a test strain 
(deletions) [Section 2.3.3.10, Page 92]). Software tools were used to produce 
phylogenetic trees to enable visual comparisons of SNP differences between UHL 
and non-UHL C. difficile isolates (Section 2.3.9, Page 91) and phenotypic assays and 
statistical analysis were performed on select isolates (UHL-1, UHL-3, UHL-19, CX-
32) to identify a phenotype unique to the UHL C. difficile isolates (Sections 2.2.6, 
Page 73 to 2.2.10, Page 76 inclusive). 
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Table 4.1: Bacterial isolates used in chapter 4 
Table adapted from a publication by Cairns et al., (Cairns et al., 2015). 
 
* = historical isolate pre-dating the build of the hospital ward, ** = environmental 
isolate recovered from the ward and *** = community-acquired infection isolate. 
 
Isolate Provider 
Sample 
Date 
Hospital (date/s patient on elderly care ward at UHL if not the 
same as the date the sample was taken) 
*H-UHL-1 CDRN 2005 UHL (ward non-existent) 
UHL-2 CDRN 11/03/09 UHL (ward) 
UHL-3 CDRN 27/03/09 UHL (24/02/09-05/03/09) 
UHL-4 CDRN 17/04/09 UHL (ward) 
UHL-5 CDRN 16/04/09 UHL (ward) 
UHL-6 CDRN 28/09/09 UHL (ward) 
UHL-7 CDRN 20/09/09 UHL (ward) 
UHL-8 CDRN 16/10/09 UHL (ward) 
UHL-9 CDRN 29/10/09 UHL (ward) 
UHL-10 CDRN 28/01/10 UHL (ward) 
UHL-11 CDRN 08/02/10 UHL (ward) 
UHL-12 CDRN 17/02/10 UHL (ward) 
UHL-13 CDRN 01/04/10 UHL (ward) 
UHL-14 CDRN 26/04/10 UHL (ward) 
UHL-15 CDRN 17/07/10 UHL (ward) 
UHL-16 CDRN 19/07/10 UHL (ward) 
UHL-17 CDRN 06/08/10 UHL (never) 
UHL-18 CDRN 10/08/10 UHL (ward) 
**E-UHL-19 CDRN 13/08/10 UHL (ward: side-room toilet) 
**E-UHL-20 CDRN 13/08/10 UHL (ward: side-room floor) 
UHL-21 CDRN 04/10/10 UHL (never) 
UHL-22 CDRN 07/10/10 UHL (04/06/10-12/07/10) 
UHL-23 CDRN 26/04/11 UHL (15/02/1-14/04/11) 
***C-UHL-24 CDRN 08/03/13 UHL (26/12/12-28/12/12, 04/02/13-07/02/13 and 08/03/13-20/02/13) 
NP-25 CDRN 13/05/08 Northwick Park Hospital 
B-26 CDRN 27/02/09 Barnet Hospital 
NM-27 CDRN 2005 North Middlesex Hospital 
GOSH-28 CDRN 22/03/10 Great Ormond Street Hospital 
GOSH-29 CDRN 24/03/10 Great Ormond Street Hospital 
GOSH-30 CDRN 27/03/10 Great Ormond Street Hospital 
RF-31 CDRN 09/12/10 Royal Free Hospital 
CX-32 CDRN 25/01/11 Charing Cross Hospital 
B-33 CDRN 11/05/11 Barnet Hospital 
QM-34 CDRN 16/07/11 Queen Mary’s Hospital 
WX-35 CDRN 08/12/11 Whipp’s Cross Hospital 
WX-36 CDRN 16/01/12 Whipp’s Cross Hospital 
GOSH-37 CDRN 30/11/13 Great Ormond Street Hospital 
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4.4.1 Genotypic comparison of isolates from London hospitals 
4.4.1.1 PCR ribotyping 
The 34 patient and two environmental isolates (Table 4.1) were confirmed to be 
PCR ribotype 017 by PCR ribotyping and agarose gel electrophoresis (Section 
2.3.1). Reference strains R20291 (PCR ribotype 027) and M68 (PCR ribotype 017) 
were used as controls and all isolates were assumed to be toxinotype VIII, A-B+ 
based on their being PCR ribotype 017. There are no known reports of PCR ribotype 
017 having any other toxin profile other than toxinotype VIII, A-B+. 
4.4.1.2  Inference of phylogeny using SNP data 
To investigate the phylogeny and clonality of the isolates in this study, after 
sequence quality control and mapping to the control strain M68 reference genome, 
SNP analysis revealed 162 bi-allelic SNP loci in the samples within the 4,308,325 
bp of the control strain M68 with the majority 79.0% (128/162) exhibiting a MAF of 
less than 10% including 54.3% (88/162) loci being identified in one sample. Only 17 
SNP loci (10.5%) had a non-reference allele frequency above 50% and each isolate 
contained up to 46/162 (28.4%) mutations, with 64.9% (24/37) isolates containing 
between 17 and 19 (10.5-11.7%) SNPs.  
 
The complete dataset of 36 isolates revealed 23 different haplotypes designated A to 
W of between three and 47 SNPs (Table 4.2). Nine of the 23 haplotypes were only 
found in 23 isolates; H-UHL-1 and UHL-2 to UHL-23 (labelled A to I). Twenty-four 
SNP loci were unique to these 23 UHL samples; 16 non-synonymous, five 
synonymous and three non-genic (Table 4.3). Haplotype A was the ‘core’ haplotype 
consisting of 11 SNPs common to all, and unique to the UHL isolates. Haplotypes B 
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to H contained one or two extra SNPs to the haplotype A pattern. Haplotype I was 
distinguishable from haplotype A by five SNPs.  
 
Table 4.2: Haplotypes for the London isolates 
 
Haplotype Number of isolates Number of SNPs Cluster 
A 10 17 Cluster 1-UHL  
B 4 18 Cluster 1-UHL  
C 3 19 Cluster 1-UHL  
D 1 19 Cluster 1-UHL  
E 1 18 Cluster 1-UHL  
F 1 18 Cluster 1-UHL  
G 1 19 Cluster 1-UHL  
H 1 18 Cluster 1-UHL  
I 1 22 Cluster 1-UHL  
J 1 3 Cluster 2-M68 
K 1 7 Cluster 2-M68  
L 1 18 Cluster 2-M68  
M 1 19 Cluster 2-M68  
N 1 23 Cluster 2-M68  
O 1 9 Cluster 2-M68  
P 1 7 Cluster 2-M68  
Q 1 19 Cluster 2-M68  
R 1 32 Cluster 3 
S 1 38 Cluster 3 
T 1 38 Cluster 3 
U 1 38 Cluster 3 
V 1 47 Cluster 3 
W 1 38 Cluster 3 
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Table 4.3: SNPs unique to cluster 1-UHL isolates 
 
Position in genome Reference Alternative Type Product/Putative Function Haplotype 
345335 S R Non-synonymous Protein-tyrosine phosphatase reductase A to I 
433205 S S Synonymous Formate/nitrite transporter A to I 
578215 P S Non-synonymous Iron hydrogenase A to I 
707105 F L Non-synonymous Multidrug family ABC transporter permease A to I 
1123155 G S Non-synonymous Putative membrane protein A to I 
1241002 L L Synonymous NhaC family Na+/H+ antiporter A to I 
1316457 A A Synonymous 3-hydroxybutyrate dehydrogenase A to I 
2764775 P L Non-synonymous Diguanylate kinase signaling protein A to I 
3072208 G A Non-synonymous Maf-like protein A to I 
3202066 L F Non-synonymous Multidrug family ABC transporter  A to I 
4025381 . . Intergenic Unknown A to I 
1491685 . . Intergenic Unknown B, C and D 
584197 C R Non-synonymous Response regulator (quorum-sensing system) E 
1245898 H N Non-synonymous Copper-sensing transcriptional repressor CsoR H 
1395682 I L Non-synonymous Hypothetical protein H 
583796 R L Non-synonymous Response regulator (quorum-sensing system) F 
1932695 I V Non-synonymous Putative membrane protein C 
3698806 . . Intergenic Unknown G 
3056134 L I Non-synonymous Ribonuclease G (RNase G)  D 
34552 S Y Non-synonymous rpoB gene I 
2744067 E E Synonymous Putative TPR repeat-containing protein I 
2813984 E E Synonymous GntR family transcriptional regulator I 
3289962 S Y Non-synonymous ABC transporter substrate-binding protein I 
3766047 K Stop codon Non-synonymous Two-component response regulator I 
Table adapted from a publication by Cairns et al., (Cairns et al., 2015). 
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A heat map of genetic Manhattan distance (Figure 4.1) depicts the three related 
groups of samples designated cluster 1-UHL, cluster 2-M68 and cluster 3. A heat 
map acts as a graphical illustration of the relationship between data points in a data 
set. Individual pairwise comparisons are represented by a value between 0 and 1 in a 
matrix. These are represented by colour in a heat map; black is completely identical 
data points (0) and white is completely different (1). By using Manhattan distance 
between two data points of SNP data, normalised between 0 and 1, a heat map can 
easily be made. Figure 4.1 illustrates genetic similarity as darker colours based on 
SNPs; the cluster 1-UHL isolates are darker colour indicating their clonality. 
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Figure 4.1: Heat map of the inter- and intra-cluster relatedness of the C. 
difficile PCR ribotype 017 isolates from London hospitals 
 
Heat map taken from a publication by Cairns et al., (Cairns et al., 2015) to show the 
inter- and intra-cluster relatedness of the London C. difficile isolates. A normalised 
Manhattan distance between samples was used, with darker colours indicating a 
closer genetic identity between samples. The clonality of the cluster 1-UHL isolates 
is illustrated by the darker colour. 
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A maximum-likelihood phylogenetic tree (Figure 4.2) also depicts the three related 
groups of isolates designated cluster 1-UHL, cluster 2-M68 and cluster 3. Figure 4.2 
also depicts the genetic relatedness specifically between the cluster 1-UHL isolates 
(a maximum of 5 SNPs). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Maximum-likelihood phylogenetic analysis of the C. difficile PCR 
ribotype 017 isolates from London hospitals 
 
Figure adapted from a publication by Cairns et al., (Cairns et al., 2015). Maximum-
likelihood phylogenetic analysis trees of all 37 London C. difficile isolates. A) based 
on core-genome SNPs against the control strain M68 and B) cluster 1-UHL 
haplotypes.  
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The cluster 1-UHL was composed exclusively of haplotypes A to I, containing 23/24 
isolates from UHL; 96.3% of SNP loci were found exclusively in this cluster. One 
isolate in this cluster, H-UHL-1 (haplotype I) is an historical isolate from 2005 
which predates the other 22 isolates in the cluster, and even the existing building 
where the elderly care ward was located. The H-UHL-1 sample/haplotype I was 
distinguishable from the UHL core haplotype (A) by only five SNPs. The four year 
isolation gap between the historical isolate in 2005 and the first cluster 1-UHL 
isolate in 2009 is consistent with a mutation rate of 0.74SNPs/year (Eyre et al., 
2013), one to two SNPs/year (He et al., 2013) and 1.4 SNPs/year (Didelot and 
Maiden, 2010) suggesting that the historical H-UHL-1 isolate shares a common 
ancestor with cluster 1-UHL or is itself the ancestral strain. Haplotypes A to H were 
indistinguishable based on a ≤ 2 SNP difference suggesting they are the same strain 
and transmission has occurred between patients and/or via ward contamination. 
Additionally, the two environmental isolates (E-UHL-19 and E-UHL-20) recovered 
from the toilet and floor of the elderly care ward side-room were indistinguishable 
from the cluster 1-UHL; the environment was therefore contaminated with this 
strain. Two UHL isolates (UHL-17 and UHL-21) from patients who were never 
admitted onto the elderly care ward were found to be part of the cluster 1-UHL, 
strongly suggesting inter-ward transmission. One isolate (C-UHL-24) recovered 
from a patient taken on the day of admittance to the elderly care ward was 
distinguishable from the cluster 1-UHL; however, this CDI was defined as 
community-acquired based on the patient developing CDI < 48 hours of hospital 
admission. Although the patient had spent time on the elderly care ward in the past, 
this CDI episode was likely picked up in the community or visit/s to other healthcare 
institution/s. Subsequent to the hydrogen peroxide ward decontamination that was 
151 
 
performed in September 2010, two isolates of C. difficile PCR ribotype 017 
indistinguishable from the cluster 1-UHL were recovered from patients in October 
2010 and April 2011 (UHL-22 and UHL-23). This strain has persisted at UHL with 
a possible internal reservoir that was never eliminated during the HPV 
decontamination. With the historical isolate from 2005 being indistinguishable from 
the more recent clonal isolates, the possibility of an external source that has re-
introduced this strain to the elderly care ward or a patients exit and re-entry to the 
ward cannot be excluded. 
 
All isolates in cluster 1-UHL (haplotypes A to I) contained a gene putatively 
associated with virulence; a multidrug family ABC transporter (Table 4.3). These 
have been associated with contributing to antimicrobial resistance where they play a 
role in active efflux of antimicrobial agents from the bacterial cell rendering it 
ineffective against the bacteria (Lubelski et al., 2007). Cluster 2-M68 (containing the 
control strain M68) encompassed the outer London hospitals and a UHL patient 
(UHL-24) who had spent time on the elderly care ward (26/12/12 to 28/12/12, 
04/02/13 to 07/02/13 and 08/03/13 to 20/02/13), though their CDI was defined as 
community acquired due to their symptoms beginning < 48 hours post hospital 
admission. Cluster 3 contains all of the isolates from the three inner London 
hospitals (Great Ormond Street, Royal Free and Charing Cross).  All 162 SNPs were 
the same mutations and the same positions across all isolates, and only six SNP loci 
(3.8%) had mutations in more than one cluster.  Cluster 3 contained isolates that 
were the most distinguishable from the control strain M68 with between 32 and 47 
SNPs. 
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As well as SNPs unique to the cluster 1-UHL haplotypes, a noteworthy SNP was 
present in both cluster 1-UHL and cluster 3 isolates but absent from cluster 2-M68 
isolates. This was a non-synonymous SNP in the bioB gene (Appendix 3, Page 256). 
This is one of four genes that play a major role in the biotin biosynthetic pathway 
(Satiaputra et al., 2016). Biotin mediates the transport of CO2 in many vital 
metabolic reactions and is essential for life. Interestingly, studies have shown 
decreased available biotin results in increased toxin synthesis by C. difficile 
(Yamakawa et al., 1996). This SNP may affect biotin production, limiting its 
availability and in-turn increasing toxin synthesis.  
4.4.1.3 De novo genome assembly analysis 
The SNP analysis tells us about single base pair changes but doesn't tell us about 
larger deletions or insertions or other rearrangements within the genome, therefore I 
undertook de novo assembly of each isolate in comparison to the control strain M68 
with programmatic and visual inspection of the comparisons using ACT software. 
This revealed a 49 kbp genetic region exclusive to the cluster 1-UHL (23/37) 
isolates (Figure 4.3). No other large structural variations between samples were 
revealed. Annotation of the region identified 30 coding sequences that had 
orthologues to known gene sequences and 15 coding sequences with no known 
orthologue (Table 4.4). These 45 predicted genes are highly conserved; 41/45 had 
100% amino acid identity across all 23 samples in the 1-UHL cluster.  
 
The genetic region contained genes suggestive for transposition; conjugative transfer 
of transposon-like mobile genetic element genes and an endonuclease relaxase 
MobA/VirD2 (Byrd and Matson, 1997, Silby et al., 2007). Transposons are known 
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to carry additional genes associated with virulence and/or transmissibility (Brouwer 
et al., 2011). The 49 kbp genetic region in this study does contain genes putatively 
associated with virulence and transmissibility (Table 4.4); sortase B gene (Spirig et 
al., 2011), the sporulation gene spo0J (Wu and Errington, 2003) and genes 
associated with antimicrobial resistance; tetracycline resistance transcriptional 
regulator and a multi antimicrobial extrusion protein (Nies et al., 2012). 
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Figure 4.3: ACT illustration of the 49 kbp genetic region exclusive to the cluster 
1-UHL isolates 
 
Figure adapted from a publication by Cairns et al., (Cairns et al., 2015). 
Comparative genomic analyses were performed using ACT software with the 
C. difficile genomes for the reference control strain M68 and strain H-UHL-19. Red 
bars indicate sequence similarity. The ACT analysis revealed a genetic region 
exclusive to isolates in cluster 1-UHL (including H-UHL-19) which is encircled.  
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Table 4.4: Predicted coding sequences found in the 49 kbp genetic region 
exclusive to cluster 1-UHL isolates 
 
 
Table adapted from a publication by Cairns et al., (Cairns et al., 2015). 
Genetic region in the 
H-UHL-19 genome 
Putative Product/Role/Function according to NCBI Blast and UniProt 
Data01.09_00455 Uncharacterised protein  
Data01.09_00456 Uncharacterised protein  
Data01.09_00457 Soj (parA) protein (plasmid and chromosome partitioning) 
Data01.09_00458 Spo0J (parB) protein (plasmid and chromosome partitioning) 
Data01.09_00459 Collagen-binding Cna protein, TonB-dependent receptor 
Data01.09_00460 Uncharacterised protein 
Data01.09_00461 RadA - ATP-dependent protein (DNA repair and degradation of proteins) protease 
Data01.09_00462 Uncharacterised protein 
Data01.09_00463 Superfamily II DNA and RNA helicase (RNA and DNA metabolism) 
Data01.09_00464 Uncharacterised protein 
Data01.09_00465 None 
Data01.09_00466 Uncharacterised protein 
Data01.09_00467 Uncharacterised protein 
Data01.09_00468 Endonuclease relaxase, MobA/VirD2 
Data01.09_00469 Uncharacterised protein 
Data01.09_00470 Uncharacterised protein 
Data01.09_00471 Conjugative transfer of transposon-like mobile genetic elements 
Data01.09_00472 Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase 
Data01.09_00473 Adenine-specific methyltransferase (macrolide resistance) 
Data01.09_00474 Uncharacterised protein 
Data01.09_00475 Phd_YefM (antitoxins in type II toxin-antitoxin systems) 
Data01.09_00476 Plasmid stabilisation system protein 
Data01.09_00477 Uncharacterised protein  
Data01.09_00478 PrgI family protein (uncharacterised protein)   
Data01.09_00479 AAA-like domain protein (uncharacterised protein) 
Data01.09_00480 Modification methylase MboII (DNA methylation) 
Data01.09_00481 Uncharacterised protein 
Data01.09_00482 Sortase B (surface protein attachment) 
Data01.09_00483 Transglycosylase (enzymatic activity) 
Data01.09_00484 MerR family transcriptional regulator (DNA binding) 
Data01.09_00485 Uncharacterised protein 
Data01.09_00486 Uncharacterised protein 
Data01.09_00487 Conjugative transposon protein (enzymatic activity) 
Data01.09_00488 Tetracycline resistance, transcriptional regulator 
Data01.09_00489 Iron-sulfur protein (4Fe-4S binding domain) 
Data01.09_00490 Multi antimicrobial extrusion protein (drug transportation) 
Data01.09_00491 DNA binding, transcriptional regulator   
Data01.09_00492 ABC transporter family protein (membrane transport) 
Data01.09_00493 ftsX-like permease family protein (membrane structure) 
Data01.09_00494 Two-component response regulator (uncharacterised protein)  
Data01.09_00495 Two-component sensor histidine kinase (environmental stimuli response) 
Data01.09_00496 Cysteine-rich KTR (uncharacterised protein) 
Data01.09_00497 RNA polymerase ECF-type sigma factor (RNA transcription) 
Data01.09_00498 PemK family transcriptional regulator (cell growth regulation) 
Data01.09_00499 Short C-terminal (SHOCT) domain (oligomerisation and nucleic acid binding) 
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4.4.2 Phenotypic comparison of isolates from London hospitals 
With the findings that isolates of cluster 1-UHL haplotypes contained a gene 
putatively associated with antimicrobial resistance (multidrug family ABC 
transporter permease) and a 49 kbp genetic region exclusive to the cluster 1-UHL 
isolates with genes potentially involved in sporulation and antimicrobial resistance 
(sortase B gene, the sporulation gene spo0J and genes associated with antimicrobial 
resistance; tetracycline resistance and a multi antimicrobial extrusion protein), 
phenotypic assays were performed to try and identify a phenotype unique to the UHL 
clonal isolates that may play a role in environmental persistence and/or transmission. 
Isolates were selected to identify characteristics that would contribute to the ability 
of the cluster 1-UHL isolates to persist and spread in a population and environment; 
a strain with increased speed of growth, sporulation, germination, resistant 
antibiogram and resistance to hospital disinfectant/s would be at advantage to persist 
and spread. Four London isolates were selected based on them having the most 
variation with regards to isolation date and geographical location; UHL-1, UHL-3, 
UHL-19 and CX-32.  
4.4.2.1 Growth kinetics 
In vitro growth curves were performed to identify any differences in growth kinetics 
between the UHL and non-UHL isolates. In order to measure growth rates, isolates 
were grown at 37 °C anaerobically in BHIS broth and cell densities were measured 
by monitoring the OD590 over time, this was performed in duplicate and with three 
independent biological experiments.  
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Overall the growth rates of strains UHL-3, UHL-19, CX-32 and the control strain 
M68 were similar to one another (Figure 4.4), all entering stationary phase at around 
six hours. However, the growth rate of UHL-1 was consistently slower entering 
stationary phase at around seven hours. At four hours, the cell density for UHL-19 
was marginally higher compared to UHL-1 (p≤ 0.05) and at five hours, the cell 
density for UHL-19 and CX-32 was significantly higher (p≤ 0.0001) and for M68 
was marginally higher (p≤ 0.05) compared to UHL-1. The cell density for UHL-3 
was also marginally higher compared CX-32 (p≤ 0.05). The cell density for M68 and 
UHL-3 at six hours was significantly higher compared to UHL-1 (p≤ 0.01). At 24 
hours, the cell density for CX-32 was significantly higher compared to M68, UHL-
19 and UHL-1 (p≤ 0.001, p≤ 0.0001 and p≤ 0.01 respectively) and that for UHL-3 
was marginally higher compared to M68 and significantly higher compared UHL-19 
(p≤ 0.05 and p≤ 0.001 respectively).  
 
These experiments show the historical isolate from UHL (UHL-1) to have a slower 
growth rate compared to the more recent isolates from UHL (UHL-3 and UHL-19), 
the reference strain M68 and the isolate from Charing Cross hospital (CX-32). 
However, no statistically significant differences in growth rate between UHL and 
non-UHL isolates were observed. 
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Figure 4.4: Growth kinetics for the London C. difficile phenotypic study isolates 
 
The data represent the average of three independent experiments and duplicate 
technical replicates from separate cultures of five strains. Statistical significance was 
assessed using Two-Way ANOVA followed with Tukey’s multiple comparison tests 
in GraphPad Prism. Although there was some variation between isolates, no 
statistically significant differences in growth rate between UHL and non-UHL 
isolates were observed that could explain the persistence of the cluster 1-UHL clone. 
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4.4.2.2 Sporulation 
To investigate the rate at which the four London C. difficile phenotypic study isolates 
formed spores in vitro, the isolates were grown in medium supplemented with 
cysteine and yeast extract as the organism is known to sporulate well under these 
conditions (Sorg and Sonenshein, 2008). Cells were inoculated to fresh secondary 
cultures and grown anaerobically; samples were taken at 24 hours, 72 hours and 144 
hours and were subjected to heat treatment at 60 ºC for 30 minutes to kill vegetative 
cells but not the spores. Colony forming units were enumerated on blood agar 
supplemented with sodium taurocholate which has been shown to induce 
germination of C. difficile. 
  
The control strain M68 appears to have a slower sporulation rate than the other 
strains, but they all peak at a similar cfu by 144 hours (Figure 4.5). The sporulation 
rate of the control strain M68 increases from log 4 to log 5 between 24 hours and 72 
hours then log 5 to log 6.5 at 72 hours to 144 hours. This is in comparison to the 
other strains that were already sporulating between log 5 to log 6.5 hours at 24 hours 
and 72 hours but then reached their peak sporulation and did not increase anymore 
between 72 hours and 144 hours. At 24 hours, CX-32 had a higher spore count 
compared to UHL-19 and the control strain M68 (p≤ 0.001 and p≤ 0.0001 
respectively) and UHL-1 was significantly higher than control strain M68 (p≤ 0.01). 
At 72 hours, UHL-19 had a significantly higher spore count compared to control 
strain M68, UHL-3, CX-32 and a marginally higher spore count compared to UHL-1 
(p≤ 0.01, p≤ 0.01, p≤ 0.01 and p≤ 0.05 respectively). UHL-19 had a higher spore 
count at 144 hours, though this was not statistically significant.  
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These spore assays showed variation in sporulation rates with the isolate from 
Charing Cross hospital (CX-32) producing more spores after 24 hours incubation 
compared with the other four isolates, and the environmental isolate from UHL 
produced more spores after 72 hours incubation. Four isolates were found to 
sporulate to higher cfus than the control strain M68 at 24 hours and 72 hours, 
however, no statistically significant differences in sporulation rate between cluster 1-
UHL and non-cluster 1-UHL isolates were observed. 
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Figure 4.5: Total spores recovered at 24 hours, 72 hours and 144 hours for the London C. difficile phenotypic study isolates 
 
The data represent the average of three independent experiments and duplicate technical replicates from separate cultures. Statistical significance 
was assessed using One-Way ANOVA followed with Tukey’s multiple comparison tests in GraphPad Prism. Error bars indicate the standard 
error of the means and significant differences are marked with a bracket (* = p≤ 0.05, ** = p≤ 0.01, *** = p≤ 0.001 and **** = p≤ 0.0001). 
Although there was some variation between isolates, no statistically significant differences in spore production between UHL and non-UHL 
isolates were observed that could explain the persistence of the cluster 1-UHL clone. 
48 hours 24 hours 72 hours 
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4.4.2.3 Percentage spore production 
To estimate the rate of sporulation more accurately, and to take into account possible 
variation in cell growth rate, the sporulation rates were expressed as percentage of 
spores to vegetative cells and calculated as follows: [N spore count *100] / N all cell 
count. Percentage spore production for the study isolates are shown in Figure 4.6. 
The percentage spore production for the non-UHL isolate (CX-32) at 72 hours was 
significantly higher than the UHL isolate (UHL-3) but only marginally higher than 
the control strain M68 (p≤ 0.01 and p≤ 0.05 respectively). No significant difference 
in the percentage spore production was observed at 24 hours or 144 hours. No 
statistically significant differences in percentage spore production between cluster 1-
UHL and non-cluster 1-UHL isolates were observed. 
 
163 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Percentage spores recovered at 24 hours, 72 hours and 144 hours for the London C. difficile phenotypic study isolates 
 
The data represent the average of three independent experiments and duplicate technical replicates from separate cultures. Statistical significance 
was assessed using One-Way ANOVA followed with Tukey’s multiple comparison tests in GraphPad Prism. Error bars indicate the standard 
error of the means and significant differences are marked with a bracket (* = p≤ 0.05, ** = p≤ 0.01, *** = p≤ 0.001 and **** = p≤ 0.0001). 
Although there was some variation between isolates, no statistically significant differences in percentage spore production between UHL and 
non-UHL isolates were observed that could explain the persistence of the cluster 1-UHL clone. 
48 hours 24 hours 72 hours 
164 
 
4.4.2.4 Total cell recovery 
To investigate the total cell recovery (vegetative cells and spores) characteristics, 
cfus were enumerated on blood agar supplemented with sodium taurocholate without 
heat treatment which allows for all cells, both vegetative cells and spores to be 
recovered. These counts are shown in Figure 4.7. No significant differences were 
observed in the cell counts at 24 hours and 144 hours, however, at 72 hours, the cell 
count for the control strain M68 were marginally higher than CX-32 (p≤ 0.05). No 
statistically significant differences in all cell recovery rates between cluster 1-UHL 
and non-cluster 1-UHL isolates were observed. 
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Figure 4.7: Total cells recovered at 24 hours, 72 hours and 144 hours for the London C. difficile phenotypic study isolates 
 
The data represent the average of three independent experiments and duplicate technical replicates from separate cultures. Statistical significance 
was assessed using One-Way ANOVA followed with Tukey’s multiple comparison tests in GraphPad Prism. Error bars indicate the standard 
error of the means and significant differences are marked with a bracket (* = p≤ 0.05, ** = p≤ 0.01, *** = p≤ 0.001 and **** = p≤ 0.0001). 
Although there was some variation between isolates, no statistically significant differences in total cell production between UHL and non-UHL 
isolates were observed that could explain the persistence of the cluster 1-UHL clone. 
48 hours 24 hours 72 hours 
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4.4.2.5 Minimum inhibitory concentrations 
MICs were determined using the broth dilution method against the antibiotics; 
metronidazole, vancomycin, erythromycin, lincomycin, fusidic acid, naladixic acid, 
rifampicin and rifamycin. MIC data are shown in Table 4.5.  
 
 
Table 4.5: MIC assay data for the London phenotypic study isolates 
 
 
 
 
 
 
 
Isolate 
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Antibiotic and MIC value (µg/ml) 
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M68 2-M68 1.5 1 ≥ 256 ≥ 256 4 128 ≤ 0.5 ≤ 0.5 
UHL-3 2-M68 1.5 1 ≥ 256 ≥ 256 4 128 ≤ 0.5 ≤ 0.5 
UHL-1 1-UHL 1.5 1 ≥ 256 ≥ 256 4 128 ≤ 0.5 2 
UHL-19 1-UHL 1.5 1 ≥ 256 ≥ 256 4 128 ≤ 0.5 ≤ 0.5 
CX-32 3 1.5 1.5 ≤ 0.5 32 4 128 ≤ 0.5 ≤ 0.5 
 
Five strains were tested using an antibiotic range of 0 (negative control) to 256µg/ml. 
The data represent the average of at least two independent experiments and duplicate 
technical replicates from separate cultures. Although there was variation in MICs 
between some isolates, no defined antibiogram was exclusive to the cluster 1-UHL 
isolates. 
 
 
Although no antimicrobial susceptibility phenotype exclusive to the cluster 1-UHL 
isolates was identified, there were some notable variations. Compared with the other 
four isolates tested, the historic isolate UHL-1 had a higher MIC to the antibiotic 
rifaximin, one that is considered as intermediate resistance in the clinical setting. 
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This isolate (haplotype I) was shown in this study to have five additional SNPs 
compared to the core modern UHL sample haplotype A (Tables 4.2 and 4.3). Three 
SNPs were non-synonymous and found in; the rpoB gene, an ABC transporter and in 
a two-component response regulator resulting in a stop-codon. The remaining two 
SNPs were synonymous and found in a gntR gene (family transcriptional regulator) 
and the other a hypothetical protein of unknown function.  
 
Isolate CX-32 from a patient at Charing Cross hospital had significantly lower MICs 
to the macrolide antibiotics; erythromycin and lincomycin compared with the other 
four isolates tested (the three isolates from cluster 1-UHL tested phenotypically were 
found resistant). De novo analysis in this study revealed all isolates in cluster 1-UHL 
and isolates M68, QM-34, NM-27, B-26 and B-33 to carry the well characterised 
transposon Tn6194 which carries the ermB gene and is known to confer resistance to 
the macrolide class of antibiotics (Brouwer et al., 2013). Isolates WX-35, WX-36 
and NP-25 and all isolates in cluster 3 which includes CX-32 were found not to carry 
or have lost this transposon.  
4.4.2.6 Disinfectant susceptibility assays  
Studies have found C. difficile spores are able to survive the recommended 1000 
parts-per million strength for chlorine releasing agents (Dawson et al., 2011, 
Kulikovsky et al., 1975). This could explain the persistence of the cluster 1-UHL 
isolates. Actichlor Plus, a combined chlorine releasing agent plus a detergent was the 
commonly used disinfectant at UHL. To investigate the resistance to Actichlor Plus 
as a cause of the cluster 1-UHL isolates environmental persistence, the susceptibility 
to this disinfectant was determined for the four study isolates tested phenotypically 
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and the control strain M68. These data are shown in Figure 4.8. The disinfectant 
Actichlor Plus at a concentration of 1000 parts-per million demonstrated ≥ 99% 
efficacy with all five isolates tested. Furthermore, to take into consideration possible 
variation in germination and sporulation rates, the percentage survival was calculated 
which showed no significant variation (Figure 4.9). No statistically significant 
variation in the susceptibilities to Achtichlor Plus was observed between the isolates 
tested. 
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Figure 4.8: Total Achtichlor Plus assay data for the London C. difficile 
phenotypic study isolates 
 
The data represent the average of three independent experiments and duplicate 
technical replicates from separate cultures. Statistical significance was assessed using 
One-Way ANOVA followed with Tukey’s multiple comparison tests in GraphPad 
Prism. Error bars indicate the standard error of the means and significant differences 
are marked with a bracket (* = p≤ 0.05, ** = p≤ 0.01, *** = p≤ 0.001 and **** = p≤ 
0.0001). The disinfectant Actichlor Plus at a concentration of 1000 parts-per million 
demonstrated ≥ 99% efficacy with all five isolates tested though no statistically 
significant variation in susceptibility between isolates was observed. 
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Figure 4.9: Percentage survival following Actichlor Plus treatment for the 
London C. difficile phenotypic study isolates 
 
The data represent the average of three independent experiments and duplicate 
technical replicates from separate cultures. Statistical significance was assessed using 
One-Way ANOVA followed with Tukey’s multiple comparison tests in GraphPad 
Prism. Error bars indicate the standard error of the means and significant differences 
are marked with a bracket (* = p≤ 0.05, ** = p≤ 0.01, *** = p≤ 0.001 and **** = p≤ 
0.0001). No statistically significant variation in the percentage survival following 
Achtichlor Plus treatment between the isolates tested was observed. 
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4.5 Discussion 
Using PCR ribotyping, WGS and phenotyping assays, my study investigated a total 
of 37 C. difficile PCR ribotype 017 isolates (Table 4.1); 22 strains isolated from 
humans who at different times were present on the same hospital ward at UHL, two 
environmental strains isolated from the same hospital ward and 13 contemporaneous 
strains isolated from humans from other London hospitals. 
 
My data shows that the C. difficile isolates from UHL are clonal and genotypically 
different to C. difficile isolates from other London hospitals included in my study. 
Phylogenetic analysis of SNPs revealed three diverging sub-lineages of C. difficile 
PCR ribotype 017 (cluster 1-UHL, cluster 2-M68 and cluster 3) with 96.3% of SNP 
loci found exclusively in only cluster 1-UHL. Through de novo assembly analysis, a 
49 kbp genetic region that further differentiated cluster 1-UHL isolates from cluster 
2-M68 and cluster 3 isolates was revealed. Although not all virulence genes are on 
mobile genetic elements, mobile genetic elements commonly carry virulence genes 
(Pallen and Wren, 2007) and the presence of putative virulence genes within this 49 
kbp genetic region suggests that it may be a transposon-like putative mobile genetic 
element. To prove it is a transposon-like mobile genetic element and has been 
acquired by the clonal strains, the sequences spanning the insertion site of the 49 kbp 
genetic region could be sequenced using long read sequencing methodologies such as 
MinION or PacBio (Table 1.4, Page 61). This would confirm element and location 
and would help determine if the 49 kbp genetic region is similar to a known 
transposable element or meets the criteria to be assigned as a new transposable 
element, i.e. evidence of excision from the chromosome and presence of accessory 
genes not associated with transfer and which may encode functions that contribute to 
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a survival advantage, commonly antimicrobial resistance  (Roberts et al., 2008, 
Campbell et al., 1979). Additionally, to meet the definition of a transposable element 
“specific DNA segments that can repeatedly insert into one or more sites in one or 
more genomes” (Roberts et al., 2008), bacterial mating experiments may also be 
attempted to confirm the genetic region is mobile and the phenotype is transferable 
(Brouwer et al., 2013, Hussain et al., 2005, Roberts et al., 2001). 
 
A non-synonymous SNP in the bioB gene (Appendix 3, Page 256) was present in all 
isolates of cluster 1-UHL and cluster 3. This is one of four genes that play a major 
role in the biotin biosynthetic pathway (Satiaputra et al., 2016). Biotin mediates the 
transport of CO2 in many vital metabolic reactions and is essential for life. 
Interestingly, studies have shown decreased available biotin results in increased toxin 
synthesis by C. difficile (Yamakawa et al., 1996). This SNP may affect biotin 
production, limiting its availability and in-turn increasing toxin synthesis. It would be 
worth investigating this phenomenon by repeating the assay reported in the study by 
Yamakawa et al., which is dated. Here we could study the effect of biotin on toxin 
production between isolates from the different London clusters. 
 
With the identification of a unique genotype and to identify a phenotype exclusive to 
the UHL outbreak isolates that may play a role in environmental persistence and/or 
transmission, phenotypic assays were performed on five isolates (UHL-1, UHL-3, 
UHL-19, CX-32 and the control strain M68) to place these strains into geographical 
and historical context. Variations in growth kinetics, sporulation, sporulation rates, 
vegetative cell counts and antimicrobial susceptibility were observed, though none 
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were statistically significant that would differentiate cluster 1-UHL and non-cluster 
1-UHL isolates. There were no significant variations in susceptibility to the 
disinfectant Actichlor Plus between those isolates tested, indicating therefore that 
there was no potential survival advantage observed for the UHL isolates with regards 
to susceptibility to this disinfectant. A phenotype exclusive to the UHL outbreak 
isolates that may play a role in environmental persistence and/or transmission was 
not identified.  
 
Although no statistically significant difference in antimicrobial susceptibility 
differentiating cluster 1-UHL and non-cluster 1-UHL isolates was found, there were 
some interesting observations. The three isolates from cluster 1-UHL (UHL-1, UHL-
3 and UHL-19) were found phenotypically resistant and the isolate from Charing 
Cross hospital (CX-32) had significantly lower MICs to the macrolide antibiotics 
erythromycin and lincomycin. De novo analysis showed that isolate CX-32 did not 
carry or had lost the well characterised transposon Tn6194 which carries the ermB 
gene of which is known to confer resistance to the macrolide class of antibiotics 
whereas all isolates in cluster 1-UHL and isolates M68 did carry this transposon. 
This may explain the variation in susceptibility of these isolates to erythromycin as 
the ermB gene is required for resistance to erythromycin and lincomycin (Wust and 
Hardegger, 1983, Hachler et al., 1987, Farrow et al., 2000). As previously described, 
CDI is associated with prior antimicrobial therapy and patients > 65 years of age. A 
common cause of hospitalisation in elderly patients is for the management of 
community acquired pneumonia; this is frequently treated with the macrolide class of 
antimicrobials to cover atypical pathogens and/or those patients who are penicillin 
allergic. Of note the reference strain M68 was also resistant to the macrolide 
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antibiotics and this strain was associated with outbreaks of CDI in Ireland (Drudy et 
al., 2007b, Drudy et al., 2007c). It may be hypothesised that this resistance may have 
contributed to the establishment of the outbreak at UHL. A clonal cluster of C. 
difficile that is exclusively resistant to an antimicrobial may have implications for 
antimicrobial stewardship. The occurrence of a clonal cluster of isolates with a 
specific antibiogram combined with time of sampling, patient location with regards 
to time and place and details of antimicrobial prescriptions will enable clinicians to 
decide if they need to alter local antimicrobial stewardship. 
 
The historical isolate UHL-1 had a higher MIC to the antibiotic rifaximin, one that is 
considered as intermediate resistance in the clinical setting. This isolate (haplotype I) 
was also found to have five additional SNPs compared to the core modern UHL 
sample haplotype A (Tables 4.2 and 4.3). Three of these were non-synonymous and 
found in; the rpoB gene, an ABC transporter and in a two-component response 
regulator resulting in a stop-codon. Rifaximin resistance has been associated with 
SNPs in the rpoB gene of C. difficile (O'Connor et al., 2008, Curry et al., 2009) and 
so it is possible that the higher MIC to rifaximin in this historical isolate is a 
consequence of the non-synonymous SNP in the rpoB gene. Rifaximin is a treatment 
option for recurrent CDI, but rarely used for this indication, however, it is used for 
other bacterial infections in hospitalised patients. It would be worth investigating if 
the higher MIC to rifaximin is a consequence of the non-synonymous SNP in the 
rpoB gene since this resistance may have given the historical isolate a selective 
advantage allowing the persistence of the UHL cluster like that observed with the 
epidemic PCR ribotype 027 strain and its resistance to the fluoroquinolone class of 
antibiotics (He et al., 2013).  
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The transposon-like putative mobile genetic element identified in this study encodes 
a gene putatively associated with tetracycline resistance; a tetracycline resistance 
transcriptional regulator (Table 4.4). Transcriptional regulators are known to control 
the expression of genes associated with tetracycline resistance, for example the tet 
class of genes (Ramos et al., 2005). The presence of a putative tetracycline resistance 
transcriptional regulator may play an indirect role in resistance to tetracycline; 
however, the isolates selected for phenotypic study were not tested for susceptibility 
to tetracycline. 
 
With the observations associated with the macrolides, rifaximin and tetracycline, it 
may be hypothesised that prior administration of these antimicrobials may have 
contributed to the cluster 1-UHL outbreak; it would be plausible to investigate if use 
of these antibiotics were a contributory cause of the outbreak at UHL. A timeline of 
CDI cases and prescriptions of these antibiotics would illustrate this and may alter 
local antimicrobial stewardship as well as susceptibility testing against tetracycline. 
 
There were limitations in this study. Firstly, the choice of control isolate used for 
detection of SNPs and de novo analysis of insertions and deletions; obviously results 
will vary depending upon which control strain is used for comparison. This study 
compared the genomes of the study isolates with the reference genome of the 
C. difficile PCR ribotype 017 strain M68 GenBank accession number FN668375 (He 
et al., 2010). This was the most appropriate strain to use as a control for this study 
since only two reference genomes of C. difficile PCR ribotype 017 were available 
and there was a better understanding of strain M68 with it being involved in 
outbreaks in Ireland (Drudy et al., 2007a, Drudy et al., 2007b). Another limitation in 
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this study is the methodology applied for the detection of SNPs. The method 
obviously reads only the parts of the genome that match the control strain that it is 
assembled against; if there are regions of the genome that are not present in the 
control strain, then these regions are not analysed for SNPs. The methodology also 
does not read regions of repetitive DNA (sequences that are similar or identical to 
sequences elsewhere in the genome); therefore, any differences in repetitive regions 
between strains are not detected. Another limitation in this study is the methodology 
applied for the identification of unique genomic regions indicative of horizontal gene 
transfer; the method is programmatic and relies on visual inspection of comparisons 
using the ACT application. This has limitations in that it is manual and when 
analysing multiple strains, there is potential for user error.  
4.6 Conclusion 
This is the first study in the UK to investigate the phylohistory of isolates from 
hospitalised patients with CDI due to C. difficile PCR ribotype 017. It is a snapshot 
of isolates and suggests that a clonal strain of C. difficile toxin A-B+ PCR ribotype 
017 has persisted in a ward at one London hospital for at least five years and which is 
different to C. difficile PCR ribotype 017 strains that are circulating in other London 
hospitals. The clonal strain was found to exclusively harbour a 49 kbp genetic region 
suggestive of being a transposon-like putative mobile genetic element however, no 
phenotype exclusive to this cluster was revealed. The C. difficile PCR ribotype 017 
lineage, with its unique toxin profile and unusual global prevalence, is understudied. 
My study shows that there are existing questions about the population structure and 
epidemiology of C. difficile toxin A-B+ PCR ribotype 017 strains. 
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5 The global phylogeny of C. difficile PCR ribotype 017 
5.1 Statement of contribution 
Isolate selection, PCR ribotyping and genomic DNA extractions were performed by 
M. Cairns. WGS were performed both at the WTSI by D. Harris and at the LSHTM 
by M. Cairns. The collection of epidemiology data were performed by M. Cairns. 
SNP calling were performed by Dr Mark Preston. De novo assembly were performed 
by M. Cairns with help from Dr Richard Stabler. MIC assays were performed by 
Catherine Hall (LSHTM). Data interpretation was performed by M. Cairns.  
 
5.2 Introduction 
With testing a larger collection of strains (n=385) of multiple PCR ribotypes isolated 
from multiple sources and geographical locations using MLST, chapter 3 confirmed 
that C. difficile is made up of five phylogenetic lineages; PCR ribotypes 017, 023, 
027, 078 and a heterogeneous grouping of mixed PCR ribotypes. The MLST data 
found no association between sequence type and geographical location or source. 
The lineage associated with PCR ribotype 027 has been investigated further using 
WGS and identified the presence of two genetically diverse global sub-lineages (He 
et al., 2013), however, less is known about the in-depth phylogeny of the other four 
lineages of C. difficile.  
 
Historically, C. difficile PCR ribotype 017 strains were identified in outbreaks of 
CDI in Asia; it is thought that PCR ribotype 017 spread from Asia to Europe and 
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other continents (Hawkey et al., 2013, Collins et al., 2013) however, this hypothesis 
has never been tested. In chapter 4, I investigated PCR ribotype 017 on a local scale 
where WGS identified a clonal strain from a single ward in a London hospital. WGS 
can also be applied to a larger collection of strains from multiple sources isolated 
over a large time scale to elucidate the phylogeny of a species like that applied to 
PCR ribotype 027 (He et al., 2013). No study had yet investigated the phylogeny of a 
large, global collection of PCR ribotype 017 strains using WGS, therefore, it is 
unknown if there are sub-lineages of PCR ribotype 017 like that seen with PCR 
ribotype 027. WGS would provide far superior discrimination compared with MLST.  
 
The two lineages of PCR ribotype 027 identified through WGS had emerged in USA 
within a relatively short period of time after acquiring the same fluoroquinolone 
resistance conferring mutation (He et al., 2013). This implies that antimicrobial 
resistance played a significant role in driving the global spread of PCR ribotype 027. 
Reduced susceptibility and resistance to the first-line antimicrobial agents 
metronidazole and vancomycin have been described in C. difficile although the 
mechanisms of resistance are still not completely understood (Pelaez et al., 2008, 
Brazier et al., 2001, Chong et al., 2014, Goudarzi et al., 2013, Adler et al., 2015). It 
has been suggested that resistance to metronidazole is attributable to mutations 
within multiple genomic loci, including genes responsible for altered iron 
metabolism (Chong et al., 2014) whilst resistance to vancomycin may be due to 
amino acid changes in the peptidoglycan biosynthesis (Leeds et al., 2014). Reduced 
susceptibility to antibiotics commonly used for bacterial infections (other than C. 
difficile) not only contribute to the occurrence of CDI, but also in driving the 
evolution of C. difficile and emergence of new strains and lineages, like that 
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described with PCR ribotype 027 and fluoroquinolone resistance (He et al., 2013). 
Therefore, investigating other antimicrobials not routinely used in the treatment of 
CDI for resistance is useful for surveillance purposes. Resistance to the 
fluoroquinolone class of antimicrobials is attributable to mutations in the quinolone 
resistance determining region of the gyrA and/or gyrB genes (Ackermann et al., 
2001, Drudy et al., 2006, Drudy et al., 2007d). Resistance to rifampicin has also been 
observed in C. difficile and this is due to alterations in the rpoB gene encoding the 
RNA polymerase (Freeman et al., 2015). 
 
Antimicrobial resistance is confirmed phenotypically; an organism is grown in the 
presence of varying concentrations of an antimicrobial and the MIC is determined 
(Andrews, 2001).  The most common phenotypic methodologies are the agar dilution 
and episilometer test (Etest) however; these methods are laborious and time-
consuming. To overcome this, the molecular detection of known antimicrobial 
resistance determinants is employed. In the diagnostic setting, commercial target-
specific PCR platforms for the molecular detection of organisms and antimicrobial 
genotypes such as the Xpert
®
 platform mentioned in chapter 3 are available. This 
platform and similar have advanced the routine diagnostic microbiology laboratory 
improving the sensitivity of target detection and turn-around times of results. This is 
beneficial for organisms that possess fastidious growth requirements i.e. 
Mycobacterium tuberculosis and C. difficile. The molecular detection of a pathogen 
with a genotype associated with antimicrobial resistance in a diagnostic 
microbiology setting is also useful when prompt bed management is required. For 
example, the prompt detection of patients colonised with MRSA allowing infection 
control interventions such as cohorting and decolonisation (Jeyaratnam et al., 2008). 
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Additionally, the clinical management of a patient with sepsis is likely improved 
whereby reducing exposure to unnecessary broad-spectrum antibiotics would reduce 
the selective pressure for the development of antimicrobial resistance. However, such 
PCR platforms that are used in diagnostic microbiology laboratories are target 
specific and therefore limited to providing only the detection of that specifically 
sought. 
 
As well as SNPs that confer antimicrobial resistance, mobile genetic elements such 
as transposons are also important whereby they often carry genes associated with 
antimicrobial resistance (Wiedenbeck and Cohan, 2011). Through De novo 
assembled genome analysis, the clonal strain of PCR ribotype 017 identified in 
chapter 4 was found to exclusively possess a 49 kbp genetic region suggestive of 
being a transposon-like putative mobile element which would not have been revealed 
by conventional typing methodologies.  
 
WGS allows the unbiased analysis of the bacterial genome to detect putative 
antimicrobial resistance determinants, differentiate between varying mechanisms 
resulting in the same resistance pattern and identify new resistance determinants all 
in a single assay. Although WGS is not routinely used to detect a bacterium’s 
antimicrobial phenotype, high concordance between genotypic and phenotypic 
resistance in multiple pathogens has been shown (Zankari et al., 2013, Read and 
Massey, 2014, Palmer and Kishony, 2013). Therefore WGS acts as a useful tool to 
predict phenotypic antimicrobial resistance which is useful diagnostically for a 
patient and also for surveillance and identification of clonal expansions that may be 
driven by antimicrobial resistance. PCR ribotype 017 has been associated with higher 
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levels of antimicrobial resistance compared with other PCR ribotypes (Drudy et al., 
2007b), however, it is not known if there are sub-lineages of PCR ribotype 017 and if 
there are, if antimicrobial resistance played a role in their spread like with the sub-
lineage of PCR ribotype 027 (He et al., 2013). 
 
C. difficile is known to cause similar infection in both humans and animals and it is 
well documented that PCR ribotype 078 is the predominant PCR ribotype isolated 
from animal species with CDI (Keel et al., 2007, Jhung et al., 2008, Rupnik et al., 
2008). Although C. difficile is not a proven food-borne pathogen, there is evidence 
that the same strain can cause symptomatic disease in both pigs and humans (Debast 
et al., 2009) and data from chapter 3 indicate that strains isolated from humans, 
animals and food origins are not phylogenetically distinct by MLST. With a global 
collection of C. difficile PCR ribotype 017 strains, it is therefore plausible to 
hypothesise that C. difficile PCR ribotype 017 isolated from human and non-human 
sources are not distinct by WGS. 
5.3 Hypotheses of the research described in this chapter 
The data in chapter 4 suggests a clonal strain of C. difficile toxin A-B+ PCR ribotype 
017 has persisted in London for five years. This clonal strain was found to 
exclusively harbour a 49 kbp genetic region suggestive of being a transposon-like 
putative mobile genetic element. The PCR ribotype 017 lineage, with its unique toxin 
profile and unusual global prevalence, is understudied. There are existing questions 
about the population structure and epidemiology of toxin A-B+ PCR ribotype 017 
strains; by resolving these may have implications on the awareness of this PCR 
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ribotype and whether this needs to be heightened. This study was designed to test the 
following hypotheses: 
 
Chapter 5: hypothesis 1 
One or more SNP/s and/or insertions or deletions (including those associated with 
antimicrobial resistance) are associated with the global spread of C. difficile PCR 
ribotype 017.  
 
Chapter 5: hypothesis 2 
C. difficile PCR ribotype 017 isolated from different geographical origins are 
phylogenetically distinct by WGS.  
 
Chapter 5: hypothesis 3 
C. difficile PCR ribotype 017 isolated from human and non-human sources are not 
phylogenetically distinct by WGS.  
 
Chapter 5: hypothesis 4 
C. difficile PCR ribotype 017 originated in Asia.  
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5.4 Results  
In order to test my hypotheses, I aimed to collate the first global collection of C. 
difficile PCR ribotype 017 strains isolated from a broad range of hosts and 
geographical locations. In order to do this, I established a network of global 
collaborators which was initially started by networking with fellow researchers at 
international conferences and poster sessions. A total of 384 C. difficile isolates were 
collated from collaborators (Page 27).  
 
Upon receipt of strains from collaborators all isolates were propagated on appropriate 
culture media (Sections 2.2.2, Page 70 and 2.2.3, Page 71). Before inclusion in the 
collection of strains, I first confirmed they were PCR ribotype 017 by PCR 
ribotyping and agarose gel electrophoresis (Section 2.3.1, Page 77). A total of 277 
isolates were confirmed to be PCR ribotype 017 and were included for study. This 
collection of 277 strains were from; human (n=251), bovine (n=9), canine (n=11), 
equine (n=4) and hospital ward environment (n=2) with isolation dates between 1990 
and 2013 and included isolates from six global continents (Appendix 2, Page 249). 
Once confirmed, in preparation for WGS, DNA was quantified (Section 2.3.3.2, Page 
84) and WGS was performed using Illumina Sequencing Technology (Sections 
2.3.3.3, Page 85 and 2.3.3.4, Page 88). SNPs and haplotypes were identified by 
sequence mapping and assembly (Sections 2.3.3.5, Page 85 to 2.3.3.9, Page 92 
inclusive) and de novo genome assembly analysis and visual inspection using ACT 
was performed to identify genomic deletions and insertions (Section 2.3.3.10, Page 
92). Software tools were used to produce phylogenetic trees to enable visual 
comparisons of SNP differences in the global collection of C. difficile isolates 
(Section 2.3.9, Page 91) and phenotypic antimicrobial susceptibility testing was 
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performed on select isolates (S- 017.72, WA 1514, S- 017.92, S- 017.27, S- 017.74, I 
6 and 01-116) to identify an antibiogram that may be exclusive to a particular group 
of isolates and/or one which correspond with genotypic data (Section 2.2.7, Page 73). 
To investigate the phenomenon that C. difficile PCR ribotype 017 originated in Asia, 
global transmission events were inferred from bayesian evolutionary and geo-
temporal analyses of the collection of 277 C. difficile PCR ribotype 017 isolates 
(Section 2.3.9, Page 91).  
 
 
5.4.1 The phylogeny of a global collection of C. difficile PCR ribotype 
017 strains using PCR ribotyping and WGS 
5.4.1.1 PCR ribotyping 
All 277 isolates in this study were confirmed to be PCR ribotype 017 by PCR 
ribotyping and agarose gel electrophoresis. Reference strains R20291 (PCR ribotype 
027) and M68 (PCR ribotype 017) were used as controls and all isolates were 
assumed to be toxinotype VIII, A-B+ based on their being PCR ribotype 017. There 
are no known reports of PCR ribotype 017 having any other toxin profile other than 
toxinotype VIII, A-B+. 
5.4.1.2 Inference of phylogeny using SNP data 
To investigate the phylogeny and clonality of the isolates in this study, after 
sequence quality control and mapping to the control strain M68 reference genome, 
SNP analysis revealed 1288 bi-allelic SNPs with 311 present in greater than 1% of 
samples and greater than 1 bp from an insertion or deletion. Of these SNPs, 65.6% 
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(204/311) were non-synonymous (Appendix 3, Page 256), 17.7% (55/311) 
synonymous and 16.7% (52/311) were present in non-coding regions of the genome. 
Twelve SNPs affected stop-codons; eleven non-synonymous and one synonymous 
(Table 5.1). SNP data revealed 109 haplotypes containing between 0 and 52 SNPs 
with 76.5% (212/277) of isolates having between 10 and 35 SNPs compared to the 
reference genome. 
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Table 5.1: Stop-codon associated SNPs for the global isolates 
Position in the 
M68 genome 
M68 
Reference 
Codon 
Alternative 
Codon 
Non-
Synonymous / 
Synonymous 
Gene Predicted Function and/or Potential Impact 
No. of isolates 
with SNP 
1907433 TAA GAA NS msrAB Peptide methionine sulfoxide reductase 256 
1204039 GGA TGA NS M68_01144 Hydrolase 36 
3304067 TCA* GCA* NS Sigma-54 Controls expression of nitrogen related genes 29 
132573 TGG TGA NS M68_00168 Amino acid aminotransferase 16 
3399853 TTG* TAA* NS M68_03193 Ca2+/Na+ antiporter 13 
3704987 CCA* TGA* NS sleB Spore-cortex-lytic protein 8 
4157880 TTG* TAA* NS M68_03851 PTS system, IIc component 6 
557896 TTC* TAA* NS feoB3 Ferrous iron transport protein B 3 
1359584 GGA TGA NS M68_01270 Extracellular solute-binding protein 3 
1916756 AAT* GAT* S M68_01782 Unknown 3 
3402470 CAA TAA NS plfB Formate acetyltransferase 3 
3784055 TTC* TAA* NS M68_03513 Penicillin-binding protein 3 
* = encoded on reverse strand  
 
Table adapted from a publication by Cairns et al., (Cairns et al., 2017). 
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A maximum-likelihood phylogenetic tree based on the 1288 SNPs was generated 
with geographical and temporal data combined in a phylogeographic analysis 
generated by mclust software (Figure 5.1).  Of the 1288 SNPs, 76% (977/1288) had a 
MAF of ≤ 1% and/or were within 1 bp of an insertion or deletion. To control for 
false positive identification of SNPs (these SNPs may mask the true phylogeny of 
PCR ribotype 017) phylogenetic trees with and without these SNPs were generated. 
The inclusion of 977 SNPs only had a minor effect on the overall phylogenetic tree.  
 
The mclust software divided the isolates into 20 clusters by cluster analysis (Figure 
5.1). The combination of epidemiological, genetic and temporal data, cluster 2 (C2) 
was defined as the best fit and demonstrates the presence of two genetically diverse 
sub-lineages; SL1 and SL2.  
 
By combining Bayesian evolutionary analysis with geo-temporal modelling of the 
277 isolates, the evolution of C. difficile PCR ribotype 017 can be orientated though 
time (Figures 5.1 and 5.2). The analysis depicted in these figures indicate a split from 
SL1 (upper samples) into SL2 (lower samples) c1990. SL1 was more closely related 
to the control strain M68 of the two sub-lineages (Figure 5.2). Both Figures 5.1 and 
5.2 also illustrate that isolates from different continents are amongst both SL1 and 
SL2 indicating that both sub-lineages are global in nature. 
 
The two sub-lineages were differentiated by four SNPs; one present in a non-coding 
region and three non-synonymous SNPs (Table 5.2).  
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Figure 5.1: Temporal phylogeny and maximum likelihood clusters for the global C. difficile PCR ribotype 017 isolates 
 
Figure adapted from a publication by Cairns et al., (Cairns et al., 2017). Temporal phylogeny and maximum likelihood clusters of the 277 C. 
difficile PCR ribotype 017 isolates. The phylogenetic tree illustrates how the collection of isolates has evolved over time with continents 
identified by colour and division between SL1 and SL2 identified. The heat map on this figure splits the collection of 277 isolates into 20 
possible clusters (C1-C20) based on maximum likelihood generated by mclust software. Cluster 2 (C2) was selected as the best fit based on 
epidemiological, genetic and temporal data associated with the isolates. 
SL2  
Division into 
SL1 (upper) 
and SL2 (lower) 
 
SL1  
Year Possible clusters 
 191 
 
Table 5.2: Lineage defining SNPs for the global isolates 
*Non-Synonymous (NS), Synonymous (S), Non-Coding (NC) 
Table adapted from a publication by Cairns et al., (Cairns et al., 2017). 
 
 
5.4.1.3 De novo genome assembly analysis 
In chapter 4, de novo assembled genomes revealed a 49 kbp transposon-like putative 
mobile genetic element exclusive to a hospital clonal cluster of PCR ribotype 017 
strains. To investigate the global collection of strains in this study for this and/or 
other insertions or deletions, programmatic and visual inspection of the comparisons 
was performed. De novo assembly of each isolate and comparison to the control 
strain M68 revealed 56 regions of DNA between ~4 and ~61.5 kb that were absent in 
the control strain M68. These had 34 different insertion sites. Additionally, regions 
of DNA of between ~8 and ~29 kb at six sites were found absent from multiple 
strains but present in the control M68 strain. Details of genes of interest found in 
either an insertion or deletion are depicted in Figure 5.2 and listed in Table 5.3. 
 
Bayesian evolutionary analysis and geo-temporal modelling was combined with a 
heat map to also depict presence/absence of insertions and antimicrobial resistance 
associated SNPs in relation to the isolates and continent (Figure 5.2). The deletions 
Position 
Amino 
Acid 
Reference 
Base 
Alternative 
Base 
*NS/
S/NC 
Gene 
Predicted Function and/or 
Potential Impact 
650374 19 A G NS merR 
Altered response to 
environmental stimuli 
900866 . C T NC . . 
2914248 257  A G NS dacF  
Reduced resistance  
to heat  or β-lactam antibiotics 
3604289 329 C A NS Hypothetical Unknown 
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and insertions are well distributed geographically and temporally and the 49 kb 
transposon-like putative mobile genetic element identified in chapter 4 was also 
found to insert at a different site in single isolates from Canada, the USA and the UK 
with isolation dates of 2006, 2006 and 2011 respectively.  
 
A single SNP in the PaLoc region resulting in a synonymous change was found in 
five Korean strains in SL2 isolated between 2004 and 2008, however, visual 
inspection of the comparisons in the ACT application revealed no variations in the 
genes tcdA or tcdB compared with the reference control strain M68. 
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Figure 5.2: Bayesian evolutionary analysis of the global C. difficile PCR 
ribotype 017 isolates 
 
Figure adapted from a publication by Cairns et al., (Cairns et al., 2017). Bayesian 
evolutionary analysis of 277 global C. difficile PCR ribotype 017 isolates based on 
core-genome SNPs against the control strain M68. Using a geo-temporal model the 
evolution of the PCR ribotype 017 isolates can be orientated though time. The 
analysis indicates a split from SL1 (upper samples) into SL2 (lower samples) c1990, 
with the control strain M68 in SL1. The introduction of resistance associated SNPs 
(such as in rpoC) fall within closely related groups in the phylogeny. The heat map 
depicts the sub-lineage, presence/absence of insertions and antimicrobial resistance 
associated SNPs in relation to the isolates and continent. Details for insertions and 
deletions are shown in Table 5.3. 
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Table 5.3: Genes of interest found in either an insertion or deletion when compared to the M68 reference strain referred to in Figure 5.2 
 
 Abbreviation Insertion/Deletion Number of isolates Sub -lineage Gene/s of Interest/Putative Function 
London insertion Insertion 23 SL1 & SL2 Sporulation protein J and putative sortase B 
AGs Deletion  99 SL1 & SL2 Aminoglycoside 6-adenylyltransferase 
ErmB Deletion 53 SL1 & SL2 Dimethyladenosine transferase (ermB) 
KstR2 Insertion 3 SL2 HTH-type transcriptional repressor KstR2 
TetR Insertion  15 SL1 TetR-family transcriptional regulator 
PadR Insertion 6 SL2 Transcriptional regulator PadR-like family protein 
DHFR Insertion 32 SL1 & SL2 Dihydrofolate reductase region 
DicA Insertion 7 SL1 Transcriptional repressor DicA 
MDRP Insertion  14 SL1 Multidrug resistance protein 
C-P/M Insertion 6 SL1 Putative corrin/porphyrin methyltransferase 
Na
+
 /drug anti Insertion 5 SL1 & SL2 Putative drug/sodium antiporter 
CS protein Insertion 8 SL1 & SL2 Putative cell surface protein 
Cfr Insertion 2 SL2 Putative radical SAM enzyme and Cfr family 
Spo Insertion 3 SL1 
Sporulation initiation inhibitor, Radical SAM protein, 
putative cell wall hydrolase, Stage 0 sporulation protein J 
SAM Insertion 2 SL1 SAM protein 
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5.4.2 Genotypic antimicrobial resistance determinants and phenotypic 
antimicrobial resistance 
The data revealed SNPs commonly associated with antimicrobial resistance (Table 
5.4 and Appendix 4, Page 265); 89.5% (248/277) and 5% (13/277) of isolates were 
found to have the amino acid substitutions found in the gyrB gene (V426D) and 
(V426I) respectively and 64.6% (179/277) to have the amino acid substitution found 
in the gyrA gene (T82I) which are known to confer resistance to the fluoroquinolone 
class of antibiotics. Additionally, substitutions in the 81 bp rifampicin resistance 
determining region of the rpoB gene; R505K, H502N and S485F were found in 
32.5% (90/277), 33.2% (92/277) and 1.1% (3/277) respectively. These data are 
depicted and listed according to sub-lineage in Figure 5.2 and Table 5.4 respectively 
(also in Appendix 4, Page 265). 
 
Genes potentially involved in antimicrobial resistance were also found in insertions 
and deletions; these are listed in Tables 5.5 and 5.6 respectively. 
 
 
 
 
Antimicrobial resistance 
associated SNPs 
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Table 5.4: SNPs associated with antimicrobial resistance found in the global isolates 
* Reference residue/amino acid/ alternative residue. 
 
Table 5.5: Genes found in insertions potentially involved in antimicrobial resistance 
 
Table 5.6: Genes found in deletions potentially involved in antimicrobial resistance 
Sub-
lineage 
Number  
of 
Isolates 
Rifampicin resistance Fluoroquinolone resistance Resistance inferred 
34,687 34,697 34,747 112,752 113,641 113,642 Position 
rpoB rpoB rpoB gyrA gyrB gyrB Gene 
R505K H502N S485F T82I V426D V426I *Amino acid change 
SL1 163 73 (44.8%) 79 (48.5%) 0 (0%) 124 (76.1%) 134 (82.2%) 4 (2.5%)  
SL2 114 17 (15%) 13 (11.4%) 3 (2.6%) 55 (48.2%) 114 (100%) 9 (7.9%)  
Insertion 
designation 
Insertion site 
in M68 (base) 
Size of 
insertion (bps) 
Number 
of isolates 
Sub-lineage Gene/s of Interest/Putative Function Potential antimicrobial resistance 
A 697659 10,260 15 SL1 
Drug/sodium antiporter & TetR-family transcriptional 
regulator 
Tetracycline and others unknown 
B 3873711 32,589 14 SL1 
Streptogramin A acetyltransferase, antibiotic resistance 
ABC transporter & multidrug resistance protein 
Streptogramin and others unknown 
C 3879955 12,555 5 SL1 and SL2 Drug/sodium antiporter Unknown 
D 2633741 9,297 1 SL2 TetR-family transcriptional regulator Tetracycline 
E 3854778 6,571 1 SL2 Chloramphenicol o-acetyltransferase Chloramphenicol 
Deletion 
designation 
Deletion site 
in M68 (base) 
Size of  
deletion (bps) 
Number 
of isolates 
Sub-lineage Gene/s of Interest/Putative Function Potential antimicrobial resistance 
F 480308 27,982 67 SL1 and SL2 Dimethyladenosine transferase (ermB) Erythromycin 
G 2527343 9,890 99 SL1 and SL2 Aminoglycoside 6-adenylyltransferase Aminoglycoside class 
H 2969461 16,713 5 SL1 and SL2 Teicoplanin resistance gene & beta-lactamase Teicoplanin & β-lactam antibiotics 
 198 
 
To determine if any of the SNPs or genes found in insertions or deletions listed in 
Tables 5.4, 5.5 and 5.6 correlated with phenotypic antimicrobial resistance, seven 
isolates were selected for MIC testing based on maximising variation with regards to 
isolation date, geographical location, presence or absence of resistant SNPs and 
presence or absence of insertions and deletions containing genes potentially 
associated with antimicrobial resistance; S- 017.72, WA 1514, S- 017.92, S- 017.27, 
S- 017.74, I 6 and 01-116. MICs were determined (Section 2.2.7) against the 
antibiotics; chloramphenicol, rifampicin, tetracycline, erythromycin, naladixic acid, 
gentamicin, teicoplanin and ampicillin. MIC values are shown in Table 5.7.  
 
All eight isolates were resistant to naladixic acid, ampicillin, gentamicin and all were 
sensitive to teicoplanin. Two isolates (2/8) were resistant and six (6/8) were sensitive 
to chloramphenicol. Four isolates (4/8) were resistant, two (2/8) were intermediate 
and two (2/8) were sensitive to rifampicin. Six isolates (6/8) were resistant and two 
isolates (2/8) were found with intermediate resistance to tetracycline. Seven isolates 
(7/8) were resistant and one isolates (1/8) was sensitive to erythromycin.  
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Table 5.7:  Genotypic and phenotypic antimicrobial resistance data for the global isolates 
 
 
Table adapted from a publication by Cairns et al., (Cairns et al., 2017). 
  Strain M68 S- 017.72 WA 1514 S- 017.92 S- 017.27 S- 017.74 I 6 01-116 
 Location Ireland Walsall Australia China Wrexham Walsall Indonesia Korea 
 Date Isolated 2006 2011 2012 2009 1996 2011 2011 2001 
Sub-lineage SL1 SL1 SL1 SL1 SL2 SL2 SL2 SL1 
*Insertion   A, B A  C D, E  
**Deletion F, G, H  F F, G H F, H F, H  
R
es
is
ta
n
t 
S
N
P
s 
rpoB ( R505K)         
rpoB (H502N)         
rpoB (S485F)         
gyrA (T82I)         
gyrB (V426I)         
gyrB (V426D)         
A
n
ti
m
ic
ro
b
ia
l 
A
g
en
t 
a
Chloramphenicol 8 (S) 8 (S) 4 (S) 64 (R) 8 (S) 8 (S) 256 (R) 8 (S) 
a
Rifampicin 0.008 (I) 2 (I) 0.004 (S) >256 (R) >256 (R) 0.004 (S) >256 (R) >256 (R) 
b
Tetracycline 32 (R) 32 (R) 0.25 (I) 32 (R) 32 (R) 0.25 (I) 32 (R) 32 (R) 
b
Erythromycin >256 (R) >256 (R) >256 (R) >256 (R) >256 (R) <2 (S) >256 (R) >256 (R) 
b
Nalidixic acid 256 (R) 256 (R) 256 (R) 256 (R) 256 (R) 256 (R) 256 (R) 256 (R) 
c
Gentamicin >256 (R) >256 (R) 256 (R) >256 (R) 256 (R) 256 (R) >256 (R) >256 (R) 
c
Teicoplanin <1 (S) <1 (S) <1 (S) <1 (S) <1 (S) <1 (S) <1 (S) <1 (S) 
b
Ampicillin 8 (R) 8 (R) 8 (R) 8 (R) 8 (R) 4 (R) 4 (R) 8 (R) 
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 (S) = sensitive, (I) = intermediate resistance (R) = resistant 
 
a 
Recommended by the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST). 
b 
Recommended by CLSI (M11-A8, 2012, and M-100-S23, 2013). 
c 
No guidance from CLSI or EUCAST, cut-offs based on data according to the CLSI 
M-100-S23 (interpretative values for Staphylococcus aureus). 
 
 
*Genes carried by insertions potentially involved in antimicrobial resistance: 
Insertion A: Putative drug/sodium antiporter and radical SAM protein TetR-family 
transcriptional regulator 
Insertion B: Streptogramin A acetyltransferase and multidrug resistance protein 
Insertion C: Putative drug/sodium antiporter 
Insertion D: TetR-family transcriptional regulator 
Insertion E: Chloramphenicol o-acetyltransferase (M68 has one copy of 
chloramphenicol) 
 
** Genes carried by deletions potentially involved in antimicrobial resistance: 
Deletion F: Dimethyladenosine transferase (ermB) 
Deletion G: Putative teicoplanin resistance gene and putative beta-lactamase  
Deletion H: Aminoglycoside 6-adenylyltransferase 
 
 
To investigate the correlation between genotypic determinants of antimicrobial 
resistance with the actual phenotype data, both were compared. Based on the gyrA 
and gyrB SNP data, 76.2% (211/277) of isolates had a genotypic SNP associated 
with resistance to the fluoroquinolone class of antibiotics. All eight isolates (8/8) 
were phenotypically resistant to naladixic acid indicating resistance to the 
fluoroquinolone class of antimicrobials. Based on the rpoB SNP data, this study 
found 34.7% (96/277) of isolates with a genotypic SNP associated with resistance to 
the rifampicin class of antibiotics and 82% (152/185) of these mutations were found 
in SL1. Only two isolates (2/8) were sensitive to rifampicin with one isolate 
containing the R505K and H502N SNP indicating that these alone do not confer 
phenotypic resistance. The SNP S485F was found in three historical isolates from 
Wrexham, UK. All isolates (8/8) were sensitive to teicoplanin despite one isolate 
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with the deletion containing a putative teicoplanin resistance gene. Six isolates (6/8) 
were resistant and two isolates (2/8) were found with intermediate resistance to 
tetracycline, however, the two TetR-family transcriptional regulator genes found in 
insertions (insertions A and D) did not correlate with this variation in resistance 
indicating that neither of the two TetR-family transcriptional regulator genes alone 
conferred resistance or there is another mechanism involved. Seven isolates (7/8) 
were resistant and one isolates (1/8) was sensitive to erythromycin, however, the 
deletion that contained the dimethyladenosine transferase (ermB) gene (deletion F) 
did not correlate with this variation in phenotypic resistance. Two isolates (2/8) were 
resistant and six (6/8) were sensitive to chloramphenicol, however, the insertion that 
contained the chloramphenicol o-acetyltransferase gene (insertion E) did not 
correlate with this variation in phenotypic resistance. All isolates (8/8) were 
phenotypically resistant to gentamicin despite only three isolates with the deletion 
containing an aminoglycoside 6-adenylyltransferase (deletion H). All eight isolates 
(8/8) were resistant ampicillin despite the presence or absence of the genotypic 
determinants of antimicrobial resistance in Table 5.7. 
 
By investigating the SNPs, insertions and deletions of a global collection of 277 PCR 
ribotype 017 isolates revealed two sub-lineages (SL1 and SL2), however, when 
comparing with phenotypic data, no SNPs, insertions, deletions or phenotypic 
antimicrobial resistance was associated with a clonal expansion of C. difficile PCR 
ribotype 017. 
 
 
 202 
 
5.4.3 Genotypic comparison of isolates between geographical locations 
To investigate if strains of C. difficile PCR ribotype 017 isolated from different 
geographical origins are phylogenetically distinct by WGS, Table 5.8 lists the 
isolates by geographical origin and a maximum-likelihood phylogenetic tree based 
on the 1288 SNPs was generated (Figure 5.3) with separation by continent (Figure 
5.4). The majority of isolates are from Europe (137/277), Asia (59/277) and North 
America (59/277). The data in Table 5.8 and as illustrated in Figures 5.3 and 5.4 
indicate that isolates from varying geographical locations are widespread amongst 
both sub-lineages. 
 
 
Table 5.8: Number and percentage of isolates by origin and sub-lineage 
 
Geographical 
Location 
Number of 
isolates 
Percentage of 
isolates 
Sub-lineage/s 
Europe 137 49.5% 1 and 2 
Asia 59 21.3% 1 and 2 
North America 59 21.3% 1 and 2 
Africa 9 3.3% 1 and 2 
Oceania 7 2.5% 1 and 2 
South America 4 1.4% 1 
Middle East 2 0.7% 1 
TOTAL 277 100% 1 and 2 
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Figure 5.3: Maximum-likelihood phylogenetic analysis for the global C. difficile 
isolates 
 
Figure adapted from a publication by Cairns et al., (Cairns et al., 2017). Maximum-
likelihood phylogenetic analysis of 277 global C. difficile PCR ribotype 017 isolates 
based on core-genome SNPs against the M68 reference. Non-rare (>1% MAF) SNPs 
that were not in close proximity to insertions or deletions to determine the 
phylogenetic tree were used. The SL1 and SL2 sub-lineages were differentiated by 
four SNPs with the reference strain M68 falling into SL1. The coloured nodes 
indicate the geographical source of isolates. 
 
 
SL2 
SL1 
Africa 
Asia 
Europe 
Middle East 
North America 
Oceania 
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Figure 5.4: Maximum-likelihood phylogenetic analysis (separated by continent) 
for the global C. difficile PCR ribotype 017 isolates 
 
Figure adapted from a publication by Cairns et al., (Cairns et al., 2017). Maximum-
likelihood phylogenetic analysis of 277 global C. difficile PCR ribotype 017 isolates 
based on core-genome SNPs against the control strain M68 separated into individual 
panels corresponding to continent. Data from five out of seven continental 
designations (Africa, Europe, Asia, Oceania and USA) include SL1 and SL2 isolates 
indicating that both sub-lineages are global in nature. 
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Europe  
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North 
America 
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5.4.4 Genotypic comparison of isolates between sources  
 
To investigate if strains of C. difficile PCR ribotype 017 isolated from non-human 
sources are phylogenetically distinct by WGS, Table 5.9 lists the isolates by source 
and a maximum-likelihood phylogenetic tree based on the 1288 SNPs was generated 
with separation by source (Figure 5.5). There is no sub-lineage exclusively 
associated with non-human isolates, all non-human isolates are in sub-lineage 1 
amongst human isolates. 
 
Table 5.9: Number and percentage of isolates by source and sub-lineage 
 
Geographical 
Location 
Number of 
isolates 
Percentage of 
isolates 
Sub-Lineage/s 
*Human 253 91.3% 1 and 2 
Canine 11 4% 1 
Bovine 9 3.3% 1 
Equine 4 1.4% 1 
TOTAL 277 100% 1 and 2 
 
*includes the two environmental strains isolated from a hospital ward 
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Figure 5.5: Maximum-likelihood phylogenetic analysis (separated by source) for 
the global C. difficile PCR ribotype 017 isolates 
 
Figure adapted from a publication by Cairns et al., (Cairns et al., 2017). Maximum-
likelihood phylogenetic analysis of the global C. difficile PCR ribotype 017 isolates 
based on core-genome SNPs against the control strain M68 depicting the 24 animal 
isolates by coloured nodes. Note the three equine isolates are positioned (and 
masked) by the bovine and canine cluster. The two bovine isolates on the bottom of 
the tree have a SNP distance of 17 from the bovine, canine, and equine cluster on the 
top. All animal isolates are from Ontario, Canada and isolated between 2002 and 
2005.  
Bovine 
Canine 
Equine 
 207 
 
5.4.5 The origins of C. difficile PCR ribotype 017 
To investigate the belief that C. difficile PCR ribotype 017 originated in Asia, global 
transmission events inferred from Bayesian evolutionary analysis was performed 
and inferred global transmission as depicted in Figure 5.6. The data indicates a USA 
origin and suggests that it was Europe that introduced C. difficile PCR ribotype 017 
to Asia and Australia, with subsequent spread from Asia to the Middle East, South 
America and South Africa. The analysis indicates over 40 movements back and forth 
over the span of 30 years. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: Inferred global transmission events of the global C. difficile PCR 
ribotype 017 isolates 
 
Figure adapted from a publication by Cairns et al., (Cairns et al., 2017). Global 
transmission events inferred from bayesian evolutionary analysis of C. difficile PCR 
ribotype 017 isolates. From geo-temporal analyses the first movement into each 
continent of isolates in this study can be inferred, with the date and originating 
continent. The analysis indicates a USA origin with an expansion into Europe in the 
mid-1980s, followed by a move into Asia and on to Africa and South America 
through the 1990s and early 2000s. PCR ribotype 017 was not identified in Oceania 
(Australia) until the late 2000s, via a jump from Europe. 
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5.5 Discussion 
Using PCR ribotyping, WGS and MIC assays, my study investigated a total of 277 
C. difficile isolates (Appendix 2, Page 249). This collection of 277 strains were from; 
human (n=251), bovine (n=9), canine (n=11), equine (n=4) and hospital ward 
environment (n=2) with isolation dates between 1990 and 2013 and included isolates 
from six global continents (Europe, North America, South America, Asia, Oceania 
and Africa). 
 
No SNP/s and/or insertions or deletions (including those associated with 
antimicrobial resistance) were found associated with the global spread of C. difficile 
PCR ribotype 017 in my study. It is possible that one or more were associated yet not 
identified using the methods described in this thesis. Reminiscent of the C. difficile 
PCR ribotype 027 lineage, two distinct sub-lineages of C. difficile PCR ribotype 017 
that contain multiple independent clonal expansions were revealed in this study 
(Figures 5.1 and 5.2). These two sub-lineages differed by four SNPs; one present in a 
non-coding region and three non-synonymous SNPs (Table 5.2) with isolates in both 
sub-lineages being geographically and temporally diverse. My data shows that the 
multiple haplotypes revealed for C. difficile PCR ribotype 017 is similar to PCR 
ribotype 027 where >100 distinct genotypes were found in 151 isolates (He et al., 
2013). The insertions and deletions were well distributed geographically and 
temporally suggesting either the rapid dissemination of strains or the multiple 
independent acquisition and loss of DNA regions. The insertion of different clusters 
of genes at the same site suggests ‘hot-spot’ sites for the uptake of DNA and a 49 
kbp putative transposon-like putative mobile genetic element found exclusive to the 
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clonal cluster of 23/37 London isolates from chapter 4 were also found to insert at a 
different site in single isolates from Canada, the USA and the UK with isolation 
dates of 2006, 2006 and 2011 respectively (Figure 5.2) suggesting these isolates have 
independently acquired this insertion.  
 
The data revealed SNPs, insertions and deletions associated with antimicrobial 
resistance and variation in phenotypic resistance (Tables 5.4, 5.5 and 5.6), however, 
no antimicrobial resistance genotype or phenotype was found associated with the 
geographical spread of C. difficile PCR ribotype 017 like that seen with PCR 
ribotype 027 and the SNP associated with fluoroquinolone resistance (He et al., 
2013).  
 
The majority of isolates (76%) were found to possess a SNP present in either the 
gyrA or gyrB genes which are associated with phenotypic resistance to the 
fluoroquinolone class of antibiotics (gyrA [T82I], gyrB [V426I] and gyrB [V426D]). 
All eight isolates tested phenotypically, were resistant to the fluoroquinolone 
naladixic acid. The SNP T82I found in the gyrA gene is the same mutation reported 
in the global outbreak of C. difficile PCR ribotype 027 (He et al., 2013) however, it 
was not shown to lead to the expansion of a sub-lineage like seen with PCR ribotype 
027. Interestingly, the control strain M68 was resistant yet it did not possess any of 
the gyrA and gyrB associated SNPs or genes carried by insertions potentially 
involved in antimicrobial resistance suggesting that there is another mechanism for 
resistance to the fluoroquinolone class of antibiotics. This resistance amongst all 
eight strains tested is not unusual; other studies have found high levels of resistance 
to one or more of the fluoroquinolone class of antimicrobials. Barbut et al., (Barbut 
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et al., 2007) found 33% (134/411) of isolates were intermediate susceptibility or 
resistant to moxifloxacin. Spigaglia et al., (Spigaglia et al., 2008) further tested 83 of 
these isolates, eleven of which were PCR ribotype 017. All 11 isolates were resistant 
to the fluoroquinolones tested (moxifloxacin, ciprofloxacin, gatifloxacin, 
levofloxacin).  
 
My study found 34.7% of isolates to possess a SNP present in the rpoB gene which 
is associated with phenotypic resistance to the rifampicin class of antibiotics. My 
phenotypic data found four, two and two isolates to be resistant, intermediate 
resistance and sensitive to rifampicin respectively. The SNPs R505K and H502N 
have previously been associated with rifampicin resistance in C. difficile (Curry et 
al., 2009) however, based on MIC data from my study, one of the two isolates that 
were sensitive to rifampicin contained the R505K and H502N SNPs indicating that 
these SNPs alone do not confer phenotypic resistance. My study also identified a 
third SNP in the rpoB gene (S485F) which was found in three historical isolates from 
Wrexham, UK. This resistance conferring SNP has not previously been reported in 
C. difficile, only in Mycobacterium tuberculosis (Bahrmand et al., 2009). All three 
isolates were phenotypically resistant to rifampicin, however, all three isolates also 
contained the SNP R505K and so confirming the SNPs (S485F) contribution to 
resistance was not possible. Gene expression profiling in tandem with phenotypic 
assays could be performed to confirm the contribution of this SNP to phenotypic 
resistance to rifampicin since not all genotypic determinants are expressed. 
 
All eight isolates tested phenotypically were sensitive to teicoplanin despite one 
isolate with the deletion containing a putative teicoplanin resistance gene. This 
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indicates that the presence of the genetic region containing the putative teicoplanin 
resistance gene played no role alone or at all in the MIC of the seven isolates tested. 
 
Phenotypic susceptibility to the antimicrobials tetracycline, ampicillin, erythromycin, 
gentamicin and chloramphenicol was found not to correlate with genotypic resistance 
determinants identified through WGS (Table 5.7) suggesting that there are other 
mechanisms required for phenotypic resistance to these antimicrobials. All isolates 
demonstrated phenotypic resistance to gentamicin. This is to be expected as C. 
difficile as an anaerobic organism is intrinsically resistant to the aminoglycoside class 
of antimicrobials. Anaerobes lack the oxygen-dependent transport mechanism 
required for cellular uptake (Bryan et al., 1979). This indicates that the determination 
of MICs to this class of antimicrobial in this thesis was futile. 
 
C. difficile PCR ribotype 017 has previously been associated with high level 
antimicrobial resistance (Drudy et al., 2007c, Kuijper et al., 2001, Pituch et al., 2007, 
Freeman et al., 2015) and different countries appear to have different levels of 
antimicrobial resistance (for all PCR ribotypes) which is likely a result of varying 
antimicrobial prescribing and subsequent selective pressure (Freeman et al., 2015). 
With a large collection of C. difficile PCR ribotype 017 strains, it would be 
interesting to test the susceptibilities of more of the strain collection in this study. 
The geographical patterns of antimicrobial resistance for this toxin A-B+ PCR 
ribotype could then be determined. 
 
C. difficile PCR ribotype 017 isolated from different geographical origins were not 
phylogenetically distinct by WGS.  The transcontinental spread of both sub-lineages 
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containing strains from varied global locations showing no distinct pattern of spread 
(Figures 5.3 and 5.4) suggests that C. difficile PCR ribotype 017 isolated from 
different geographical origins are not phylogenetically distinct by WGS. This was 
not known previously and is a significant finding, as it suggests that neither sub-
lineage of C. difficile PCR ribotype 017 has had a selective advantage in its ability to 
spread globally like that found with PCR ribotype 027 (He et al., 2013) 
  
C. difficile PCR ribotype 017 isolated from human and non-human sources were not 
phylogenetically distinct by WGS (Figure 5.5). All non-human isolates were in SL1 
only, however, the collection of non-human isolates was small (n=24) and were 
isolated from a similar location (Ontario, Canada) over a relatively short period of 
time (2002 and 2005) suggesting they were clonal by time and place. Importantly, all 
non-human isolates were placed phylogenetically amongst human isolates suggesting 
possible transmission between humans and animals. Although it is known that C. 
difficile can cause similar infection in both humans and animals (Limaye et al., 
2000), transmission and phylogenetic associations have previously only been shown 
using MLST and not WGS. Therefore, this data shows that the same strain of PCR 
ribotype 017 can cause infection in both humans and animals using WGS. 
 
C. difficile PCR ribotype 017 did not originate in Asia (Figure 5.6). Traditionally, it 
has been considered that C. difficile PCR ribotype 017 strains emerged from Asia 
due to its reported high incidence that could not relate to nor depend on toxin A-
based assays for diagnosis (Collins et al., 2013). However, the global transmission 
events inferred from Bayesian evolutionary analyses in my study supports a USA 
origin for C. difficile PCR ribotype 017 with multiple, global transmission events 
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with its earliest movement into Europe in 1986 (Figure 5.6). This is similar to that 
found with PCR ribotype 027; the USA health system and practices appeared to have 
facilitated the evolution and epidemic spread of C. difficile PCR ribotype 027 (He et 
al., 2013) and now in this study with PCR ribotype 017. This is consistent with 
population movements of a globalised society (Soto, 2009). 
 
The non-synonymous SNP found in the dacF gene was one of four SNPs that 
differentiated the two sub-lineages and was present in all 114/277 isolates in sub-
lineage 2 (Table 5.2). The dacF gene codes for D-alanyl-D-alanine carboxypeptidase 
and has been shown to regulate peptidoglycan crosslinking in Bacillus subtilis 
(Popham et al., 1999). The β-lactam class of antibiotics target the peptidoglycan of 
the bacterial cell wall; the antibiotic inhibits the final step of peptidoglycan synthesis 
and inactivates penicillin-binding proteins that form the peptidoglycan layer of the 
cell wall. Due to the loss of the cell wall, this leads to cell death as a result of osmotic 
pressure (Tipper and Strominger, 1965). It is possible that a SNP in the dacF gene 
may result in a fitness advantage to strains possessing this genotype within the 
healthcare environment rendering the bacteria resistant to β-lactam antibiotics. 
Conversely, a study found that knockout mutants lacking the dacF gene in C. 
perfringens, reduced heat resistance, likely due to reduced cortex integrity when 
subjected to high heat (Orsburn et al., 2009). However, no difference in susceptibility 
to the β-lactam antibiotics teicoplanin or ampicillin between isolates in both sub-
lineages was observed (Table 5.7) suggesting that this SNP did not affect 
susceptibility to β-lactam antibiotics nor did it lead to a clonal expansion of either 
sub-lineage like that seen with fluoroquinolone resistance and PCR ribotype 027 (He 
et al., 2013). 
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It has been well documented that fluoroquinolone use preceded resistance and 
subsequent global outbreaks of a clonal strain of C. difficile PCR ribotype 027 (He et 
al., 2013). PCR ribotype 017 is associated with higher rates of antimicrobial 
resistance when compared with other PCR ribotypes and in my study, a significant 
number of isolates had SNPs associated with phenotypic antimicrobial resistance 
(76% of isolates had a SNP present in either the gyrA or gyrB genes and 34.7% of 
isolates had a SNP present in the rpoB gene). It would therefore be plausible to 
consider that a clone of PCR ribotype 017 could be as problematic as PCR ribotype 
027. However, my data shows no global clonal expansion of a strain of PCR ribotype 
017. The strains used in my study also date back to 1990 which is prior to the 
concept of antimicrobial stewardship and its role in controlling C. difficile outbreaks 
in healthcare facilities. This would suggest that there are other phenotypic 
characteristics as well as antimicrobial resistance that are required for the global 
spread of a clonal strain like that seen with PCR ribotype 027. Future work to this 
study could include comparing the genotypic and phenotypic characteristics of PCR 
ribotype 017 and the clonal strain of PCR ribotype 027 to establish why the PCR 
ribotype 027 strain was clonal and spread globally and why PCR ribotype 017 has 
not. Previous studies have found PCR ribotype 027 to have phenotypic 
characteristics that could be associated with its global spread however; there is 
conflicting evidence for a phenotype specific to PCR ribotype 027 that would enable 
a strain to be clonal (Section 1.10, Page 50). No study has yet compared the 
phenotypic characteristics of the clonal strain of 027 with a large collection of 
isolates of other PCR ribotypes with known genotype. This could be performed with 
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select isolates from this study with the WGS data available for strains of PCR 
ribotype 017. 
 
There were limitations in this study. Similar to chapter 4, there were limitations to 
the choice of control strain and methodologies used for detection of SNPs and de 
novo analysis of insertions and deletions (as described in Section 4.5, Page 175). 
Furthermore, the choice of control strain for the detection of phenotypic resistance 
was likely flawed. All isolates with MIC testing (both chapters 4 and 5) were 
resistant to naladixic acid including the reference control strain M68. Therefore, 
there was no negative control for this antibiotics effectiveness and achievement of a 
successful MIC assay. There may have been deterioration of the antibiotic, error in 
inoculum or the control strain was resistant to this antibiotic. Further phenotypic 
MIC studies should seek to include a fully sensitive control strain of C. difficile.  
 
5.6 Conclusion 
This study investigated the genetic diversity of 277 C. difficile PCR ribotype 017 
isolates with isolation date, geographical, and source variation using WGS. 
Phylogenetic analysis of the SNPs suggests there are two main sub-lineages of PCR 
ribotype 017 that share an ancestry and are globally disseminated. Both sub-lineages 
contain isolates from diverse geographical locations and isolation dates, with animal 
isolates spread among human isolates. Together with the haplotype diversity and 
geographical and temporal diverse presence of insertions and deletions, these data 
suggest widespread transcontinental spread and recombination with independent 
acquisition and loss within different clusters. Antimicrobial resistant genotypic 
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determinants were well distributed geographically and none were found exclusive to 
phenotypic resistance suggesting there are other genotypic determinants associated 
with phenotypic antimicrobial resistance in this collection of strains. 
 217 
 
 
 
 
 
Chapter 6 
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6 Final Discussion 
C. difficile continues to be a leading cause of healthcare-associated infections in the 
developed world. Its spores are able to survive, persist and spread in hostile 
environments and cause outbreaks of CDI amongst susceptible hosts in wards, 
hospitals and other healthcare facilities. This species was selected for study as there 
was a deficiency in our understanding of its phylogenetics and phylohistory. Genetic 
exploration using PCR ribotyping, MLST, WGS and phenotypic assays was 
performed and has provided an insight into how this species is evolving. 
 
Clostridium difficile – a multifarious pathogen 
Previous MLST and WGS studies identified five divergent phylogenetic lineages of 
C. difficile PCR ribotypes; 017, 027, 078, 023 and a group containing multiple PCR 
ribotypes (Griffiths et al., 2010, Dingle et al., 2011a, Lemee et al., 2004, Lemee et 
al., 2005). However, these studies were limited by only focusing on either; various 
hosts, geographic sources, various PCR ribotypes, or hospital and community and 
various PCR ribotypes. Chapter 3 of this thesis applied MLST to a larger collection 
of isolates (n=385) from diverse human, animal and food sources from three 
continents and of multiple PCR ribotypes and confirmed the five lineages of 
C. difficile previously identified. Chapter 3 also demonstrated that the typing 
techniques PCR ribotyping and REA do not correlate as well as previously thought 
and genotypes identified by one technique are incorrectly assumed a genotype based 
on a different typing technique. For example, strains previously assigned as PCR 
ribotype 027 but subsequently confirmed to be PCR ribotypes 176 and 198 but are 
sequence type 1 and cluster with lineage 2. Similarly, PCR ribotype 244 shares the 
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same genetic lineage as PCR ribotype 027 according to SNP analysis (Eyre et al., 
2015) and like PCR ribotype 027, patients present with severe CDI and higher 
mortality (Lim et al., 2014). It is a concern that emerging PCR ribotypes 
phylogenetically similar to other PCR ribotypes by MLST and associated with 
hypervirulence and increased transmission are not initially associated as having a 
similar phenotype (Lim et al., 2014, Polivkova et al., 2016).  
 
Since chapter 3 was performed, the number of PCR ribotypes and sequence types has 
dramatically increased; the PCR ribotype and MLST databases now comprises 877 
PCR ribotypes (12/04/2018, Dr Warren Fawley, personal communication) and 488 
sequence types (19/04/2018, MLST database https://pubmlst.org/cdifficile/).This 
suggests further evolution. This MLST analysis has broadened our understanding of 
the pathogen C. difficile by demonstrating how evolution can be observed using SNP 
variation in MLST alleles, however, investigating the individual lineages in more 
depth with finer resolution will enable us to monitor the emergence of evolving 
virulent and highly transmissible clones. There is need for immediate awareness of a 
hypervirulent clone which would prompt earlier intervention as has already been 
shown with other pathogens such as Listeria monocytogenes (Jackson et al., 2016, 
Kvistholm Jensen et al., 2016), Streptococcus pyogenes (Tagini et al., 2017), MRSA 
(Azarian et al., 2015),  Salmonella (Inns et al., 2017), S. aureus and C. difficile (Eyre 
et al., 2012). 
 
PCR ribotype 017 – Historical London clone 
The MLST data in chapter 3 confirmed previous findings that C. difficile PCR 
ribotype 017 strains cluster as an individual lineage (Griffiths et al., 2010, Dingle et 
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al., 2011a, Stabler et al., 2012). This coupled with its unique toxin profile (Alfa et al., 
2000), unusual global prevalence (Hawkey et al., 2013) and multiple clusters of CDI 
caused by PCR ribotype 017 in a London hospital elderly care ward between 2009 
and 2011, led to hypothesising that these cluster isolates would be clonal and a 
phenotype that may explain a persistent trait could be characterised.  
 
Phylogenetic analysis of WGS SNPs of 37 C. difficile PCR ribotype 017 isolates 
ascertained that a clone was present at UHL which included a historical isolate from 
2005 and was thought to be the ancestral cluster strain. Additionally, a 49 kbp 
genetic region suggestive of being a transposon-like putative mobile genetic element 
was found exclusive to the clonal strains. This putative mobile genetic element 
contained genes potentially involved in virulence and/or transmissibility and with the 
clonal nature of this cluster, phenotypic assays were performed, however, no 
phenotype exclusive to the clonal cluster was characterised. It is unknown if the 
clonal strain identified in this chapter possessed genetic attributes that contributed to 
a persistence phenotypic trait and/or if any of the SNPs or genes carried by the 49 
kbp genetic region contributed to this. It is equally possible that the clonal strain did 
not possess any attributable phenotype and was simply re-introduced into the new 
hospital build and was never eradicated from the environment. 
 
Although the observations detailed within chapter 4 were derived from a small sub-
set of isolates, this was the first report in the UK investigating the phylohistory of 
isolates from hospitalised patients with CDI due to PCR ribotype 017.  
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PCR ribotype 017 – a global perspective 
In chapter 3 the evolution of individual lineages of C. difficile was confirmed and in 
chapter 4 a historical clone of PCR ribotype 017 unique to a hospital ward that 
exclusively possessed a genetic region suggestive of being a transposon-like putative 
mobile genetic element was identified. Studies have investigated the in-depth 
phylogenetics of C. difficile PCR ribotype 027 using WGS and significant to chapter 
5, He et al., revealed the global expansion of a fluoroquinolone resistant sub-lineage 
of PCR ribotype 027 (He et al., 2013). However, no studies have reported the global 
phylogeny of other lineages of C. difficile.  
 
A hypothesis of chapter 5 was to investigate the global population structure of 
C. difficile PCR ribotype 017. It was postulated that PCR ribotype 017 evolved 
similar to PCR ribotype 027 but from a different geographical location; due to the 
unusual global prevalence of PCR ribotype 017 previously reported, it was 
hypothesised that PCR ribotype 017 evolved out of Asia unlike PCR ribotype 027 
which evolved out of USA (He et al., 2013). An advantage of chapter 5 was the 
collection of isolates; it was large (n=277) and a global representation of PCR 
ribotype 017. Chapter 5 identified two distinct sub-lineages (SL1 and SL2) of PCR 
ribotype 017 containing multiple independent clonal expansions and multiple 
antimicrobial resistant SNP determinants. The gyrA T82I SNP reported in the global 
outbreak of PCR ribotype 027 (He et al., 2013) was found, however, this did not 
result in the global expansion of a strain like that seen with PCR ribotype 027, nor 
did any other antimicrobial genotype or phenotype. Similar to the PCR ribotype 027 
study, the data did reveal multiple haplotypes suggesting both lineages have evolved 
in a similar fashion (He et al., 2013). The data alludes to possible transmission 
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between humans and animals with 24 animal strains placed amongst human isolates. 
The animal isolates were amongst human isolates which is not surprising as studies 
have already indicated this for PCR ribotype 078 using PCR ribotyping and MLST 
(Debast et al., 2009, Jhung et al., 2008, Goorhuis et al., 2007, Gould and Limbago, 
2010). This data shows that the same strain of PCR ribotype 017 can cause CDI in 
both humans and animals using WGS. 
 
Chapter 5 identified multiple insertions and deletions which were well distributed 
geographically and temporally. Isolates from Canada, USA and UK harboured the 49 
kb transposon-like putative mobile genetic element found in chapter 4 although 
inserted at different sites suggesting integration ‘hot-spot’ sites for horizontal transfer 
of genetic material. These data suggest either the rapid dissemination of strains or the 
multiple independent acquisition and loss of DNA regions.  
 
Like that found with PCR ribotype 027 (He et al., 2013), using geo-temporal 
analyses, the findings in chapter 5 support a USA origin for PCR ribotype 017 with 
multiple, global transmission events, movement to Europe in ~1986, and subsequent 
spread to Asia and Australia, and from Asia to the Middle East, South America and 
South Africa. The data indicates over 40 movements back and forth over the span of 
30 years which is consistent with population movements of a globalised society 
(Soto, 2009). This is surprising considering the published data indicating an Asian 
origin for PCR ribotype 017, however, the USA health system and practices 
appeared to facilitate the ready evolution and epidemic spread of PCR ribotype 027 
(He et al., 2013) and the same appears possible in this chapter with PCR ribotype 
017.  
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Conclusions and future direction 
The key findings of this thesis are that C. difficile as a species is continually evolving 
with the appearance of divergent sub-lineages and mini-clusters within lineages, with 
further description of SNPs associated with antimicrobial resistance, haplotypes and 
genetic deletions and insertions. This knowledge contributes to our understanding of 
the evolution of C. difficile and more specifically PCR ribotype 017. However, it 
remains to be identified why PCR ribotype 017 is so successful and has spread 
globally yet lacks toxin A. It could be postulated that toxins are not as important in 
strain dissemination as was previously thought. There may be other compensatory 
factors that PCR ribotype 017 has that have enabled it to spread globally and be so 
transmissible. For example, improved environmental survival by spore formation; 
may be this is more important for PCR ribotype 017. Interestingly, data subsequent 
to this thesis compared strains of PCR ribotype 023 from across Europe and China 
using WGS and showed great similarity between strains which was consistent with a 
recently emerged lineage that appears to be under little selective pressure to evolve 
(Shaw et al., submitted, Page 23). This is similar to the findings in this thesis for 
PCR ribotype 017 and in contrast to PCR ribotype 027 where a sub-lineage was 
shown to spread globally as a result of antimicrobial selective pressure (He et al., 
2013). It remains to be determined why evolutionary distinct lineages of C. difficile 
are simultaneously emerging to cause disease. 
 
The application and utility of WGS for tracking transmission, outbreak investigation 
and studying the evolution of many pathogens has demonstrated WGS to be superior 
to routine typing tools. Examples include; the prompt investigation of a clonal strain 
of Escherichia coli (Rasko et al., 2011), improved epidemiological inferences and 
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linkages of M. tuberculosis (Gardy et al., 2011) and real-time investigation enabling 
actionable results and transmission monitoring of an outbreak of Salmonella (Quick 
et al., 2015). WGS has demonstrated to be superior to routine typing tools for 
outbreak investigation of C. difficile enabling the involvement of infection control to 
promptly reduce the incidence of CDI (Eyre et al., 2017). If WGS were available in 
2003, detection of the C. difficile fluoroquinolone resistant genotype outbreak strain, 
PCR ribotype 027 would likely have been confirmed much earlier (He et al., 2013, 
Dingle et al., 2017) and would have enabled appropriate antimicrobial stewardship 
and subsequent reduction in the global outbreaks that this strain caused. 
 
WGS allows for the identification and description of selective pressures acting on 
microbial pathogens; the global spread of C. difficile PCR ribotype 027 is an 
example of the selective pressure of antimicrobial prescribing where use of 
fluoroquinolones selected for this clone (He et al., 2013).  
 
In addition to the detection of known genetic virulence determinants (i.e. the Xpert
®
 
C. difficile assay and detection of PCR ribotype 027), WGS performed alongside 
phenotypic studies enables the identification and characterisation of virulent 
genotypes, for example the identification of genetic markers associated with C. 
difficile PCR ribotype 027 (Stabler et al., 2009). This is valuable for the diagnostic 
laboratory and patient/s. 
 
Despite this, WGS does have its limitations. To scientists and clinicians in the 
diagnostic field of microbiology, it can present unknown genotypes for which the 
phenotype and clinical significance maybe unknown. Relying on WGS will also not 
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detect new and emerging phenotypes as clearly as if phenotypic testing was 
performed. WGS requires sophisticated bioinformatics, quick data processing, large 
data storage capabilities and experienced bioinformaticians to analyse and interpret 
data and put it into clinical context (Tsai et al., 2016, Fricke and Rasko, 2014); this is 
currently too costly for most diagnostic microbiology laboratories. A number of 
global organisations, collaborative projects and laboratory consortia are actively 
working to overcome technical barriers, develop bioinformatic solutions and pilot 
studies of WGS-based typing for public health protection and to develop standards 
(European Centre for Disease Prevention and Control, 2016).  
 
Before genotypic data can be relied upon clinically, sufficient data must be collated 
and compared with phenotype to ensure reliable correlation. Further studies 
comparing genotype to phenotype and expression profiles using WGS, knockout 
mutant studies (Lyras et al., 2009, Bradshaw et al., 2017, Ngernsombat et al., 2017) 
and proteomic studies (Pettit et al., 2014, Dresler et al., 2017) will lead the way to 
improving the inference and ultimately confidence in WGS. 
 
Improvements to the limitations described will progress diagnostic microbiology. 
The integration of WGS into routine diagnostic laboratories will lead the way for 
real-time identification and monitoring of outbreaks (local and national), surveillance 
of global transmission, and identification of novel pathogenic genotypes which may 
have otherwise evaded detection by current diagnostic techniques. This will 
ultimately improve the management of patients and populations with infectious 
diseases. 
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Appendix 1: Bacterial isolates used in chapter 3 
 
NT = nontypeable (PCR ribotype not recognised by the London CDRN reference laboratory), * = Novel sequence type, ** = Isolates used in the 
PCR ribotype 027 depth study. 
 
Isolate Provider 
PCR 
ribotype 
Sequence 
type 
Alleles Sequence 
type lineage 
Origin Location 
Date 
isolated adk atpA dxr glyA recA sodA tpi 
630 J. Brazier 012 54 1 4 7 1 1 3 3 Lineage 1 Human Switzerland 1982 
IS58 T. V. Riley 033 11 5 8 5 11 9 11 8 Lineage 5 Human Australia < 2004 
2046 J. Brazier 001 3 1 1 2 1 1 1 1 Lineage 1 unknown unknown unknown 
2047 J. Brazier NT 8 1 1 2 6 1 5 1 Lineage 1 unknown unknown unknown 
2050 J. Brazier 015 44 2 5 2 1 1 3 1 Lineage 1 unknown unknown unknown 
2052 J. Brazier 023 5 1 6 4 7 2 8 7 Lineage 3 unknown unknown unknown 
**2053 J. Brazier 027 1 1 1 1 10 1 3 5 Lineage 2 unknown unknown unknown 
2054 J. Brazier NT 11 5 8 5 11 9 11 8 Lineage 5 unknown unknown unknown 
2055 J. Brazier 106 42 1 1 2 1 1 7 1 Lineage 1 unknown unknown unknown 
5342 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
5350 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
**5359 J. G. Songer NT 1 1 1 1 10 1 3 5 Lineage 2 unknown unknown unknown 
5361 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 26/12/2006 
5363 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 20/03/2007 
**5370 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Bovine USA 26/06/2007 
**5373 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Bovine USA 20/03/2007 
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Isolate Provider 
PCR 
ribotype 
Sequence 
type 
Alleles Sequence 
type lineage 
Origin Location 
Date 
isolated adk atpA dxr glyA recA sodA tpi 
5379 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
5384 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 20/03/2007 
5397 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 26/06/2007 
5407 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 26/09/2006 
5408 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 26/06/2007 
5416 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 2006 
5416 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 2006 
**5427 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Bovine USA 31/07/2007 
5428 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 20/03/2007 
5429 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 15/10/2007 
5432 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 23/01/2007 
5444 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 15/10/2007 
5468 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
5898 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 20/03/2007 
5904 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 15/10/2007 
5911 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 17/04/2007 
5912 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
5917 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 15/10/2007 
5920 J. G. Songer NT 3 1 1 2 1 1 1 1 Lineage 1 Bovine USA 31/07/2007 
5921 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 20/11/2006 
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Isolate Provider 
PCR 
ribotype 
Sequence 
type 
Alleles Sequence 
type lineage 
Origin Location 
Date 
isolated adk atpA dxr glyA recA sodA tpi 
5927 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
5927 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
5933 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
5938 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 20/11/2006 
5946 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 20/03/2007 
5954 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
5963 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 20/11/2006 
5968 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 20/03/2007 
5982 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 20/11/2006 
5983 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 20/03/2007 
5984 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 15/10/2007 
5986 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 31/07/2007 
5987 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 15/10/2007 
5992 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
5996 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 15/10/2007 
6004 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
6005 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 26/06/2007 
6007 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 2007 
6007 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 2007 
**6014 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Bovine USA unknown 
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Isolate Provider 
PCR 
ribotype 
Sequence 
type 
Alleles Sequence 
type lineage 
Origin Location 
Date 
isolated adk atpA dxr glyA recA sodA tpi 
6015 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 15/10/2007 
6021 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 20/03/2007 
6065 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
6067 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
**8864 J. Brazier 036 62 1 1 1 9 1 3 1 Lineage 2 Human UK < 2004 
10/33 E. Kuijper 078 11 5 8 5 11 9 11 8 Lineage 5 unknown unknown unknown 
30256 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
31807 E. Kuijper NT 11 5 8 5 11 9 11 8 Lineage 5 unknown unknown unknown 
13/03 E. Kuijper 078 11 5 8 5 11 9 11 8 Lineage 5 unknown unknown unknown 
19/07 E. Kuijper 078 11 5 8 5 11 9 11 8 Lineage 5 unknown unknown unknown 
19/09 E. Kuijper 078 11 5 8 5 11 9 11 8 Lineage 5 unknown unknown unknown 
17/10 E. Kuijper 078 11 5 8 5 11 9 11 8 Lineage 5 unknown unknown unknown 
3/11 E. Kuijper 078 11 5 8 5 11 9 11 8 Lineage 5 unknown unknown unknown 
80249 E. Kuijper 078 11 5 8 5 11 9 11 8 Lineage 5 unknown unknown 20/03/2007 
**2004101 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Human USA 2004 
**2004102 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Human USA 2004 
**2004118 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Human USA 2004 
**2004163 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Human USA 2004 
**2005079 J. G. Songer NT 1 1 1 1 10 1 3 5 Lineage 2 Human USA 2005 
2005088 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Porcine USA 2005 
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Isolate Provider 
PCR 
ribotype 
Sequence 
type 
Alleles Sequence 
type lineage 
Origin Location 
Date 
isolated adk atpA dxr glyA recA sodA tpi 
2005093 J. G. Songer 126 11 5 8 5 11 9 11 8 Lineage 5 Porcine USA 2005 
2005094 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Porcine USA 2005 
2005325 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Human USA 2005 
2005508 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Porcine USA 2005 
2005511 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Porcine USA 2005 
2005515 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Porcine USA 2005 
2005517 J. G. Songer NT 48 1 1 2 1 1 5 1 Lineage 1 Porcine USA 2005 
2005519 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Porcine USA 2005 
**2006237 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Equine USA 2006 
2006238 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 2006 
2006239 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 2006 
2006240 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 2006 
2006241 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 2006 
2006243 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 2006 
2006244 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 2006 
2006245 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 2006 
2006246 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 2006 
2006253 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 2006 
2006254 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 2006 
2006354 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Human USA 2006 
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Isolate Provider 
PCR 
ribotype 
Sequence 
type 
Alleles Sequence 
type lineage 
Origin Location 
Date 
isolated adk atpA dxr glyA recA sodA tpi 
2006379 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Human  USA 2006 
2006437 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Food USA 2006 
2006438 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Food USA 2006 
**2006439 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Food USA 2006 
2006460 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Human  USA 2006 
2007007 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Human  USA 2007 
2007011 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Human USA 2007 
2007019 J. G. Songer 126 11 5 8 5 11 9 11 8 Lineage 5 Human  USA 2007 
2007024 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Human USA 2007 
**2007042 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Food USA 2007 
2007054 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Human  USA 2007 
**2007098 J. G. Songer NT 32 1 1 11 1 1 3 2 Lineage 2 Human  USA 2007 
2007134 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Human USA 2007 
**2007140 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Human USA 2007 
**2007195 J. G. Songer NT 41 1 1 9 9 1 3 2 Lineage 2 Human USA 2007 
2007206 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Human USA 2007 
**2007218 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Food USA 2007 
2007219 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Food USA 2007 
**2007222 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Food USA 2007 
**2007223 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Food USA 2007 
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Isolate Provider 
PCR 
ribotype 
Sequence 
type 
Alleles Sequence 
type lineage 
Origin Location 
Date 
isolated adk atpA dxr glyA recA sodA tpi 
2007224 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Food USA 2007 
2007229 J. G. Songer 126 11 5 8 5 11 9 11 8 Lineage 5 Food USA 2007 
2007230 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Food USA 2007 
**2007235 J. G. Songer NT 1 1 1 1 10 1 3 5 Lineage 2 Food USA 2007 
2007334 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Human USA 2007 
2007361 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Human USA 2007 
2007380 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Human USA 2007 
2007600 J. G. Songer 126 11 5 8 5 11 9 11 8 Lineage 5 Human Spain 2007 
2007601 J. G. Songer 126 11 5 8 5 11 9 11 8 Lineage 5 Human Spain 2007 
2007606 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Food USA 2007 
2007607 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Food USA 2007 
2007786 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Human Italy 2007 
2007792 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Human Italy 2007 
**2007825 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Human USA 2007 
**2007826 J. G. Songer NT 61 1 5 11 1 1 3 2 Lineage 2 Human USA 2007 
**2007827 J. G. Songer 262 67 1 1 9 9 1 3 5 Lineage 2 Human USA 2007 
**2007828 J. G. Songer NT 1 1 1 1 10 1 3 5 Lineage 2 Human USA 2007 
**2007829 J. G. Songer 262 67 1 1 9 9 1 3 5 Lineage 2 Human USA 2007 
**2007830 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Human USA 2007 
2007831 J. G. Songer 001 3 1 1 2 1 1 1 1 Lineage 1 Human USA 2007 
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Alleles Sequence 
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Origin Location 
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isolated adk atpA dxr glyA recA sodA tpi 
**2007832 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Human USA 2007 
**2007833 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Human USA 2007 
2007834 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Human USA 2007 
2007835 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Human USA 2007 
2007838 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Human USA 2007 
**2007839 J. G. Songer NT 1 1 1 1 10 1 3 5 Lineage 2 Human USA 2007 
2007841 J. G. Songer NT 3 1 1 2 1 1 1 1 Lineage 1 Human USA 2007 
**2007843 J. G. Songer NT 61 1 5 11 1 1 3 2 Lineage 2 Food USA 2007 
**2007844 J. G. Songer NT 61 1 5 11 1 1 3 2 Lineage 2 Food USA 2007 
**2007850 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Household USA 2007 
**2007855 J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Bovine USA 2007 
6600639 M. Holland 078 11 5 8 5 11 9 11 8 Lineage 5 Human UK unknown 
6600726 M. Holland 050 18 1 1 2 5 1 3 1 Lineage 1 Human UK unknown 
6601158 M. Holland NT 17 1 1 2 1 1 5 3 Lineage 1 Human UK unknown 
6601667 M. Holland 002 8 1 1 2 6 1 5 1 Lineage 1 Human UK unknown 
6603036 M. Holland 015 10 2 1 2 1 1 3 1 Lineage 1 Human UK unknown 
6603061 M. Holland NT 2 1 1 2 1 5 3 1 Lineage 1 Human UK unknown 
6604395 M. Holland 015 44 2 5 2 1 1 3 1 Lineage 1 Human UK unknown 
6605117 M. Holland 005 *131 2 1 6 8 1 5 1 Lineage 1 Human UK unknown 
6605475 M. Holland 015 44 2 5 2 1 1 3 1 Lineage 1 Human UK unknown 
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6614282 M. Holland 023 5 1 6 4 7 2 8 7 Lineage 3 Human UK unknown 
6614376 M. Holland 078 11 5 8 5 11 9 11 8 Lineage 5 Human UK unknown 
6615591 M. Holland 002 8 1 1 2 6 1 5 1 Lineage 1 Human UK unknown 
6615723 M. Holland 014 49 1 1 2 1 5 3 3 Lineage 1 Human UK unknown 
6616023 M. Holland 078 11 5 8 5 11 9 11 8 Lineage 5 Human UK unknown 
6616104 M. Holland 078 11 5 8 5 11 9 11 8 Lineage 5 Human UK unknown 
001-01 M. Holland 001 3 1 1 2 1 1 1 1 Lineage 1 unknown UK unknown 
001-02 M. Holland 001 3 1 1 2 1 1 1 1 Lineage 1 unknown UK unknown 
001-03 M. Holland 001 3 1 1 2 1 1 1 1 Lineage 1 unknown UK unknown 
001-04 M. Holland 001 3 1 1 2 1 1 1 1 Lineage 1 unknown UK unknown 
001-05 M. Holland 001 3 1 1 2 1 1 1 1 Lineage 1 unknown UK unknown 
001-06 M. Holland 001 3 1 1 2 1 1 1 1 Lineage 1 unknown UK unknown 
001-07 M. Holland 001 3 1 1 2 1 1 1 1 Lineage 1 unknown UK unknown 
001-08 M. Holland 001 2 1 1 2 1 5 3 1 Lineage 1 unknown UK unknown 
001-09 M. Holland 001 3 1 1 2 1 1 1 1 Lineage 1 unknown UK unknown 
001-10 M. Holland 001 3 1 1 2 1 1 1 1 Lineage 1 unknown UK unknown 
078W M. Holland 078 11 5 8 5 11 9 11 8 Lineage 5 unknown unknown unknown 
106- 01 M. Holland 106 42 1 1 2 1 1 7 1 Lineage 1 Human UK unknown 
106- 02 M. Holland 106 42 1 1 2 1 1 7 1 Lineage 1 Human UK unknown 
106- 04 M. Holland 106 42 1 1 2 1 1 7 1 Lineage 1 Human UK unknown 
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isolated adk atpA dxr glyA recA sodA tpi 
106- 05 M. Holland 106 42 1 1 2 1 1 7 1 Lineage 1 Human UK unknown 
106- 06 M. Holland 106 42 1 1 2 1 1 7 1 Lineage 1 Human UK unknown 
106-07 M. Holland 106 42 1 1 2 1 1 7 1 Lineage 1 Human UK unknown 
106-10 M. Holland 106 42 1 1 2 1 1 7 1 Lineage 1 Human UK unknown 
17/50 E. Kuijper 078 11 5 8 5 11 9 11 8 Lineage 5 unknown unknown unknown 
18/21 E. Kuijper 078 11 5 8 5 11 9 11 8 Lineage 5 unknown unknown unknown 
19/44 E. Kuijper 078 11 5 8 5 11 9 11 8 Lineage 5 unknown unknown unknown 
19/52 E. Kuijper 078 11 5 8 5 11 9 11 8 Lineage 5 unknown unknown unknown 
19/72 E. Kuijper 078 11 5 8 5 11 9 11 8 Lineage 5 unknown unknown unknown 
20/28 E. Kuijper 078 11 5 8 5 11 9 11 8 Lineage 5 unknown unknown unknown 
22/31 E. Kuijper 078 11 5 8 5 11 9 11 8 Lineage 5 unknown unknown unknown 
23/41 E. Kuijper 078 11 5 8 5 11 9 11 8 Lineage 5 unknown unknown unknown 
25/40 E. Kuijper 078 11 5 8 5 11 9 11 8 Lineage 5 unknown unknown unknown 
3623 -03 J. G. Songer NT 26 1 1 6 1 4 3 4 Lineage 1 Human Germany < 2004 
5353 (3/20) J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 20/03/2007 
**5354 (17/4) J. G. Songer 027 1 1 1 1 10 1 3 5 Lineage 2 Bovine USA unknown 
5379 (26/12) J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
5404 (17/4) J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 17/04/2007 
5404 (9/26) J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 26/09/2006 
5424 (2/20) J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 20/02/2007 
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5945 (2/21)  J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 20/11/2006 
5964 (20/11) J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 20/11/2006 
5964 (9/1) J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 09/01/2007 
5994 (9/4) J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA 04/09/2007 
6612-065 M. Holland 002 8 1 1 2 6 1 5 1 Lineage 1 Human UK unknown 
6612-590 M. Holland 015 44 2 5 2 1 1 3 1 Lineage 1 Human UK unknown 
6612-647 M. Holland NT 55 1 1 6 6 1 12 12 Lineage 1 Human UK unknown 
6612-820 M. Holland 094 12 1 1 6 4 3 5 1 Lineage 1 Human UK unknown 
6612-978 M. Holland 094 12 1 1 6 4 3 5 1 Lineage 1 Human UK unknown 
6613-373 M. Holland 002 8 1 1 2 6 1 5 1 Lineage 1 Human UK unknown 
6613-833 M. Holland 087 46 4 1 6 1 1 10 1 Lineage 1 Human UK unknown 
AI149 T. V. Riley 126 11 5 8 5 11 9 11 8 Lineage 5 Kangaroo Australia unknown 
AI15 T. V. Riley 237 11 5 8 5 11 9 11 8 Lineage 5 Porcine Australia unknown 
AI152 T. V. Riley NT 11 5 8 5 11 9 11 8 Lineage 5 Porcine Australia unknown 
AI18 T. V. Riley 014 *132 5 1 6 1 5 3 1 Lineage 1 Porcine Australia unknown 
AI24 T. V. Riley 237 11 5 8 5 11 9 11 8 Lineage 5 Porcine Australia unknown 
AI35 T. V. Riley 237 11 5 8 5 11 9 11 8 Lineage 5 Porcine Australia unknown 
**B1 D. N. Gerding NT 63 1 1 7 5 1 3 3 Lineage 1 Human UK 1978 
BI-1 D. N. Gerding 027 1 1 1 1 10 1 3 5 Lineage 2 Human USA 26/02/1988 
**BI-10 D. N. Gerding 027 1 1 1 1 10 1 3 5 Lineage 2 Human USA 10/08/2001 
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**BI-13 D. N. Gerding 027 1 1 1 1 10 1 3 5 Lineage 2 Human USA 09/09/2004 
**BI-15 D. N. Gerding 027 1 1 1 1 10 1 3 5 Lineage 2 Human USA 09/09/2004 
**BI-2 D. N. Gerding 027 1 1 1 1 10 1 3 5 Lineage 2 Human USA 14/01/1991 
**BI-5 D. N. Gerding 027 1 1 1 1 10 1 3 5 Lineage 2 Human USA 25/08/1995 
**BI-6 D. N. Gerding 027 (176) 1 1 1 1 10 1 3 5 Lineage 2 Human USA 20/05/2003 
**BI-6p D. N. Gerding 027 1 1 1 1 10 1 3 5 Lineage 2 Human USA 09/09/2004 
**BI-7 D. N. Gerding 027 1 1 1 1 10 1 3 5 Lineage 2 Human USA 20/05/2003 
**BI-8 D. N. Gerding 027 1 1 1 1 10 1 3 5 Lineage 2 Human USA 22/01/2004 
BI-9 D. N. Gerding 001 3 1 1 2 1 1 1 1 Lineage 1 Human USA unknown 
CD DE2 E. Kuijper NT 3 1 1 2 1 1 1 1 Lineage 1 unknown unknown unknown 
CD#101 E. Kuijper NT 63 1 1 7 5 1 3 3 Lineage 1 unknown unknown unknown 
CD#17 E. Kuijper NT 37 3 7 3 8 6 9 11 Lineage 4 unknown unknown unknown 
CD#371 E. Kuijper NT 3 1 1 2 1 1 1 1 Lineage 1 unknown unknown unknown 
**CD1 CDRN 027 1 1 1 1 10 1 3 5 Lineage 2 Human UK 12/07/2007 
CD1010 CDRN 274 *133 1 1 7 1 1 3 3 Lineage 1 Human UK 20/01/2010 
CD1049 CDRN 013 45 4 1 6 1 1 5 1 Lineage 1 Human UK 03/03/2010 
CD1061 CDRN 283 *134 1 3 2 15 1 3 3 Lineage 1 Human UK 19/03/2010 
CD1075 CDRN 070 55 1 1 6 6 1 12 12 Lineage 1 Human UK 04/03/2010 
CD1077 CDRN 106 *135 1 1 2 8 1 7 1 Lineage 1 Human UK 29/03/2010 
CD1079 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Human USA 27/03/2010 
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CD1080 CDRN 052 *136 2 1 6 16 1 5 13 Lineage 1 Human UK 27/03/2010 
CD1099 CDRN 059 53 1 2 2 1 1 5 1 Lineage 1 Human UK 02/04/2010 
**CD11 CDRN 027 1 1 1 1 10 1 3 5 Lineage 2 Human UK 21/05/2007 
CD1108 CDRN 097 21 2 2 2 1 1 1 3 Lineage 1 Human UK 18/04/2010 
CD1128 CDRN 118 42 1 1 2 1 1 7 1 Lineage 1 Human UK 04/05/2010 
CD1132 CDRN 216 33 1 1 2 1 6 5 3 Lineage 1 Human UK 07/05/2010 
CD1141 CDRN 020 2 1 1 2 1 5 3 1 Lineage 1 Human UK 17/05/2010 
CD1143 CDRN 140 26 1 1 6 1 4 3 4 Lineage 1 Human UK 04/05/2010 
CD1144 CDRN 003 57 1 1 6 4 3 5 13 Lineage 1 Human UK 17/05/2010 
CD1149 CDRN 186 51 1 1 2 6 1 7 6 Lineage 1 Human UK 23/05/2010 
CD1153 CDRN 139 52 1 1 2 16 1 12 1 Lineage 1 Human UK 27/05/2010 
CD1157 CDRN 046 35 2 5 8 1 1 3 6 Lineage 1 Human UK 24/05/2010 
CD1165 CDRN 053 63 1 1 7 5 1 3 3 Lineage 1 Human UK 28/05/2010 
CD1170 CDRN 018 17 1 1 2 1 1 5 3 Lineage 1 Human UK 22/05/2010 
CD1171 CDRN 029 *137 1 1 2 3 1 3 1 Lineage 1 Human UK 26/05/2010 
CD1199 CDRN 021 56 1 3 6 3 1 5 1 Lineage 1 Human UK 09/06/2010 
**CD12 CDRN 027 1 1 1 1 10 1 3 5 Lineage 2 Human UK 06/07/2007 
CD1201 CDRN 015 10 2 1 2 1 1 3 1 Lineage 1 Human UK 11/06/2010 
CD1202 CDRN 012 54 1 4 7 1 1 3 3 Lineage 1 Human UK 09/05/2010 
CD1210 CDRN 054 43 1 7 6 1 1 5 6 Lineage 1 Human UK 18/06/2010 
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CD1214 CDRN 011 *138 2 1 2 16 1 5 1 Lineage 1 Human UK 04/12/2009 
CD1220 CDRN 005 6 2 1 6 1 1 5 1 Lineage 1 Human UK 20/06/2010 
CD1224 CDRN 107 *139 2 1 2 1 1 1 3 Lineage 1 Human UK 14/06/2010 
**CD20 CDRN 027 1 1 1 1 10 1 3 5 Lineage 2 Human UK 07/08/2007 
**CD25 CDRN 027 1 1 1 1 10 1 3 5 Lineage 2 Human UK 31/07/2007 
CD305 CDRN 023 22 1 1 4 7 2 8 7 Lineage 3 Human UK 24/04/2008 
CD453 CDRN 023 5 1 6 4 7 2 8 7 Lineage 3 Human UK 30/09/2008 
CD527 CDRN 030 48 1 1 2 1 1 5 1 Lineage 1 Human UK 06/01/2009 
CD586 CDRN 017 37 3 7 3 8 6 9 11 Lineage 4 Human UK 11/03/2009 
**CD59 CDRN 027 1 1 1 1 10 1 3 5 Lineage 2 Human UK 11/08/2007 
**CD60 CDRN 027 1 1 1 1 10 1 3 5 Lineage 2 Human UK 04/10/2007 
**CD630 CDRN 027 1 1 1 1 10 1 3 5 Lineage 2 Human UK 04/04/2009 
CD637 CDRN 017 37 3 7 3 8 6 9 11 Lineage 4 Human UK 16/04/2009 
**CD679 CDRN 027 1 1 1 1 10 1 3 5 Lineage 2 Human UK 16/04/2009 
**CD682 CDRN 027 1 1 1 1 10 1 3 5 Lineage 2 Human UK 27/04/2009 
**CD683 CDRN 027 1 1 1 1 10 1 3 5 Lineage 2 Human UK 23/04/2009 
CD689 CDRN 064 33 1 1 2 1 6 5 3 Lineage 1 Human UK 11/05/2009 
CD714 CDRN 050 16 1 1 2 6 1 3 1 Lineage 1 Human UK 12/06/2009 
CD718 CDRN 085 39 3 7 10 8 7 2 10 Lineage 4 Human UK 08/06/2009 
CD735 CDRN 081 *139 2 1 2 1 1 1 3 Lineage 1 Human UK 03/07/2009 
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CD742 CDRN 243 *139 2 1 2 1 1 1 3 Lineage 1 Human UK 01/01/2009 
CD759 CDRN 050 6 2 1 6 1 1 5 1 Lineage 1 Human UK 15/07/2009 
**CD762 CDRN 111 *140 1 1 9 9 1 1 2 Lineage 2 Human UK 31/07/2009 
CD767  CDRN 015 10 2 1 2 1 1 3 1 Lineage 1 Human UK 27/07/2009 
**CD790 CDRN 027 1 1 1 1 10 1 3 5 Lineage 2 Human UK 02/08/2009 
**CD806 CDRN 027 1 1 1 1 10 1 3 5 Lineage 2 Human UK 02/09/2009 
**CD81 CDRN 027 1 1 1 1 10 1 3 5 Lineage 2 Human UK 28/08/2007 
CD816 CDRN 017 37 3 7 3 8 6 9 11 Lineage 4 Human UK 28/09/2009 
CD825 CDRN 017 37 3 7 3 8 6 9 11 Lineage 4 Human UK 01/10/2009 
CD839 CDRN 017 37 3 7 3 8 6 9 11 Lineage 4 Human UK 29/10/2009 
CD853 CDRN 062 44 2 5 2 1 1 3 1 Lineage 1 Human UK 21/10/2009 
CD871 CDRN 259 *141 1 3 7 1 3 1 6 Lineage 1 Human UK 06/11/2009 
**CD877 CDRN 135 41 1 1 9 9 1 3 2 Lineage 2 Human UK 22/11/2009 
CD886 CDRN 116 10 2 1 2 1 1 3 1 Lineage 1 Human UK 06/12/2009 
CD909 CDRN 264 *142 8 7 14 8 6 25 15 Lineage 4 Human UK 17/12/2009 
CD914 CDRN 010 15 1 1 6 1 8 5 1 Lineage 1 Human UK 14/12/2009 
CD915 CDRN 126 11 5 8 5 11 9 11 8 Lineage 5 Human UK 02/12/2009 
CD917 CDRN 022 66 1 1 2 6 1 5 3 Lineage 1 Human UK 20/12/2009 
CD955 CDRN 268 3 1 1 2 1 1 1 1 Lineage 1 Human UK 15/01/2010 
CD959 CDRN 262 *143 1 11 6 16 1 1 1 Lineage 1 Human UK 13/01/2010 
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CD966 CDRN 196 *144 1 1 2 2 1 5 3 Lineage 1 Human UK 22/01/2010 
CD970 CDRN 271 6 2 1 6 1 1 5 1 Lineage 1 Human UK 23/01/2010 
CD973 CDRN 002 8 1 1 2 6 1 5 1 Lineage 1 Human UK 24/11/2009 
CD134 CDRN 002 8 1 1 2 6 1 5 1 Lineage 1 Human UK unknown 
CF3 J. Brazier 017 37 3 7 3 8 6 9 11 Lineage 4 Human Belgium 1995 
CF5 J. Brazier 017 86 3 7 3 8 6 19 11 Lineage 4 Human Belgium 1995 
**DS209/06  M. Holland NT 1 1 1 1 10 1 3 5 Lineage 2 unknown UK unknown 
E327 -98 T. V. Riley 126 11 5 8 5 11 9 11 8 Lineage 5 Equine Switzerland < 2004 
ES173 T. V. Riley 017 37 3 7 3 8 6 9 11 Lineage 4 Human Australia 18/12/2006 
ES130 T. V. Riley 280 11 5 8 5 11 9 11 8 Lineage 5 Human unknown unknown 
ES166 T. V. Riley 281 11 5 8 5 11 9 11 8 Lineage 5 Human Australia 28/06/1905 
ES67 T. V. Riley 014 13 1 1 6 1 5 3 1 Lineage 1 unknown Australia unknown 
**ES84 T. V. Riley 027 1 1 1 1 10 1 3 5 Lineage 2 unknown Canada unknown 
J9 J. G. Songer NT 3 1 1 2 1 1 1 1 Lineage 1 Human USA unknown 
JGS 6047 J. G. Songer NT 3 1 1 2 1 1 1 1 Lineage 1 Equine USA unknown 
JGS 679 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
JGS344 J. G. Songer NT 35 2 5 8 1 1 3 6 Lineage 1 Murine USA unknown 
JGS355 J. G. Songer 002 35 2 5 8 1 1 3 6 Lineage 1 Murine USA unknown 
JGS356 J. G. Songer 002 35 2 5 8 1 1 3 6 Lineage 1 Murine USA unknown 
JGS357 J. G. Songer 002 35 2 5 8 1 1 3 6 Lineage 1 Murine USA unknown 
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JGS360 J. G. Songer 002 35 2 5 8 1 1 3 6 Lineage 1 Murine USA unknown 
JGS6042 J. G. Songer 002 8 1 1 2 6 1 5 1 Lineage 1 Equine USA unknown 
JGS6050 J. G. Songer 020 2 1 1 2 1 5 3 1 Lineage 1 Canine USA unknown 
JGS655 J. G. Songer NT 8 1 1 2 6 1 5 1 Lineage 1 Porcine USA unknown 
JGS673 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
JGS674 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
JGS675 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
JGS676 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
JGS677 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
JGS688 J. G. Songer 126 11 5 8 5 11 9 11 8 Lineage 5 Porcine USA unknown 
JGS691 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Porcine USA unknown 
JGS692 J. G. Songer 002 48 1 1 2 1 1 5 1 Lineage 1 Porcine USA unknown 
M1 D. Drudy NT 64 1 1 6 1 1 13 1 Lineage 1 unknown unknown unknown 
M120 D. Drudy 078 11 5 8 5 11 9 11 8 Lineage 5 Human Ireland unknown 
M13 D. Drudy NT 15 1 1 6 1 8 5 1 Lineage 1 Human unknown unknown 
M68 D. Drudy 017 37 3 7 3 8 6 9 11 Lineage 4 Human Ireland 2006 
metal 1 J. G. Songer NT 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
**O1-027 M. Holland 027 1 1 1 1 10 1 3 5 Lineage 2 Human UK unknown 
O1-078 M. Holland 078 11 5 8 5 11 9 11 8 Lineage 5 Human UK unknown 
PMH13 T. V. Riley 010 15 1 1 6 1 8 5 1 Lineage 1 Human Australia 09/01/2007 
 246 
 
Isolate Provider 
PCR 
ribotype 
Sequence 
type 
Alleles Sequence 
type lineage 
Origin Location 
Date 
isolated adk atpA dxr glyA recA sodA tpi 
PMH44 T. V. Riley 126 11 5 8 5 11 9 11 8 Lineage 5 Human Australia 16/08/2008 
**R10287 J. Brazier 027 1 1 1 1 10 1 3 5 Lineage 2 Human France unknown 
R1040  J. Brazier 212 5 1 6 4 7 2 8 7 Lineage 3 Human unknown unknown 
R10459 J. Brazier 106 42 1 1 2 1 1 7 1 Lineage 1 Human unknown unknown 
**R20291 J. Brazier 027 1 1 1 1 10 1 3 5 Lineage 2 Human UK 2006 
**R20352 J. Brazier 027 1 1 1 1 10 1 3 5 Lineage 2 Human Canada 2005 
R279  J. Brazier NT 5 1 6 4 7 2 8 7 Lineage 3 Human unknown unknown 
R711 J. Brazier 031 29 1 1 2 16 1 3 1 Lineage 1 Human unknown unknown 
R714 J. Brazier 001 3 1 1 2 1 1 1 1 Lineage 1 Human unknown unknown 
R8366 J. Brazier 001 3 1 1 2 1 1 1 1 Lineage 1 Human unknown unknown 
R839 J. Brazier NT 3 1 1 2 1 1 1 1 Lineage 1 Human unknown unknown 
R894 J. Brazier 002 8 1 1 2 6 1 5 1 Lineage 1 Human unknown unknown 
RPH101 T. V. Riley NT 11 5 8 5 11 9 11 8 Lineage 5 Human Australia 27/01/2007 
RPH13 T. V. Riley NT 63 1 1 7 5 1 3 3 Lineage 1 Human Australia 24/08/2006 
RPH35 T. V. Riley 087 *145 4 1 6 1 1 10 12 Lineage 1 Human Australia 30/08/2006 
RPH56 T. V. Riley 014 2 1 1 2 1 5 3 1 Lineage 1 Human Australia 02/06/2006 
RPH61 T. V. Riley 005 6 2 1 6 1 1 5 1 Lineage 1 Human Australia 04/11/2006 
RT023 M. Holland 023 5 1 6 4 7 2 8 7 Lineage 1 unknown unknown unknown 
RT026 M. Holland 026 7 1 1 7 1 1 5 1 Lineage 1 unknown unknown unknown 
RT042 M. Holland 042 6 2 1 6 1 1 5 1 Lineage 1 unknown unknown unknown 
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RT050 M. Holland 050 18 1 1 2 5 1 3 1 Lineage 1 unknown unknown unknown 
**RT176 M. Holland 176 1 1 1 1 10 1 3 5 Lineage 2 unknown unknown unknown 
**S10.1014 M. Holland 027 1 1 1 1 10 1 3 5 Lineage 2 Human UK 2010 
S10.1486 M. Holland NT 13 1 1 6 1 5 3 1 Lineage 1 Human UK 2010 
S10.1920 M. Holland 002 *146 1 1 2 6 1 5 4 Lineage 1 Human UK 2010 
S10.358 M. Holland 078 11 5 8 5 11 9 11 8 Lineage 5 Human UK 2010 
**S10.564 M. Holland 027 1 1 1 1 10 1 3 5 Lineage 2 Human UK 2010 
Slaughter 1 J. G. Songer 078 11 5 8 5 11 9 11 8 Lineage 5 Bovine USA unknown 
T7 M. Holland NT 3 1 1 2 1 1 1 1 Lineage 1 Human unknown unknown 
VPI 10463 J. G. Songer 087 46 4 1 6 1 1 10 1 Lineage 1 Human USA 1935 
WA 107 T. V. Riley 127 11 5 8 5 11 9 11 8 Lineage 5 Human Australia 01/03/2006 
WA 12 T. V. Riley 239 *147 10 8 5 11 9 11 8 Lineage 5 Human Australia unknown 
WA 122 T. V. Riley 002 8 1 1 2 6 1 5 1 Lineage 1 Human Australia 14/04/2006 
WA 13 T. V. Riley 291 *148 5 8 5 11 9 11 20 Lineage 5 Human Australia 31/12/2005 
WA 146 T. V. Riley NT 55 1 1 6 6 1 12 12 Lineage 1 Human Australia 27/12/2005 
WA 15 T. V. Riley 002 8 1 1 2 6 1 5 1 Lineage 1 Human Australia 05/01/2009 
WA 151 T. V. Riley 237 11 5 8 5 11 9 11 8 Lineage 5 Human Australia 11/07/2006 
WA 156 T. V. Riley 012 54 1 4 7 1 1 3 3 Lineage 1 Human Australia 14/06/2006 
WA 158 T. V. Riley NT 34 1 5 7 1 1 3 1 Lineage 1 Human Australia 08/06/2006 
WA 161 T. V. Riley 010 15 1 1 6 1 8 5 1 Lineage 1 Human Australia 05/07/2006 
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WA 169 T. V. Riley 081 9 1 1 6 1 1 6 1 Lineage 1 Human Australia 02/06/2006 
WA 48 T. V. Riley 127 11 5 8 5 11 9 11 8 Lineage 5 Human Australia 14/11/2005 
WA 52 T. V. Riley 014 2 1 1 2 1 5 3 1 Lineage 1 Human Australia 02/09/2005 
WA 68 T. V. Riley 009 3 1 1 2 1 1 1 1 Lineage 1 Human Australia 09/10/2005 
WA 76 T. V. Riley 001 3 1 1 2 1 1 1 1 Lineage 1 Human Australia 13/10/2005 
WA 77 T. V. Riley 127 11 5 8 5 11 9 11 8 Lineage 5 Human Australia 14/10/2005 
WA 80 T. V. Riley NT 55 1 1 6 6 1 12 12 Lineage 1 Human Australia 19/10/2005 
WA 93 T. V. Riley 054 43 1 7 6 1 1 5 6 Lineage 1 Human Australia 28/01/2006 
WA 94 T. V. Riley 078 11 5 8 5 11 9 11 8 Lineage 5 Human Australia 19/01/2006 
 249 
 
Appendix 2: Bacterial isolates used in chapter 5 
Isolate Provider Location Date Isolated Origin 
M04-34 K. Solomon Dublin, Ireland 2004 Human 
M04-21 K. Solomon Dublin, Ireland 2004 Human 
M04-30 K. Solomon Dublin, Ireland 2004 Human 
M04-40 K. Solomon Dublin, Ireland 2004 Human 
M04-50 K. Solomon Dublin, Ireland 2004 Human 
M05-213 K. Solomon Dublin, Ireland 2005 Human 
M05-195 K. Solomon Dublin, Ireland 2005 Human 
M05-214 K. Solomon Dublin, Ireland 2005 Human 
M04-9 K. Solomon Dublin, Ireland 2004 Human 
M08-127 K. Solomon Dublin, Ireland 2008 Human 
M08-150 K. Solomon Dublin, Ireland 2008 Human 
IE 1104 K. Solomon Dublin, Ireland 2009 Human 
SV04-54 K. Solomon Dublin, Ireland 2005 Human 
S3 K. Solomon Dublin, Ireland 2006 Human 
MOH849 J. S. Weese Ontario, Canada 2003 Human 
CD257 J. S. Weese Ontario, Canada 2003 Human 
CD334 J. S. Weese Ontario, Canada 2003 Human 
CD459 J. S. Weese Ontario, Canada 2003 Human 
S- 017.8 P.M Hawkey Dublin, Ireland 2000 Human 
S- 017.9 P.M Hawkey Dublin, Ireland 2000 Human 
S- 017.10 P.M Hawkey Dublin, Ireland 2000 Human 
MOH82 J. S. Weese Ontario, Canada 2003 Human 
CD656
 
 J. S. Weese Ontario, Canada 2004 Bovine 
CD657
 
 J. S. Weese Ontario, Canada 2004 Bovine 
S- 017.5 P.M Hawkey Carlisle, UK 1994 Human 
GAI 95601 H. Kato Japan 1995 Human 
S- 017.13 P.M Hawkey Japan 1999 Human 
B-33 CDRN London, UK 2011 Human 
M04-106 K. Solomon Dublin, Ireland 2005 Human 
M05-185 K. Solomon Dublin, Ireland 2005 Human 
7081082 E. J. Kuijper The Netherlands 2007 Human 
8083571 E. J. Kuijper The Netherlands 2008 Human 
MRL 1135 D. N. Gerding North Dakota, USA 2007 Human 
UHL-24 CDRN London, UK 2013 Human 
MRL 981 D. N. Gerding California, USA 2007 Human 
S- 017.12 P.M Hawkey Japan 1999 Human 
11-383 H. Kim Korea 2011 Human 
PT 1307 E. J. Kuijper Portugal 2009 Human 
S- 017.22 P.M Hawkey Poole, UK 2003 Human 
S- 017.23 P.M Hawkey Poole, UK 2003 Human 
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Isolate Provider Location Date Isolated Origin 
S- 017.24 P.M Hawkey Poole, UK 2003 Human 
S- 017.25 P.M Hawkey Poole, UK 2003 Human 
MRL 529 D. N. Gerding Michigan, USA 2007 Human 
SV04-9 K. Solomon Dublin, Ireland 2004 Human 
SV04-17 K. Solomon Dublin, Ireland 2004 Human 
SV04-29 K. Solomon Dublin, Ireland 2004 Human 
MRL 532 D. N. Gerding Michigan, USA 2007 Human 
CD552
 
 J. S. Weese Ontario, Canada 2002 Equine 
CD577
 
 J. S. Weese Ontario, Canada 2003 Equine 
CD409 J. S. Weese Ontario, Canada 2003 Human 
CD159 J. S. Weese Ontario, Canada 2003 Human 
CD210 J. S. Weese Ontario, Canada 2003 Human 
CD160 J. S. Weese Ontario, Canada 2003 Human 
CD425 J. S. Weese Ontario, Canada 2003 Human 
CD345 J. S. Weese Ontario, Canada 2003 Human 
CD538
 
 J. S. Weese Ontario, Canada 2003 Equine 
CD562 J. S. Weese Ontario, Canada 2004 Human 
CD744
 
 J. S. Weese Ontario, Canada 2004 Bovine 
CD472
 
 J. S. Weese Ontario, Canada 2004 Bovine 
CD748
 
 J. S. Weese Ontario, Canada 2004 Bovine 
CD754
 
 J. S. Weese Ontario, Canada 2004 Bovine 
CD755
 
 J. S. Weese Ontario, Canada 2004 Bovine 
CD746
 
 J. S. Weese Ontario, Canada 2004 Bovine 
CD762
 
 J. S. Weese Ontario, Canada 2004 Bovine 
CD479
 
 J. S. Weese Ontario, Canada 2005 Canine 
CD493
 
 J. S. Weese Ontario, Canada 2005 Canine 
CD504 J. S. Weese Ontario, Canada 2005 Canine 
CD515
 
 J. S. Weese Ontario, Canada 2005 Canine 
CD523
 
 J. S. Weese Ontario, Canada 2005 Canine 
CD527
 
 J. S. Weese Ontario, Canada 2005 Canine 
CD528
 
 J. S. Weese Ontario, Canada 2005 Canine 
CD529
 
 J. S. Weese Ontario, Canada 2005 Canine 
CD531
 
 J. S. Weese Ontario, Canada 2005 Canine 
CD578
 
 J. S. Weese Ontario, Canada 2005 Equine 
CD524
 
 J. S. Weese Ontario, Canada 2005 Canine 
CD514
 
 J. S. Weese Ontario, Canada 2005 Canine 
S- 017.15 P.M Hawkey Kuwait 2001 Human 
S- 017.16 P.M Hawkey Kuwait 2001 Human 
DS 1383 T. D. Lawley Singapore 2003 Human 
SI 032 T. D. Lawley Singapore 2008 Human 
MOH207 J. S. Weese Ontario, Canada 2003 Human 
MRL 270 D. N. Gerding Ontario, Canada 2006 Human 
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Isolate Provider Location Date Isolated Origin 
MRL 102 D. N. Gerding Ohio, USA 2006 Human 
09-275 H. Kim Korea 2009 Human 
BG 181 E. J. Kuijper Bulgaria 2009 Human 
GR 0108 E. J. Kuijper Greece 2009 Human 
S- 017.43 P.M Hawkey Hong Kong 2011 Human 
S- 017.75 P.M Hawkey Coventry, UK 2011 Human 
S- 017.40 P.M Hawkey Hong Kong 2011 Human 
SCH5842529 S. Reid South Africa 2012 Human 
SI 064 T. V. Riley Singapore 2012 Human 
WX-36 CDRN London, UK 2012 Human 
S- 017.79 P.M Hawkey Nottinghamshire, UK 2012 Human 
02-210 H. Kim Korea 2002 Human 
SI 1101 E. J. Kuijper Slovenia 2009 Human 
S- 017.55 P.M Hawkey Nottinghamshire, UK 2009 Human 
S- 017.91 P.M Hawkey China 2009 Human 
S- 017.32 P.M Hawkey Hong Kong 2010 Human 
S- 017.33 P.M Hawkey Hong Kong 2010 Human 
WX-35 CDRN London, UK 2011 Human 
WA 1514 T. V. Riley Australia 2012 Human 
MRL 3836 D. N. Gerding Illinois, USA 2009 Human 
S- 017.77 P.M Hawkey Coventry, UK 2012 Human 
S- 017.92 P.M Hawkey China 2009 Human 
CZ 1201 E. J. Kuijper Czech Republic 2009 Human 
675 E. J. Kuijper Romania 2009 Human 
S- 017.20 P.M Hawkey Poland 2003 Human 
S- 017.1 P.M Hawkey Argentina 2001 Human 
S- 017.2 P.M Hawkey Argentina 2001 Human 
S- 017.3 P.M Hawkey Argentina 2001 Human 
NP-25 CDRN London, UK 2008 Human 
ES 531 T. V. Riley Australia 2011 Human 
S- 017.35 P.M Hawkey Hong Kong 2010 Human 
S- 017.37 P.M Hawkey Hong Kong 2010 Human 
S- 017.38 P.M Hawkey Hong Kong 2010 Human 
ES 580 T. V. Riley Australia 2012 Human 
ES 720 T. V. Riley Australia 2012 Human 
12H001405 CDRN London, UK 2013 Human 
6797 D. N. Gerding Argentina 2011 Human 
PL 1204 E. J. Kuijper Poland 2009 Human 
01-116 H. Kim Korea 2001 Human 
S- 017.19 P.M Hawkey Poland 2003 Human 
6050595 E. J. Kuijper The Netherlands 2006 Human 
7036732 E. J. Kuijper The Netherlands 2007 Human 
 252 
 
Isolate Provider Location Date Isolated Origin 
S- 017.58 P.M Hawkey Nottinghamshire, UK 2010 Human 
03-182 H. Kim Korea 2003 Human 
06-378 H. Kim Korea 2006 Human 
07-613 H. Kim Korea 2007 Human 
0 9-02 H. Kim Korea 2009 Human 
08-191 H. Kim Korea 2008 Human 
06-472 H. Kim Korea 2006 Human 
07-527 H. Kim Korea 2007 Human 
04-247 H. Kim Korea 2004 Human 
05-269 H. Kim Korea 2005 Human 
0 8-26 H. Kim Korea 2008 Human 
S- 017.48 P.M Hawkey Coventry, UK 2008 Human 
S- 017.47 P.M Hawkey Coventry, UK 2008 Human 
S- 017.60 P.M Hawkey Nottinghamshire, UK 2010 Human 
S- 017.62 P.M Hawkey Nottinghamshire, UK 2010 Human 
S- 017.68 P.M Hawkey Coventry, UK 2011 Human 
S- 017.69 P.M Hawkey Coventry, UK 2011 Human 
S- 017.46 P.M Hawkey Coventry, UK 2008 Human 
S- 017.50 P.M Hawkey Coventry, UK 2008 Human 
S- 017.49 P.M Hawkey Coventry, UK 2008 Human 
S- 017.51 P.M Hawkey Coventry, UK 2008 Human 
S- 017.52 P.M Hawkey Coventry, UK 2008 Human 
05-302 H. Kim Korea 2005 Human 
S- 017.72 P.M Hawkey Walsall, UK 2011 Human 
S- 017.73 P.M Hawkey Walsall, UK 2011 Human 
S- 017.64 P.M Hawkey Walsall, UK 2011 Human 
S- 017.65 P.M Hawkey Walsall, UK 2011 Human 
S- 017.66 P.M Hawkey Walsall, UK 2011 Human 
S- 017.90 P.M Hawkey China 2009 Human 
S- 017.57 P.M Hawkey Nottinghamshire, UK 2009 Human 
S- 017.59 P.M Hawkey Nottinghamshire, UK 2010 Human 
S- 017.70 P.M Hawkey Lincolnshire, UK 2011 Human 
S- 017.86 P.M Hawkey China 2009 Human 
S- 017.87 P.M Hawkey China 2009 Human 
S- 017.95 P.M Hawkey China 2010 Human 
S- 017.88 P.M Hawkey China 2009 Human 
S- 017.89 P.M Hawkey China 2009 Human 
S- 017.93 P.M Hawkey China 2009 Human 
S- 017.94 P.M Hawkey China 2009 Human 
5992 D. N. Gerding Illinois, USA 1996 Human 
S- 017.80 P.M Hawkey Wolverhampton, UK 2012 Human 
S- 017.78 P.M Hawkey Wolverhampton, UK 2012 Human 
 253 
 
Isolate Provider Location Date Isolated Origin 
S- 017.36 P.M Hawkey Hong Kong 2010 Human 
95-24 H. Kim Korea 1995 Human 
95-25 H. Kim Korea 1995 Human 
S- 017.14 P.M Hawkey Japan 1999 Human 
T-14 P. J. Tsai Taiwan 2011 Human 
MRL 991 D. N. Gerding California, USA 2007 Human 
QM-34 CDRN London, UK 2011 Human 
S- 017.11 P.M Hawkey Fife, UK 2002 Human 
S- 017.21 P.M Hawkey Poland 2003 Human 
MRL 738 D. N. Gerding Washington, USA 2007 Human 
S- 017.30 P.M Hawkey Hong Kong 2010 Human 
S- 017.31 P.M Hawkey Hong Kong 2010 Human 
S- 017.41 P.M Hawkey Hong Kong 2011 Human 
S- 017.45 P.M Hawkey Hong Kong 2011 Human 
S- 017.44 P.M Hawkey Hong Kong 2011 Human 
WA 1196 T. V. Riley Australia 2012 Human 
S- 017.4 P.M Hawkey Aylesbury, UK 2005 Human 
00-108 H. Kim Korea 2000 Human 
5572 D. N. Gerding Minnesota, USA 1992 Human 
6084529 E. J. Kuijper The Netherlands 2006 Human 
SI 010 T. V. Riley Singapore 2008 Human 
S- 017.56 P.M Hawkey Birmingham, UK 2009 Human 
7038446 E. J. Kuijper The Netherlands 2007 Human 
7047343 E. J. Kuijper The Netherlands 2007 Human 
WA 1428 T. V. Riley Australia 2012 Human 
SI 004 T. V. Riley Singapore 2008 Human 
S- 017.67 P.M Hawkey Coventry, UK 2011 Human 
S- 017.71 P.M Hawkey Staffordshire, UK 2011 Human 
S- 017.81 P.M Hawkey Walsall, UK 2012 Human 
SI 007 T. V. Riley Singapore 2008 Human 
S- 017.76 P.M Hawkey Coventry, UK 2012 Human 
DS 21 T. D. Lawley Singapore 2003 Human 
I 6 T. V. Riley Indonesia 2011 Human 
9029054 E. J. Kuijper The Netherlands 2009 Human 
S- 017.7 P.M Hawkey Dorchester, UK 1996 Human 
NM-27 CDRN Middlesex, UK 2005 Human 
S- 017.6 P.M Hawkey Dorchester, UK 1996 Human 
4241 D. N. Gerding Minnesota, USA 1990 Human 
S- 017.53 P.M Hawkey Worcestershire, UK 2009 Human 
SI 047 T. V. Riley Singapore 2012 Human 
SI 099 T. V. Riley Singapore 2012 Human 
B-26 CDRN London, UK 2009 Human 
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Isolate Provider Location Date Isolated Origin 
S- 017.27 P.M Hawkey Wrexham, UK 1996 Human 
S- 017.28 P.M Hawkey Wrexham, UK 1996 Human 
S- 017.29 P.M Hawkey Wrexham, UK 1996 Human 
T-79 P. J. Tsai Taiwan 2011 Human 
T-16 P. J. Tsai Taiwan 2011 Human 
SV04-6 K. Solomon Dublin, Ireland 2004 Human 
SV05-3 K. Solomon Dublin, Ireland 2005 Human 
SV05-25 K. Solomon Dublin, Ireland 2005 Human 
SV04-10 K. Solomon Dublin, Ireland 2004 Human 
SV04-18 K. Solomon Dublin, Ireland 2004 Human 
SV04-19 K. Solomon Dublin, Ireland 2004 Human 
SCH6148880 S. Reid South Africa 2012 Human 
UHL-4 CDRN London, UK 2009 Human 
SCH5806999 S. Reid South Africa 2012 Human 
SCH6098043 S. Reid South Africa 2012 Human 
SCH5824693 S. Reid South Africa 2012 Human 
SCH5845556 S. Reid South Africa 2012 Human 
MRL 985 D. N. Gerding California, USA 2007 Human 
UHL-1 CDRN London, UK 2005 Human 
UHL-6 CDRN London, UK 2009 Human 
UHL-8 CDRN London, UK 2009 Human 
UHL-5 CDRN London, UK 2009 Human 
UHL-7 CDRN London, UK 2009 Human 
UHL-2 CDRN London, UK 2009 Human 
UHL-3 CDRN London, UK 2009 Human 
UHL-9 CDRN London, UK 2009 Human 
UHL-12 CDRN London, UK 2010 Human 
UHL-10 CDRN London, UK 2010 Human 
UHL-11 CDRN London, UK 2010 Human 
UHL-13 CDRN London, UK 2010 Human 
UHL-14 CDRN London, UK 2010 Human 
UHL-22 CDRN London, UK 2010 Human 
SI 006 T. V. Riley Singapore 2008 Human 
CDP08WTH7 T. D. Lawley Liverpool, UK 2010 Human 
UHL-15 CDRN London, UK 2010 Human 
UHL-16 CDRN London, UK 2010 Human 
UHL-17 CDRN London, UK 2010 Human 
UHL-21 CDRN London, UK 2010 Human 
UHL-23 CDRN London, UK 2011 Human 
UHL-19 CDRN London, UK 2010 Hospital ward 
UHL-21 CDRN London, UK 2010 Hospital ward 
UHL-18 CDRN London, UK 2010 Human 
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Isolate Provider Location Date Isolated Origin 
MRL 2923 D. N. Gerding Colorado, USA 2008 Human 
5733 D. N. Gerding Illinois, USA 1995 Human 
8070899 E. J. Kuijper The Netherlands 2008 Human 
CX-32 CDRN London, UK 2011 Human 
MRL 2259 D. N. Gerding California, USA 2008 Human 
4092 D. N. Gerding Minnesota, USA 1990 Human 
4139 D. N. Gerding Minnesota, USA 1990 Human 
H-219 D. N. Gerding Illinois, USA 2006 Human 
12H400159 CDRN London, UK 2013 Human 
5264 D. N. Gerding Minnesota, USA 1992 Human 
5265 D. N. Gerding Minnesota, USA 1992 Human 
5340 D. N. Gerding Minnesota, USA 1993 Human 
S- 017.84 P.M Hawkey Northamptonshire, UK 2012 Human 
S- 017.82 P.M Hawkey Northamptonshire, UK 2012 Human 
S- 017.83 P.M Hawkey Northamptonshire, UK 2012 Human 
GOSH-28 CDRN London, UK 2010 Human 
GOSH-29 CDRN London, UK 2010 Human 
GOSH-30 CDRN London, UK 2010 Human 
RF-31 CDRN London, UK 2010 Human 
S- 017.61 P.M Hawkey Birmingham, UK 2010 Human 
S- 017.74 P.M Hawkey Walsall, UK 2011 Human 
S- 017.85 P.M Hawkey Northamptonshire, UK 2012 Human 
WA 0908 T. V. Riley Australia 2012 Human 
GOSH-37 CDRN London, UK 2013 Human 
SCH5865760 S. Reid South Africa 2012 Human 
SCH5864722 S. Reid South Africa 2012 Human 
SCH6163235 S. Reid South Africa 2012 Human 
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Appendix 3: Chapter 5 isolates: non-synonymous SNPs and predicted function (includes isolates from chapter 4) 
Position in 
genome 
Reference 
Base 
Alternative 
Base 
Amino 
Acid 
Gene/Predicted Function and/or Potential Impact 
Number of 
isolates with SNP 
23868 G T 6 rpsJ (tigecyline resistance) 265 
1907433 T G 282 msrAB (altered response to environmental stress) 256 
113641 A T 426 gyrB (fluoroquinolone resistance) 248 
288057 C A 56 phnM (degradation of phosphonate compounds) 248 
1869520 A G 144 hisC (histidinol-phosphate aminotransferase) 248 
112752 G A 82 gyrA (fluoroquinolone resistance) 179 
650374 A G 19 MerR (altered response to environmental stimuli) 114 
2914248 A G 257 dacF Reduced resistance to heat  or β-lactam antibiotics 
to heat  or β-lactam antibiotics 
114 
3604289 C A 329 Hypothetical protein 114 
34697 G T 502 rpoB (rifampicin resistance) 92 
34687 C T 505 rpoB (rifampicin resistance) 90 
1918864 T C 292 
bioB (altered biotin production, limiting its availability and in-turn increasing 
toxin synthesis) 
59 
3419885 A C 314 Signalling protein 59 
800885 C T 20 PTS system, IIa component (altered sensitivity to bacteriocins) 55 
72976 C T 218 Beta-glucosidase (hydrolysis of cellobiose to two molecules of glucose) 39 
3355379 C A 346 Signalling protein 39 
1204039 G T 141 HAD superfamily hydrolase (hydrolytic enzyme reactions) 36 
213561 C T 193 Hypothetical protein 29 
345335 A C 31 
Protein-tyrosine-phosphatase (control of the biosynthesis of capsular and 
extracellular polysaccharides) 
29 
465423 T C 97 Hypothetical protein 29 
1666328 T C 87 Signalling protein 29 
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Position in 
genome 
Reference 
Base 
Alternative 
Base 
Amino 
Acid 
Gene/Predicted Function and/or Potential Impact 
Number of 
isolates with SNP 
1669112 G T 392 Signalling protein 29 
2155937 G A 134 Glyoxalase (altered response to environmental stress) 29 
2761655 T C 104 MerR (altered response to environmental stimuli) 29 
3304067 T G 559 Sigma-54 (controls expression of nitrogen related genes) 29 
3366100 G T 164 Permease (membrane transporter) 29 
400308 C A 321 cbiK (iron transport system) 26 
2764775 C T 676 Signalling protein 26 
3067079 C G 497 Penicillin-binding protein (B-lactam resistance) 26 
4025381 G A 11 FlgG (altered formation of flagella) 26 
3066391 G A 726 Penicillin-binding protein (B-lactam resistance) 25 
3202066 T A 332 ABC transporter, permease/ATP-binding protein 25 
578215 C T 252 Iron-only hydrogenase 23 
707105 C A 98 ABC transporter, permease protein 23 
1123155 G A 125 Membrane protein 23 
1541265 G A 394 Sensor histidine kinase 23 
2236997 C T 429 aroA 23 
3072208 C G 66 maf 23 
3403871 G T 115 plfA 23 
2881638 T G 223 tepA 20 
457651 C A 37 Multidrug efflux protein 19 
1178734 G T 223 Cell surface protein 19 
1942550 T A 158 Signalling protein 19 
1997615 A T 133 Xanthine/uracile permease 19 
3053095 C T 162 obg 19 
3364434 G A 227 CoA-transferase 19 
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Position in 
genome 
Reference 
Base 
Alternative 
Base 
Amino 
Acid 
Gene/Predicted Function and/or Potential Impact 
Number of 
isolates with SNP 
3916418 G A 239 Hypothetical protein 19 
3511614 T C 9 Transporter 18 
132573 G A 330 Amino acid aminotransferase 16 
850525 C T 163 bglG1 16 
2764219 G T 491 Signalling protein 16 
1032720 C T 275 ABC transporter, substrate-binding protein 15 
2060217 G A 67 argC 15 
2075525 G T 854 clpB 15 
2800650 C A 356 Oxidoreductase 15 
3382194 G A 555 Penicillin-binding protein (B-lactam resistance) 15 
4024527 G A 31 flgG 15 
113642 C T 426 gyrB 13 
2284466 G T 174 Nitrite and sulfite reductase subunit 13 
2733799 G A 55 folP 13 
3399853 G A 310 Ca2+/Na+ antiporter 13 
4184694 T A 197 buk 13 
50281 C A 317 Dual-specificity prolyl/cysteinyl-tRNA synthetase 12 
1115288 G A 48 Aromatic amino acid aminotransferase 12 
1303022 G A 9 Lipoprotein 12 
1394996 C A 145 TetR-family transcriptional regulator 12 
3066199 A G 790 Penicillin-binding protein (B-lactam resistance) 12 
3066407 A G 721 Penicillin-binding protein (B-lactam resistance) 12 
2764414 G A 556 Diguanylate kinase signalling protein 11 
3066235 G A 778 Penicillin-binding protein (B-lactam resistance) 11 
1382195 A G 641 Exported protein 10 
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Position in 
genome 
Reference 
Base 
Alternative 
Base 
Amino 
Acid 
Gene/Predicted Function and/or Potential Impact 
Number of 
isolates with SNP 
1977841 G T 212 Xanthine/uracil permease 10 
2961596 C T 498 smc 10 
3174341 A C 90 Cell surface protein (Putative N-acetylmuramoyl-L-alanine amidase) 10 
3174343 T C 89 Cell surface protein (Putative N-acetylmuramoyl-L-alanine amidase) 10 
388057 G T 323 cbiP 9 
470760 G C 264 bclA3 9 
585426 C T 50 Peptidase 9 
657360 G T 515 Sensor histidine kinase 9 
1048935 G A 67 Drug/sodium antiporter 9 
1276180 C A 78 Hypothetical protein 9 
1381396 A G 375 Exported protein 9 
1458207 C T 358 Bifunctional protein 9 
1474488 C T 364 Sodium: dicarboxylate symporter family protein 9 
1538843 T C 249 selB 9 
2495508 G A 81 Exported protein 9 
2646577 A G 339 Iron-sulfur protein 9 
2656639 C T 691 feoB2 9 
2902717 T C 473 acd 9 
3066331 G A 746 Penicillin-binding protein (B-lactam resistance) 9 
3166570 C T 449 Helicase 9 
3229965 C A 675 Two-component sensor histidine kinase 9 
3300923 C A 281 PTS system lactose/cellobiose-family transporter subunit IIC 9 
3514262 G A 302 Transposase-like protein b 9 
3514307 A G 287 Transposase-like protein b 9 
3514802 C T 122 Transposase-like protein b 9 
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Position in 
genome 
Reference 
Base 
Alternative 
Base 
Amino 
Acid 
Gene/Predicted Function and/or Potential Impact 
Number of 
isolates with SNP 
3514805 G A 121 Transposase-like protein b 9 
567449 G T 632 Two-component sensor histidine kinase 8 
1252965 A C 86 Two-component response regulator 8 
1491685 T C 27 kstR2 8 
1949814 T G 265 Membrane protein 8 
3239437 G A 337 leuC 8 
3382096 A G 522 Penicillin-binding protein (B-lactam resistance) 8 
3704987 C T 19 sleB 8 
3751894 T G 1315 Cell surface protein (Putative hemagglutinin/adhesin) precursor 8 
644128 C T 259 Two-component sensor histidine kinase 7 
2629377 C A 475 Signalling protein 7 
2636947 A G 631 ABC transporter, permease protein 7 
382360 T G 171 Aldose epimerase00416 6 
682915 G A 305 xdhA3 6 
763280 C T 152 Hypothetical protein 6 
839287 C T 148 Transcription antiterminator 6 
1165584 G T 537 secA2 6 
1828018 C A 289 Signalling protein 6 
4157880 G A 395 PTS system, IIc component 6 
15593 C T 20 rpsE 5 
51607 C A 487 proS 5 
221342 C T 274 pyrAB1_2 5 
232498 C T 200 Hypothetical protein 5 
383181 C A 26 Hypothetical protein 5 
395438 A G 3 cbiT 5 
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Position in 
genome 
Reference 
Base 
Alternative 
Base 
Amino 
Acid 
Gene/Predicted Function and/or Potential Impact 
Number of 
isolates with SNP 
850279 C T 81 bglG1 5 
906912 G A 39 glvC 5 
939561 A G 61 Hypothetical protein 5 
1208476 A G 478 Signalling protein 5 
1242643 A T 4 Aminotransferase 5 
1303484 G A 163 Lipoprotein 5 
1508773 C A 18 Two-component sensor histidine kinase 5 
1694380 G A 221 Oligoendopeptidase 5 
1698282 G A 77 grdE 5 
1927579 G T 59 Serine/threonine protein kinase 5 
3066400 G A 723 Penicillin-binding protein (B-lactam resistance) 5 
3147022 G A 117 Phosphoesterase 5 
3267110 A G 24 speE 5 
51218 A T 4 Dual-specificity prolyl/cysteinyl-tRNA synthetase 4 
127314 A G 47 soj_1 4 
1873506 G T 199 Acetyl-CoA synthetase 4 
2438942 G T 158 Lipoprotein 4 
2444939 C T 143 Iron compound ABC transporter, permease protein 4 
2830244 A T 256 Phage protein 4 
2933682 C A 225 topA 4 
3581263 G C 496 hrsA_2 4 
3784489 C T 373 Penicillin-binding protein (B-lactam resistance) 4 
3850253 A G 86 Hypothetical protein 4 
34747 G A 485 rpoB (rifampicin resistance) 3 
464168 G A 11 Transcriptional regulator 3 
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Position in 
genome 
Reference 
Base 
Alternative 
Base 
Amino 
Acid 
Gene/Predicted Function and/or Potential Impact 
Number of 
isolates with SNP 
511931 C T 43 hydN1 3 
557896 C A 342 feoB3 3 
569182 C T 181 Hypothetical protein 3 
612296 C A 21 bclA2_1 3 
660220 T C 285 ABC transporter (salivaricin lantibiotic) 3 
714135 G A 112 Hypothetical protein 3 
918006 T C 299 Hypothetical protein 3 
941032 A G 96 Thioredoxin 3 
941686 C T 287 Aaminotransferase 3 
996373 G A 212 ABC transporter, substrate-binding protein 3 
1050326 C T 709 Signalling protein 3 
1064970 A C 394 Sigma-54-dependent transcriptional regulator 3 
1161805 T C 74 slpA 3 
1162228 A G 215 slpA 3 
1185215 C T 451 pgm2 3 
1206681 G A 259 N-acetylmuramoyl-L-alanine amidase" 3 
1220630 C T 417 Radical SAM family protein 3 
1250085 C T 138 Transferase 3 
1359584 G T 272 Extracellular solute-binding protein 3 
1405479 T C 247 Carbon starvation 3 
1463838 G A 207 Sugar transporter, permease protein 3 
1553544 G C 104 Lipoprotein 3 
1795359 G A 343 PTS system, IIbc component 3 
1907960 G T 89 Hypothetical protein 3 
1920960 G T 8 ATP/GTP-binding protein 3 
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Position in 
genome 
Reference 
Base 
Alternative 
Base 
Amino 
Acid 
Gene/Predicted Function and/or Potential Impact 
Number of 
isolates with SNP 
1932695 G A 43 Membrane protein 3 
2036515 T C 212 Hypothetical protein 3 
2060944 C T 309 argC 3 
2084143 T G 96 TetR-family transcriptional regulator 3 
2373940 A G 159 Molybdopterin-guanine biosynthesis protein 3 
2401429 G T 101 Membrane protein 3 
2457775 C T 580 Calcium-transporting ATPase 3 
2523615 G A 142 Arylesterase 3 
2704311 C T 180 Ruberythrin 3 
2719354 G A 143 ABC transporter, ATP-binding protein 3 
2764540 G A 598 Signalling protein 3 
2801003 G A 239 Oxidoreductase 3 
2943677 G A 66 Hypothetical protein 3 
2987909 C A 103 Penicillin-binding protein (B-lactam resistance) 3 
3036429 G A 47 fabH 3 
3067082 T C 496 Penicillin-binding protein (B-lactam resistance) 3 
3253744 G T 343 opuCC 3 
3306641 T A 136 oppF 3 
3340579 A C 78 Oxidative stress regulatory protein 3 
3382086 T G 519 Penicillin-binding protein (B-lactam resistance) 3 
3402470 C T 445 plfB 3 
3522538 G A 135 RNA polymerase sigma factor  3 
3626504 T G 222 Two-component sensor histidine kinase 3 
3627605 T A 160 Hypothetical protein 3 
3660789 G A 144 Chemosensory protein 3 
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Position in 
genome 
Reference 
Base 
Alternative 
Base 
Amino 
Acid 
Gene/Predicted Function and/or Potential Impact 
Number of 
isolates with SNP 
3784055 C A 518 Penicillin-binding protein (B-lactam resistance) 3 
3831154 T C 51 DNA-binding transcriptional activator YeiL 3 
3832857 G A 63 Acetyltransferase 3 
3924724 G T 628 ABC transporter, permease protein 3 
4000580 T C 5 ABC transporter, permease protein 3 
4130077 G A 76 Amidohydrolase/peptidase 3 
4169330 G A 37 fabZ 3 
4180249 C T 148 Phosphoglucomutase/phosphomannomutase mutase 3 
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Appendix 4: Chapter 5 isolates: total genotypic breakdown (includes isolates from chapter 4) 
 
Non-human isolates are indicated by strain names followed by “C” (canine), “B” (bovine), “E” (equine) and “HW” (hospital ward).  
S
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Strain Name Location 
Iso
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n
 
Y
ea
r 
H
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S
N
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s 
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ser
tio
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Rifampicin resistance Fluoroquinolone resistance Resistance inferred 
34,687 34,697 34,747 112,752 113,641 113,642 Position 
rpoB rpoB rpoB gyrA gyrB gyrB Gene 
R505K H502N S485F T82I V426D V426I *Amino acid change 
1 M04-34 Dublin, Ireland 2004 1 0  
 
  
 
  
 
 
1 M04-21 Dublin, Ireland 2004 1 0  
 
  
 
  
 
 
1 M04-30 Dublin, Ireland 2004 1 0  
 
  
 
  
 
 
1 M04-40 Dublin, Ireland 2004 1 0  
 
  
 
  
 
 
1 M04-50 Dublin, Ireland 2004 1 0  
 
  
 
  
 
 
1 M05-213 Dublin, Ireland 2005 1 0  
 
  
 
  
 
 
1 M05-195 Dublin, Ireland 2005 1 0  
 
  
 
  
 
 
1 M05-214 Dublin, Ireland 2005 1 0  
 
  
 
  
 
 
1 M04-9 Dublin, Ireland 2004 2 2  
 
  
 
  
 
 
1 M08-127 Dublin, Ireland 2008 3 3  
 
  
 
  
 
 
1 M08-150 Dublin, Ireland 2008 3 3  
 
  
 
  
 
 
1 IE 1104 Dublin, Ireland 2009 3 3  
 
  
 
  
 
 
1 SV04-54 Dublin, Ireland 2005 4 5  
 
  
 
  
 
 
1 S3 Dublin, Ireland 2006 4 5  
 
  
 
  
 
 
1 MOH849 Ontario, Canada 2003 5 6  
 
  
 
  
 
 
1 CD257 Ontario, Canada 2003 5 6  
 
  
 
  
 
 
1 CD334 Ontario, Canada 2003 5 6  
 
  
 
  
 
 
1 CD459 Ontario, Canada 2003 5 6  
 
  
 
   
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Rifampicin resistance Fluoroquinolone resistance Resistance inferred 
34,687 34,697 34,747 112,752 113,641 113,642 Position 
rpoB rpoB rpoB gyrA gyrB gyrB Gene 
R505K H502N S485F T82I V426D V426I *Amino acid change 
1 S- 017.8 Dublin, Ireland 2000 6 7          
1 S- 017.9 Dublin, Ireland 2000 6 7  
 
  
 
  
 
 
1 S- 017.10 Dublin, Ireland 2000 6 7  
 
  
 
  
 
 
1 MOH82 Ontario, Canada 2003 7 8  
 
  
 
  
 
 
1 CD656
 B
 Ontario, Canada 2004 7 8  
 
  
 
  
 
 
1 CD657
 B
 Ontario, Canada 2004 7 8  
 
  
 
  
 
 
1 S- 017.5 Carlisle, UK 1994 8 9  
 
  
 
  
 
 
1 GAI 95601 Japan 1995 8 9  
 
  
 
  
 
 
1 S- 017.13 Japan 1999 8 9  
 
  
 
  
 
 
1 B-33 London, UK 2011 8 9  
 
  
 
  
 
 
1 M04-106 Dublin, Ireland 2005 9 10  
 
  
 
  
 
 
1 M05-185 Dublin, Ireland 2005 9 10  
 
  
 
  
 
 
1 7081082 The Netherlands 2007 10 10  
 
  
 
  
 
 
1 8083571 The Netherlands 2008 10 10  
 
  
 
  
 
 
1 MRL 1135 North Dakota, USA 2007 11 10     
 
  
 
 
1 UHL-24 London, UK 2013 12 11  
 
  
 
  
 
 
1 MRL 981 California, USA 2007 13 11     
 
    
1 S- 017.12 Japan 1999 14 11  
 
  
 
  
 
 
1 11-383 Korea 2011 15 11     
 
  
 
 
1 PT 1307 Portugal 2009 16 13     
 
  
 
 
1 S- 017.22 Poole, UK 2003 17 13  
 
  
 
  
 
 
1 S- 017.23 Poole, UK 2003 17 13  
 
  
 
  
 
 
1 S- 017.24 Poole, UK 2003 17 13  
 
  
 
  
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Rifampicin resistance Fluoroquinolone resistance Resistance inferred 
34,687 34,697 34,747 112,752 113,641 113,642 Position 
rpoB rpoB rpoB gyrA gyrB gyrB Gene 
R505K H502N S485F T82I V426D V426I *Amino acid change 
1 S- 017.25 Poole, UK 2003 17 13          
1 MRL 529 Michigan, USA 2007 18 13          
1 SV04-9 Dublin, Ireland 2004 19 14  
 
  
 
  
 
 
1 SV04-17 Dublin, Ireland 2004 19 14  
 
  
 
  
 
 
1 SV04-29 Dublin, Ireland 2004 19 14  
 
  
 
  
 
 
1 MRL 532 Michigan, USA 2007 20 15     
 
  
 
 
1 CD552
 E
 Ontario, Canada 2002 21 15  
 
  
 
  
 
 
1 CD577
 E
 Ontario, Canada 2003 21 15  
 
  
 
  
 
 
1 CD409 Ontario, Canada 2003 21 15  
 
  
 
  
 
 
1 CD159 Ontario, Canada 2003 21 15  
 
  
 
  
 
 
1 CD210 Ontario, Canada 2003 21 15  
 
  
 
  
 
 
1 CD160 Ontario, Canada 2003 21 15  
 
  
 
  
 
 
1 CD425 Ontario, Canada 2003 21 15  
 
  
 
  
 
 
1 CD345 Ontario, Canada 2003 21 15     
 
  
 
 
1 CD538
 E
 Ontario, Canada 2003 21 15  
 
  
 
  
 
 
1 CD562 Ontario, Canada 2004 21 15  
 
  
 
  
 
 
1 CD744
 B
 Ontario, Canada 2004 21 15  
 
  
 
  
 
 
1 CD472
 B
 Ontario, Canada 2004 21 15     
 
  
 
 
1 CD748
 B
 Ontario, Canada 2004 21 15  
 
  
 
  
 
 
1 CD754
 B
 Ontario, Canada 2004 21 15  
 
  
 
  
 
 
1 CD755
 B
 Ontario, Canada 2004 21 15  
 
  
 
  
 
 
1 CD746
 B
 Ontario, Canada 2004 21 15  
 
  
 
  
 
 
1 CD762
 B
 Ontario, Canada 2004 21 15  
 
  
 
  
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Rifampicin resistance Fluoroquinolone resistance Resistance inferred 
34,687 34,697 34,747 112,752 113,641 113,642 Position 
rpoB rpoB rpoB gyrA gyrB gyrB Gene 
R505K H502N S485F T82I V426D V426I *Amino acid change 
1 CD479
 C
 Ontario, Canada 2005 21 15          
1 CD493
 C
 Ontario, Canada 2005 21 15          
1 CD504
C
 Ontario, Canada 2005 21 15          
1 CD515
 C
 Ontario, Canada 2005 21 15  
 
  
 
  
 
 
1 CD523
 C
 Ontario, Canada 2005 21 15  
 
  
 
  
 
 
1 CD527
 C
 Ontario, Canada 2005 21 15  
 
  
 
  
 
 
1 CD528
 C
 Ontario, Canada 2005 21 15  
 
  
 
  
 
 
1 CD529
 C
 Ontario, Canada 2005 21 15  
 
  
 
  
 
 
1 CD531
 C
 Ontario, Canada 2005 21 15  
 
  
 
  
 
 
1 CD578
 E
 Ontario, Canada 2005 21 15  
 
  
 
  
 
 
1 CD524
 C
 Ontario, Canada 2005 21 15  
 
  
 
  
 
 
1 CD514
 C
 Ontario, Canada 2005 21 15  
 
  
 
  
 
 
1 S- 017.15 Kuwait 2001 22 15  
 
  
 
  
 
 
1 S- 017.16 Kuwait 2001 22 15  
 
  
 
  
 
 
1 DS 1383 Singapore 2003 23 16  
 
  
 
  
 
 
1 SI 032 Singapore 2008 23 16  
 
  
 
  
 
 
1 MOH207 Ontario, Canada 2003 24 16  
 
  
 
  
 
 
1 MRL 270 Ontario, Canada 2006 24 16     
 
  
 
 
1 MRL 102 Ohio, USA 2006 24 16     
 
  
 
 
1 09-275 Korea 2009 25 16     
 
  
 
 
1 BG 181 Bulgaria 2009 25 16     
 
  
 
 
1 GR 0108 Greece 2009 25 16     
 
  
 
 
1 S- 017.43 Hong Kong 2011 25 16     
 
  
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Rifampicin resistance Fluoroquinolone resistance Resistance inferred 
34,687 34,697 34,747 112,752 113,641 113,642 Position 
rpoB rpoB rpoB gyrA gyrB gyrB Gene 
R505K H502N S485F T82I V426D V426I *Amino acid change 
1 S- 017.75 Coventry, UK 2011 25 16          
1 S- 017.40 Hong Kong 2011 25 16          
1 SCH5842529 South Africa 2012 25 16          
1 SI 064 Singapore 2012 25 16          
1 WX-36 London, UK 2012 25 16     
 
  
 
 
1 S- 017.79 Nottinghamshire, UK 2012 25 16     
 
  
 
 
1 02-210 Korea 2002 27 17     
 
  
 
 
1 SI 1101 Slovenia 2009 28 17     
 
  
 
 
1 S- 017.55 Nottinghamshire, UK 2009 28 17     
 
  
 
 
1 S- 017.91 China 2009 28 17     
 
  
 
 
1 S- 017.32 Hong Kong 2010 28 17     
 
  
 
 
1 S- 017.33 Hong Kong 2010 28 17     
 
  
 
 
1 WX-35 London, UK 2011 28 17     
 
  
 
 
1 WA 1514 Australia 2012 29 17     
 
  
 
 
1 MRL 3836 Illinois, USA 2009 30 17     
 
  
 
 
1 S- 017.77 Coventry, UK 2012 31 18     
 
  
 
 
1 S- 017.92 China 2009 32 18     
 
  
 
 
1 CZ 1201 Czech Republic 2009 32 18     
 
  
 
 
1 675 Romania 2009 32 18     
 
  
 
 
1 S- 017.20 Poland 2003 35 18  
 
  
 
  
 
 
1 S- 017.1 Argentina 2001 37 18  
 
  
 
  
 
 
1 S- 017.2 Argentina 2001 37 18     
 
  
 
 
1 S- 017.3 Argentina 2001 37 18  
 
  
 
  
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Rifampicin resistance Fluoroquinolone resistance Resistance inferred 
34,687 34,697 34,747 112,752 113,641 113,642 Position 
rpoB rpoB rpoB gyrA gyrB gyrB Gene 
R505K H502N S485F T82I V426D V426I *Amino acid change 
1 NP-25 London, UK 2008 39 19          
1 ES 531 Australia 2011 39 19          
1 S- 017.35 Hong Kong 2010 40 19          
1 S- 017.37 Hong Kong 2010 40 19          
1 S- 017.38 Hong Kong 2010 40 19          
1 ES 580 Australia 2012 41 19     
 
  
 
 
1 ES 720 Australia 2012 41 19     
 
  
 
 
1 12H001405 London, UK 2013 41 19     
 
  
 
 
1 6797 Argentina 2011 43 19  
 
  
 
  
 
 
1 PL 1204 Poland 2009 49 20  
 
  
 
    
1 01-116 Korea 2001 56 20  
 
  
 
  
 
 
1 S- 017.19 Poland 2003 57 21  
 
  
 
  
 
 
1 6050595 The Netherlands 2006 57 21  
 
  
 
  
 
 
1 7036732 The Netherlands 2007 57 21  
 
  
 
  
 
 
1 S- 017.58 Nottinghamshire, UK 2010 62 22  
 
  
 
  
 
 
1 03-182 Korea 2003 63 22     
 
  
 
 
1 06-378 Korea 2006 64 22  
 
  
 
  
 
 
1 07-613 Korea 2007 64 22     
 
  
 
 
1 0 9-02 Korea 2009 64 22  
 
  
 
  
 
 
1 08-191 Korea 2008 65 22     
 
  
 
 
1 06-472 Korea 2006 66 23  
 
  
 
    
1 07-527 Korea 2007 66 23  
 
  
 
    
1 04-247 Korea 2004 67 23     
 
  
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Rifampicin resistance Fluoroquinolone resistance Resistance inferred 
34,687 34,697 34,747 112,752 113,641 113,642 Position 
rpoB rpoB rpoB gyrA gyrB gyrB Gene 
R505K H502N S485F T82I V426D V426I *Amino acid change 
1 05-269 Korea 2005 67 23          
1 0 8-26 Korea 2008 67 23          
1 S- 017.48 Coventry, UK 2008 68 23          
1 S- 017.47 Coventry, UK 2008 68 23          
1 S- 017.60 Nottinghamshire, UK 2010 68 23          
1 S- 017.62 Nottinghamshire, UK 2010 68 23          
1 S- 017.68 Coventry, UK 2011 68 23  
 
  
 
  
 
 
1 S- 017.69 Coventry, UK 2011 68 23  
 
  
 
  
 
 
1 S- 017.46 Coventry, UK 2008 72 24  
 
  
 
  
 
 
1 S- 017.50 Coventry, UK 2008 72 24  
 
  
 
  
 
 
1 S- 017.49 Coventry, UK 2008 72 24  
 
  
 
  
 
 
1 S- 017.51 Coventry, UK 2008 72 24  
 
  
 
  
 
 
1 S- 017.52 Coventry, UK 2008 72 24  
 
  
 
  
 
 
1 05-302 Korea 2005 75 25     
 
  
 
 
1 S- 017.72 Walsall, UK 2011 79 27  
 
  
 
  
 
 
1 S- 017.73 Walsall, UK 2011 79 27  
 
  
 
  
 
 
1 S- 017.64 Walsall, UK 2011 79 27  
 
  
 
  
 
 
1 S- 017.65 Walsall, UK 2011 79 27  
 
  
 
  
 
 
1 S- 017.66 Walsall, UK 2011 79 27  
 
  
 
  
 
 
1 S- 017.90 China 2009 82 30     
 
  
 
 
1 S- 017.57 Nottinghamshire, UK 2009 83 31  
 
  
 
  
 
 
1 S- 017.59 Nottinghamshire, UK 2010 83 31  
 
  
 
  
 
 
1 S- 017.70 Lincolnshire, UK 2011 84 31     
 
  
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Rifampicin resistance Fluoroquinolone resistance Resistance inferred 
34,687 34,697 34,747 112,752 113,641 113,642 Position 
rpoB rpoB rpoB gyrA gyrB gyrB Gene 
R505K H502N S485F T82I V426D V426I *Amino acid change 
1 S- 017.86 China 2009 94 34          
1 S- 017.87 China 2009 94 34          
1 S- 017.95 China 2010 94 34          
1 S- 017.88 China 2009 95 35          
1 S- 017.89 China 2009 95 35          
1 S- 017.93 China 2009 95 35          
1 S- 017.94 China 2009 95 35          
2 5992 Illinois, USA 1996 26 17  
 
  
 
  
 
 
2 S- 017.80 Wolverhampton, UK 2012 33 18     
 
  
 
 
2 S- 017.78 Wolverhampton, UK 2012 33 18     
 
  
 
 
2 S- 017.36 Hong Kong 2010 34 18     
 
  
 
 
2 95-24 Korea 1995 36 18     
 
  
 
 
2 95-25 Korea 1995 36 18     
 
  
 
 
2 S- 017.14 Japan 1999 38 19  
 
  
 
  
 
 
2 T-14 Taiwan 2011 38 19  
 
  
 
  
 
 
2 MRL 991 California, USA 2007 42 19     
 
  
 
 
2 QM-34 London, UK 2011 42 19  
 
  
 
  
 
 
2 S- 017.11 Fife, UK 2002 44 19     
 
  
 
 
2 S- 017.21 Poland 2003 44 19     
 
  
 
 
2 MRL 738 Washington, USA 2007 44 19     
 
  
 
 
2 S- 017.30 Hong Kong 2010 44 19     
 
  
 
 
2 S- 017.31 Hong Kong 2010 44 19     
 
  
 
 
2 S- 017.41 Hong Kong 2011 44 19     
 
  
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Rifampicin resistance Fluoroquinolone resistance Resistance inferred 
34,687 34,697 34,747 112,752 113,641 113,642 Position 
rpoB rpoB rpoB gyrA gyrB gyrB Gene 
R505K H502N S485F T82I V426D V426I *Amino acid change 
2 S- 017.45 Hong Kong 2011 44 19          
2 S- 017.44 Hong Kong 2011 44 19          
2 WA 1196 Australia 2012 44 19          
2 S- 017.4 Aylesbury, UK 2005 45 19          
2 00-108 Korea 2000 46 19          
2 5572 Minnesota, USA 1992 47 20          
2 6084529 The Netherlands 2006 48 20          
2 SI 010 Singapore 2008 48 20          
2 S- 017.56 Birmingham, UK 2009 50 20  
 
  
 
  
 
 
2 7038446 The Netherlands 2007 51 20  
 
  
 
  
 
 
2 7047343 The Netherlands 2007 51 20     
 
  
 
 
2 WA 1428 Australia 2012 52 20  
 
  
 
  
 
 
2 SI 004 Singapore 2008 53 20     
 
  
 
 
2 S- 017.67 Coventry, UK 2011 54 20     
 
  
 
 
2 S- 017.71 Staffordshire, UK 2011 55 20     
 
    
2 S- 017.81 Walsall, UK 2012 55 20  
 
  
 
    
2 SI 007 Singapore 2008 58 21  
 
  
 
  
 
 
2 S- 017.76 Coventry, UK 2012 59 21     
 
    
2 DS 21 Singapore 2003 60 21     
 
  
 
 
2 I 6 Indonesia 2011 61 22     
 
  
 
 
2 9029054 The Netherlands 2009 69 23     
 
  
 
 
2 S- 017.7 Dorchester, UK 1996 70 23  
 
  
 
  
 
 
2 NM-27 Middlesex, UK 2005 71 24  
 
  
 
  
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Rifampicin resistance Fluoroquinolone resistance Resistance inferred 
34,687 34,697 34,747 112,752 113,641 113,642 Position 
rpoB rpoB rpoB gyrA gyrB gyrB Gene 
R505K H502N S485F T82I V426D V426I *Amino acid change 
2 S- 017.6 Dorchester, UK 1996 73 25          
2 4241 Minnesota, USA 1990 74 25          
2 S- 017.53 Worcestershire, UK 2009 74 25          
2 SI 047 Singapore 2012 74 25          
2 SI 099 Singapore 2012 74 25          
2 B-26 London, UK 2009 76 26          
2 S- 017.27 Wrexham, UK 1996 77 26          
2 S- 017.28 Wrexham, UK 1996 77 26          
2 S- 017.29 Wrexham, UK 1996 77 26          
2 T-79 Taiwan 2011 78 27     
 
  
 
 
2 T-16 Taiwan 2011 78 27     
 
  
 
 
2 SV04-6 Dublin, Ireland 2004 80 28  
 
  
 
  
 
 
2 SV05-3 Dublin, Ireland 2005 80 28  
 
  
 
  
 
 
2 SV05-25 Dublin, Ireland 2005 80 28  
 
  
 
  
 
 
2 SV04-10 Dublin, Ireland 2004 81 30  
 
  
 
  
 
 
2 SV04-18 Dublin, Ireland 2004 81 30  
 
  
 
  
 
 
2 SV04-19 Dublin, Ireland 2004 81 30  
 
  
 
  
 
 
2 SCH6148880 South Africa 2012 85 31     
 
  
 
 
2 UHL-4 London, UK 2009 86 31     
 
  
 
 
2 SCH5806999 South Africa 2012 87 32  
 
  
 
  
 
 
2 SCH6098043 South Africa 2012 87 32  
 
  
 
  
 
 
2 SCH5824693 South Africa 2012 88 32  
 
  
 
    
2 SCH5845556 South Africa 2012 88 32  
 
  
 
    
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Rifampicin resistance Fluoroquinolone resistance Resistance inferred 
34,687 34,697 34,747 112,752 113,641 113,642 Position 
rpoB rpoB rpoB gyrA gyrB gyrB Gene 
R505K H502N S485F T82I V426D V426I *Amino acid change 
2 MRL 985 California, USA 2007 89 32          
2 UHL-1 London, UK 2005 90 32          
2 UHL-6 London, UK 2009 90 32          
2 UHL-8 London, UK 2009 90 32          
2 UHL-5 London, UK 2009 90 32          
2 UHL-7 London, UK 2009 90 32          
2 UHL-2 London, UK 2009 90 32          
2 UHL-3 London, UK 2009 90 32          
2 UHL-9 London, UK 2009 90 32          
2 UHL-12 London, UK 2010 90 32          
2 UHL-10 London, UK 2010 90 32     
 
  
 
 
2 UHL-11 London, UK 2010 90 32     
 
  
 
 
2 UHL-13 London, UK 2010 90 32  
 
  
 
  
 
 
2 UHL-14 London, UK 2010 90 32  
 
  
 
  
 
 
2 UHL-22 London, UK 2010 90 32     
 
  
 
 
2 SI 006 Singapore 2008 91 33     
 
  
 
 
2 CDP08WTH7 Liverpool, UK 2010 91 33  
 
  
 
  
 
 
2 UHL-15 London, UK 2010 92 33     
 
  
 
 
2 UHL-16 London, UK 2010 92 33     
 
  
 
 
2 UHL-17 London, UK 2010 92 33     
 
  
 
 
2 UHL-21 London, UK 2010 92 33     
 
  
 
 
2 UHL-23 London, UK 2011 92 33     
 
  
 
 
2 UHL-19
 HW
 London, UK 2010 93 34     
 
  
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Rifampicin resistance Fluoroquinolone resistance Resistance inferred 
34,687 34,697 34,747 112,752 113,641 113,642 Position 
rpoB rpoB rpoB gyrA gyrB gyrB Gene 
R505K H502N S485F T82I V426D V426I *Amino acid change 
2 UHL-21
 HW
 London, UK 2010 93 34          
2 UHL-18 London, UK 2010 93 34          
2 MRL 2923 Colorado, USA 2008 96 36          
2 5733 Illinois, USA 1995 97 37          
2 8070899 The Netherlands 2008 98 37          
2 CX-32 London, UK 2011 98 37          
2 MRL 2259 California, USA 2008 99 38          
2 4092 Minnesota, USA 1990 100 38          
2 4139 Minnesota, USA 1990 100 38          
2 H-219 Illinois, USA 2006 100 38          
2 12H400159 London, UK 2013 101 39          
2 5264 Minnesota, USA 1992 102 39     
 
  
 
 
2 5265 Minnesota, USA 1992 102 39     
 
  
 
 
2 5340 Minnesota, USA 1993 102 39     
 
  
 
 
2 S- 017.84 Northamptonshire, UK 2012 103 39  
 
  
 
  
 
 
2 S- 017.82 Northamptonshire, UK 2012 103 39  
 
  
 
  
 
 
2 S- 017.83 Northamptonshire, UK 2012 103 39  
 
  
 
  
 
 
2 GOSH-28 London, UK 2010 104 41  
 
  
 
  
 
 
2 GOSH-29 London, UK 2010 105 47  
 
  
 
  
 
 
2 GOSH-30 London, UK 2010 105 47  
 
  
 
  
 
 
2 RF-31 London, UK 2010 105 47     
 
  
 
 
2 S- 017.61 Birmingham, UK 2010 106 48     
 
  
 
 
2 S- 017.74 Walsall, UK 2011 106 48     
 
  
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Rifampicin resistance Fluoroquinolone resistance Resistance inferred 
34,687 34,697 34,747 112,752 113,641 113,642 Position 
rpoB rpoB rpoB gyrA gyrB gyrB Gene 
R505K H502N S485F T82I V426D V426I *Amino acid change 
2 S- 017.85 Northamptonshire, UK 2012 106 48          
2 WA 0908 Australia 2012 106 48          
2 GOSH-37 London, UK 2013 107 49          
2 SCH5865760 South Africa  2012 108 51          
2 SCH5864722 South Africa 2012 109 52          
2 SCH6163235 South Africa 2012 109 52          
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